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Abstract
Antimicrobial resistance is a serious public health threat worldwide. The emergence of
multi-drug resistance bacteria challenges the development of novel antibiotics. Pseu-
domonas aeruginosa (P. aeruginosa) is an Gram-negative opportunistic pathogen that
infects burn, wound and cystic fibrosis (CF) patients. P. aeruginosa is intrinsically resistant
to many antibiotics, and further acquired resistance limits treatment options. The high
level of resistance to antibiotics arises mainly from the tight control of P. aeruginosa over
influx and efflux of molecules across its outer membrane. P. aeruginosa outer membrane
includes a large number of different types of porins and efflux pumps that enable nutrient
acquisition and antibiotic resistance.
Among them, P. aeruginosa UCBPP-PA14 encodes 35 TonB-dependent transporters
(TBDTs), which are defined as high-affinity active transporters and permit the transport of
siderophores, heme, heavy metals and carbohydrates. Several studies showed high levels
of TBDTs expression under iron deprivation and their importance for P. aeruginosa growth
in vivo, but, except for the high-affinity siderophores and heme transporters, few have
determined the contribution of single TBDT in vivo. In a Trojan horse approach, mimetics
of essential substrates complexed to drugs, including siderophore-antibiotics conjugates
and non-iron metalloporphyrins, are employed to induce the expression of associated
TBDT(s) and to increase the antibiotic transport through TBDTs, hijacking the bacterial
transport machinery. In spite of promising antibacterial activity in vitro, P. aeruginosa was
able to rapidly develop resistance against the Trojan horse conjugates by facile inactivation
of the TBDT involved in their transport. To circumvent this resistance mechanism, basic
research on the processes associated with P. aeruginosa transport capabilities and
substrate specificities in vivo is seriously needed to guide rational development of novel
and effective therapeutics.
In order to prevent facile inactivation of TBDT, we aim at identifying essential P. aeruginosa
TBDTs that contribute to the bacterial fitness in vivo. We addressed this aim (i) by
quantifying the abundance of TBDTs in vitro, in preclinical and human patients samples
and (ii) by evaluating the relevance of TBDTs in vivo. We thus developed an ultra-
sensitive targeted proteomic approach to determine absolutely the abundance of TBDTs
in vitro and in various hosts. Proteomic analyses revealed a clear disctinction between
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TBDTs expression in vitro and in vivo, suggesting that there is a urgent need for suitable
in vitro medium that more faithfully reflects the in vivo reality. Expression data also
highlighted a subset of TBDTs, including endogenous siderophore, heme, non-iron metal
and some xenosiderophore transporters, that was highly abundant among the different in
vivo conditions. Based on these data, we generated different mutants of the abundant
TBDTs and evaluated them in competitive fitness assays in vivo. Overall, these data
suggested that P. aeruginosa primarily used its high-affinity siderophore pyoverdine for
iron scavenging, whereas uptake capabilities for its other endogenous siderophores,
xenosiderophores, heme-associated substrates and possibly copper and zinc uptake
were all dispensable for in vivo fitness in an intranasal model. In conclusion, implications
of these results in the development of future compounds implementing the Trojan horse
approach were discussed.
Graphical abstract
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Part I
Context

1Fighting Pseudomonas
aeruginosa from inside
„We are approaching the pre-antibiotic era prior to
the 1940s when we didn’t have antibiotics.
Essentially people will start dying from simple
infections because they will be infected by
bacteria that are resistant to all antibiotics.
— Dr. Hans Wildschutte
(Bowling Green State University assistant
professor)
1.1 Antibiotic crisis due to the emergence of MDR pathogens
Antimicrobial resistance is a serious public health threat worldwide. There is an urgent
need to close the gap between the increasing number of multidrug resistant (MDR)
bacteria and the decreasing number of novel antibiotics launched by the pharmaceutical
industries (ECDC., 2017). Last resort antibiotics are failing, threatening patients and the
healthcare systems. Developing new antibiotics is a considerable challenge because
of the rapid emergence of resistance in bacteria through the genetic changes upon
antibiotics exposure and the misuses of antibiotic treatment by hospitals. The European
Center for Disease Prevention and Control (ECDC) classified Pseudomonas aeruginosa
(P. aeruginosa) among the seven pathogens of major public health importance (ECDC.,
2017) and it has also been labelled as ESKAPE pathogens (together with Enterococcus
faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii and
Enterobacter species) that are the primary causative agents of nosocomial infections
(Rice, 2008).
P. aeruginosa is a Gram-negative bacteria that is able to live in diverse niches (Nikel et al.,
2014). P. aeruginosa is an environmental bacteria, mostly found in soil and water, but
also commonly found in plants, animals and humans (Nikel et al., 2014). P. aeruginosa
is an opportunistic pathogen that causes infections in burn and wound or cystic fibrosis
(CF) patients (Obritsch et al., 2005). The pathogen is also frequently associated with
nosocomial infections such as bloodstream, respiratory and urinary tract infections and
can cause in patients both acute and chronic infections, characterized by different lifestyles
(Obritsch et al., 2005). Acute infections are characterized by a motile state of P. aeruginosa
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that causes severe damages in a short period of time (Turner et al., 2014). They can then
turn into chronic infections, which are characterized by the formation of biofilms, facilitating
infections that can persist for months or even years (Turner et al., 2014; Kramer et al.,
2006). Like most Gram-negative bacteria, P. aeruginosa is difficult to eradicate because
of the rapid emergence of multi-drug resistance. It remains one of the leading causes
of morbidity and mortality in CF patients. P. aeruginosa is intrinsically resistant to many
antibiotics (sulfonamides, trimethoprim, tetracycline, and chloramphenicol)(Mesaros et al.,
2007), and further acquired resistance limits treatment options (Lister et al., 2009). To date,
several classical classes of antibiotics have been used to treat P. aeruginosa and decrease
its colonization. A first combination is penicillin/cephalosporin with aminoglycoside, and
a second is carbapenems with fluoroquinolone and aminoglycoside (Tängdén, 2014).
Figure 1.1 recapitulates the different classical classes of antibiotics and their use for
specific infections caused by P. aeruginosa.
Figure 1.1: Different antibiotics classes used to treat various Pseudomonas aeruginosa
infections.
Since the last decade, there has been a growing interest in finding solutions to eradicate
MDR pathogens because of the huge economical burden they cause, due to the huge
economical burden represented by the expenses of the treatment, medical personal
care and hospital stay of patients (ECDC., 2017). The high rate of mortality in humans
due to infections with MDR bacteria is also a serious problem (ECDC., 2017). Every
antibiotic that has been launched, has been followed by the development of resistance
in the targeted bacteria. Carbapenems are an efficient antibiotic class against MDR
bacteria infections, however their use remains uncertain because of the emergence of
carbapenemase-producing strains, e.g. P. aeruginosa and A. baumannii (Baumgart et al.,
2010; Liu et al., 2015).
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The ECDC estimated that, in 2007, 25’000 patients died in Europe from bloodstream,
tissue, lower respiratory and urinary tract infections due to MDR bacteria, two third of
which were Gram-negative bacteria (ECDC., 2017).
1.2 Overcome the first line of bacterial defence: the outer
membrane
Gram-negative bacteria possess a bacterial envelope composed of an outer membrane, a
peptidoglycan layer and an inner membranes that delimit a periplasmic space. The outer
membrane’s composition and fluidity is clearly distinct from that of the inner membrane. It
displays a unique asymmetric lipid bilayer composed of phospholipids in its inner leaflet
and of lipopolysaccharides (LPS) in its outer leaflet. Also, the outer membrane is 15- to
100-fold less permeable than the inner membrane for hydrophobic molecules (Cohen,
2011). The outer membrane plays a crucial role thanks to its dual function. First of all
as a protective layer against toxic compounds and secondly, as an interface for nutrient
exchange with the environment. The outer membrane includes a large number of protein
channels involved in the transport, uptake and efflux of a large variety of compounds,
nutrients and toxic molecules (Galdiero et al., 2012). The asymmetric lipid bilayer of the
outer membrane is therefore the first line of bacterial defence. Hence, it can prevent rapid
permeation of hydrophobic antibiotic molecules such as tetracyclines, fluoroquinolones or
macrolides (Delcour, 2009; Galdiero et al., 2012).
1.2.1 Hydrophilic molecules diffuse through simple porins
Nutrient influx is largely enabled through open water-filled channels called porins. Porins
play an important role in the transport of sugars, amino acids, phosphates and cations
across the outer membrane (Hancock and Brinkman, 2002). Porins are pores of 6-15 Å
diameters formed by 16 to 18-stranded β-barrels (Galdiero et al., 2012). This structural
motif allows the formation of hydrophilic pores within the outer membrane. The pore is
constricted by an inward folded extracellular loop (often the loop 3, L3), so-called the eyelet
or the constriction zone (Figure 1.2) (Welte et al., 1995). The constriction zone affects
the size exclusion limit and other permeation properties of the barrel (Delcour, 2009). An
electrostatic field is created by the interaction of acidic amino acid residues located in
the loop and basic amino acid residues located in the opposite β-strand (Fernández and
Hancock, 2012). This field plays an important role in the selectivity of the pore for the size
and charge of permeating molecules (Fernández and Hancock, 2012). Two main types of
porins exist, the general porins, which are non-selective such as E. coli OmpC or OmpF
(Cowan et al., 1992; Baslé et al., 2006) and the specific porins, which are highly selective
such as OprD in P. aeruginosa with a loop that makes the pore more narrow (see Figure
1.2) (Delcour, 2009).
1.2 Overcome the first line of bacterial defence: the outer membrane 7
Figure 1.2: Constriction zones difference between OmpC from E. coli (2J1N) (Baslé
et al., 2006) and OprD from P. aeruginosa (4FOZ) (Eren et al., 2013a). The
constriction zone is represented in orange in each porin. We can thus clearly
observe a narrower pore in the case of OprD. Structure generated with visual
molecular dynamics (VMD) (Humphrey et al., 1996).
As a result, the outer membrane of P. aeruginosa is 12- to 100-fold less permeable than
the outer membrane of E. coli (Tamber and Hancock, 2006). However, a decrease in
outer membrane permeability does not correlate with a decrease in porins exclusion
limits. Hence, P. aeruginosa takes up nutrients with a molecular weight of up to 3,000
Da thanks to its large number of highly selective porins (Nikaido and Hancock, 2012).
On the other hand, E. coli harbours several general porins but few specific porins, i.e.
lacking selectivity, which restricts the pathogen to an exclusion limit of 600 Da (see Table
1.1 (Hancock and Brinkman, 2002; Keseler et al., 2013). Porin synthesis is regulated by
envelope stress response systems, post-transcriptional regulations by small regulatory
RNAs and other possible, yet unknown, mechanisms (Masi et al., 2013).
General porins Specific porins Gated porins
E. coli K12 7 4 7
P. aeruginosa UCBPP-PA14 1 39 35
Table 1.1: Predicted porin types for E. coli K12 (Keseler et al., 2013) and P. aeruginosa
UCBPP-PA14 (Lee et al., 2006; Winsor et al., 2016). The gated porins will be
described later on (Section 1.2.3).
1.2.2 Eﬄux pumps decrease intracellular antibiotic concentration
Bacterial efflux pumps are multiple-component systems that include an outer membrane
channel, a periplasmic adaptor protein and an inner membrane transporter/pump (Fig-
ure 1.3) (Hancock and Brinkman, 2002). They are thus localized in the outer membrane
and anchored in the inner membrane. The tripartite composition allows the expulsion
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of compounds from the cytoplasm and the periplasm to the extracellular environment
(Amaral et al., 2014). Efflux pumps are involved in the secretion of molecules produced
by the bacteria and are able to recognize harmful compounds that managed to penetrate
the cell wall and reach the periplasm or cytoplasm, and to expel these compounds before
they reach their intended targets (Amaral et al., 2014). This process does not involve the
alteration or degradation of the antibiotics (Fernández and Hancock, 2012).
Figure 1.3: Tripartite structure of efflux pump: a qualitative model adapted from the
hybrid complex TolC-MexA-AcrB (Higgins et al., 2004). It includes an outer
membrane channel, a periplasmic adaptor protein and an inner membrane
transporter/pump.
The pumps are classified as five different families, the Resistance-Nodulation-Division
(RND) efflux pumps family is the most important class because they are present only
in Gram-negative bacteria and they are associated with clinical significant antibiotic
resistance (Sun et al., 2014). RND pumps have been extensively studied because they
are able to transport a wide range of antibiotics but also toxins, dyes, detergents, lipids,
and molecules involved in quorum sensing (Puzari and Chetia, 2017). The best studied
multiple drug resistance (MDR) pumps are AcrAB-TolC in E. coli and MexAB-OprM in P.
aeruginosa (Sun et al., 2014).
RND efflux pumps are involved in a complex regulatory network where they are regulated
by both local and global regulators (Fernández and Hancock, 2012). Efflux pumps
seem to play a major role during infection by expelling host antimicrobials and secreting
virulence factors in order to damage host cells (Sun et al., 2014). RND efflux pumps
have been discovered as being essential for the survival, colonization and virulence of
the bacteria during infection (Puzari and Chetia, 2017). Interestingly, defects in the efflux
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pump activity impairs biofilm formation in P. aeruginosa, E. coli and Salmonella enterica
serovar Typhimurium (Rosenberg et al., 2003).
1.2.3 Gated porins enable energized substrate-specific transports
For nutrients present in low bioavailability in the extracellular environment, passive diffu-
sion is no longer efficient enough and transport occurs via substrate-specific and active
transporters, the so-called gated porins (Galdiero et al., 2012). The gated porins are
characterized by 22-stranded β-barrels forming the pore that accommodates a 4-stranded
β-sheet domain forming a gate in the center (Figure 1.4) (Koebnik et al., 2000; Hancock
and Brinkman, 2002). This gate is described as a plug domain that occludes the barrel
and thus completely obstructs unspecific molecules to pass through gated porins. Some
TBDTs can harbour a signalling domain when they are involved in cell-surface signalling
(CSS) (Llamas et al., 2014).
Nutrient acquisition is achieved upon specific ligand recognition by the transporter, which
induces a signal transduction across the outer membrane (Schalk et al., 2004). This
results in a conformational change of the plug domain that releases the so-called TonB
box (Noinaj et al., 2010), a semi-conserved sequence of five to eight amino acid residues
located on the N-terminal of the plug (Gudmundsdottir et al., 1989; Kadner, 1990). The
TonB box is stretched into the periplasm and interacts with the TonB machinery in the
inner membrane (Noinaj et al., 2010). The TonB machinery is composed of TonB, ExbB
and ExbD (1:2:7 stoichiometry) and uses the proton motive force to open the transporter,
which can then enable the translocation of the ligand substrate (Noinaj et al., 2010).
Because the gated porins require the TonB machinery to energize their ligand substrate
transport, they are also called TonB-Dependent Transporters (TBDTs). These transporters
are able to acquire a large variety of specific substrates such as heme, vitamins, heavy
metals and carbohydrates (Schauer et al., 2008). The most studied transporters are those
involved in the uptake of iron through secretion and acquisition of strong iron chelators
called siderophores. The synthesis of TBDTs is regulated in multiple ways, involving
metal-dependent regulators, σ/ anti-σ factors and possibly other mechanisms not yet
detected (Noinaj et al., 2010).
1.2.3.1 The battle for iron
Iron is one of the most abundant element on Earth (Quintero-Gutiérrez et al., 2008), and
plays an important role in biology (Abbaspour et al., 2014). Thanks to its redox activity,
iron is at the center of the most fundamental enzymatic processes such as DNA and
RNA synthesis, oxygen metabolism and electron transfer. Iron has two common oxidation
states (Abbaspour et al., 2014): ferrous iron Fe2+ and ferric iron Fe3+. Ferrous iron Fe2+
is quite soluble in water and can be oxidized to ferric iron Fe3+, which is insoluble. At
physiological pH, ferrous iron Fe2+ is rapidly oxidized (Abbaspour et al., 2014) and the
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Figure 1.4: Characteristic TBDT structure: example of FpvA, pyoverdine transporter
(2W16) (Greenwald et al., 2009). A β-barrel is occluded by a plug domain. A
semi-conservative sequence called the TonB box is located at the N-terminus
of the protein. Some TBDTs can harbour a signalling domain when they
are involved in cell-surface signalling (CSS). Structure generated with Visual
Molecular Dynamics (VMD) (Humphrey et al., 1996).
concentration of bioavailable Fe3+ is 10−9 M (Mislin and Schalk, 2014). Bacteria require
Fe3+ concentrations between 10−6 M and 10−7 M for optimal growth (Mislin and Schalk,
2014). In host environment, access of iron is restricted by the host by strong complexation
of host proteins to iron, such as transferrin, lactoferrin or hemoproteins, through a process
called nutritional immunity (Hood and Skaar, 2012). The concentration of the available
iron is consequently extremely low in the host, about 10−24 M (Hancock and Brinkman,
2002; Raymond et al., 2003).
Iron acquisition through heme
Heme is a cofactor of hemoproteins. The molecule has a porphyrin structure that cova-
lently binds iron in its center (Figure 1.5). High concentration of heme is toxic because
heme is highly hydrophobic and can pass through cell membranes, impair lipid bilay-
ers and destabilize the cellular cytoskeleton (Schmitt et al., 1993; Jarolim et al., 1990;
Anzaldi and Skaar, 2010). In the case of erythrocyte lysis, released hemoglobin is cap-
tured by the plasma protein haptoglobin to prevent the oxidative damage triggered by
hemoglobin (Abbaspour et al., 2014). The haptoglobin-hemoglobin complex is recognized
by macrophages, which removed it from the plasma (Abbaspour et al., 2014). Any free
heme that is released from hemoglobin is rapidly bound by another plasma protein known
as hemopexin (Abbaspour et al., 2014). Intracellular concentration of heme is hence
tightly controlled by the host in order to limit the toxicity associated with these molecules,
ensure iron homeostasis, and prevent microbial growth (Pishchany and Skaar, 2012).
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Figure 1.5: Heme structure. The molecule has a porphyrin structure that covalently binds
iron in its center.
Hemoglobin is the most abundant reservoir of iron in humans and is thus an attractive
nutrient and iron source for invading pathogens (Abbaspour et al., 2014). Numerous
bacterial species have evolved systems to extract iron from host hemoglobin (Cornelis
and Andrews, 2010). Under iron-limiting conditions, bacteria secrete toxins that lyse
erythrocytes in order to release hemoglobin from red blood cells (Skaar, 2010). Released
hemoglobin is then bound by specific transporters that are anchored in the cell surface
of the bacteria (Skaar, 2010). Upon binding of hemoglobin, these transporters remove
the heme moiety from hemoglobin and further translocate it across the outer membrane
(Cornelis and Dingemans, 2013). Pathogens are also able to secrete a heme extractor
protein called the hemophore, that would then pass the heme moiety to heme transporters
(Cornelis and Dingemans, 2013).
Iron acquisition through siderophores
Bacteria have evolved strategies to acquire iron through strong chelator molecules called
siderophores (Skaar, 2010). Siderophores are low-molecular-weight chelating agents
(200–2000 Da), produced by bacteria to facilitate the uptake of iron (Mislin and Schalk,
2014). They bind iron with very high affinity defined by binding constants (Ka) ranging
from 1030 M-1 to 1052 M-1 (Schalk and Cunrath, 2016). Fungi and plants are also
able to produce siderophores (Mislin and Schalk, 2014). In the soil, the concentration of
siderophore is about 10−3 to 10−7 M, which contributes considerably in extracting insoluble
iron from minerals in order to facilitate its mobilization and to maintain intracellular iron
reservoirs (Schalk et al., 2011). In the host, siderophores confer a remarkable advantage
to bacteria because they can efficiently compete with plasma proteins lactoferrin and
transferrin (binding constants of 1022-1024 M-1 and 1020-1021 M-1 respectively) (Majka
et al., 2013). Siderophores also have the ability to function as metallophores for a variety
of other metals (Schalk and Cunrath, 2016). They can also act as toxins or signalling
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molecules for quorum sensing, regulate oxidative stress, and provide antibacterial activity
(Johnstone and Nolan, 2015).
Figure 1.6: Structural classes of siderophores: Catecholate, hydroxamate and carboxy-
late.
Siderophores can have a variety of chemical structures and they form a family of at least
500 different compounds (Hider and Kong, 2010; Schalk et al., 2011). According to their
structures, they are divided into four main classes: the catecholates mostly found in
bacteria, the hydroxamates, the carboxylates mostly found in fungi and, a forth class that
includes mixed-types structures (Figure 1.6) (Mislin and Schalk, 2014). Ferrisiderophores,
i.e. iron Fe3+ bound to siderophores, are transported across the outer membrane through
dedicated specific TBDTs (Imperi et al., 2009). The ferrisiderophore is then efficiently
delivered to the cell through inner membrane ABC transporters (Miethke and Marahiel,
2007). In some case, dissociation of the ferrisiderophore occurs in the periplasm and the
siderophore is recycled by an efflux pump, in order to scavenge more iron (Imperi et al.,
2009; Guillon et al., 2013).
1.2.3.2 Trojan horse strategy based on sideromycins
Sideromycins are natural antibiotics covalently linked to siderophores, which are produced
by various microorganisms (Mislin and Schalk, 2014). Several families of sideromycins
have been discovered and characterized in the last decades. The sideromycins identified
to date include albomycins produced by Actinomyces subtropicus (Bickel et al., 1960;
Benz et al., 1982), ferrimycins (Bickel et al., 1965), danomycins (Tsukiura et al., 1964),
and salmycins (Vértesy et al., 1995) produced by Streptomyces strains, as well as certain
microcins (De Lorenzo and Pugsley, 1985; Destoumieux-Garzón et al., 2006; Nolan and
Walsh, 2008; Thomas et al., 2004) produced by Enterobacteriaceae (Möllmann et al.,
2009).
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These natural siderophore–antibiotic conjugates can chelate Fe3+ and are transported
into the bacterium via siderophore-dependent iron uptake pathways (Mislin and Schalk,
2014). This energy-coupled transport across the bacterial membranes greatly increases
the antibiotic efficacy of sideromycins (Mislin and Schalk, 2014). The minimum inhibitory
concentration (MIC) represents the lowest concentration of an antibiotic required to
inhibit the growth of an organism. Sideromycin MICs are often at least two orders of
magnitude lower than that of the antibiotic moiety without the siderophore (Mislin and
Schalk, 2014).
The Trojan horse approach bases its strategy on these natural compounds in order to
increase antibiotic uptake by the bacteria themselves (Carvalho and Fernandes, 2014).
The concept is the same as for the sideromycin: a bacterial substrate moiety is associated
with an antibiotic moiety (Carvalho and Fernandes, 2014). During infection, bacteria
use iron uptake systems in an environment that is poor in iron (Skaar, 2010). Therefore,
sideromycins coupled with iron have a high chance to be taken up by the bacteria. The
affinities of siderophore coupled-antibiotics with their transporters is high due to their
siderophore moiety (Figure 1.7) (Carvalho and Fernandes, 2014). Hijacking iron bacterial
transports in order to deliver actively antibiotics is hence a propitious strategy to cross the
outer membrane, using bacterial machinery (Möllmann et al., 2009).
Figure 1.7: Exploiting bacterial active transporters. Example of a Trojan horse strategy,
where a siderophore is coupled to an antibiotic moiety in order to increase
antibiotic uptake by the dedicated TBDT. Transport of conjugates through the
TBDT is more efficient than diffusion of the antibiotic alone.
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In order to synthesize a successful siderophore-drug candidate, the compound should
fulfill two important properties: it should exhibit a good antibiotic activity and present a
high affinity to the bacterial transporter (Mislin and Schalk, 2014). Three major hurdles
exist in the synthesis of conjugates:
• The choice of the antibiotic: the translocation of a drug through both the outer and
the inner membrane is challenging, because the drug should be able to cross both
membranes and still be active. The most used antibiotic class in the Trojan horse
strategy are derivatives of the β-lactams, because they directly act in the periplasm
by blocking cell wall biosynthesis (Mislin and Schalk, 2014);
• The choice of the arm linker, i.e. in order to associate the antibiotic moiety to the
siderophore, the ideal linker should stay stable during the translocation across
the outer membrane but should be easily cleaved once inside the bacteria (in the
periplasm or in the cytoplasm depending on the drug) (Mislin and Schalk, 2014);
• The choice of the siderophore: the siderophore should be able to reach a wide
spectrum of pathogens.
Due to the complexity of the outer membrane envelope, overcoming the bacterial first
line of defence is difficult. The outer membrane confers P. aeruginosa a higher intrinsic
resistance due to its low permeability and the pathogen benefit from sophisticated efflux
mechanisms that expel intruding antibiotics (Nikaido and Hancock, 2012). These two
major bacterial strategies make the development of new therapeutic approaches even
more challenging. In this context, the Trojan horse approach seems promising.
1.3 Acquired resistance of P. aeruginosa challenges antibiotic
development
In addition to intrinsic resistance, bacteria can acquire or develop resistance to antibiotics.
The resistance can be mediated by three major mechanisms (Dever and Dermody, 1991):
• decrease of the intracellular concentration of antibiotics by controlling influx and
efflux;
• modification of the antibiotics target by genetic mutations;
• inactivation of antibiotics by hydrolysis or chemical modification.
Porins allow the entry of key nutrients but together with efficient efflux systems, seem to
play an important role in restricting the influx of numerous antibiotics (Hancock, 1987;
Ochs et al., 1999b; Ruiz, 2003; Olesky et al., 2006). Understanding the mechanisms by
which pathogens control their influx and efflux is of particular importance for developing
new therapeutic options.
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1.3.1 Pseudomonas aeruginosa UCBPP-PA14, our model
organism
P. aeruginosa have the remarkable ability to colonize diverse environments and infect a
wide range of organisms, from plants to humans (Rahme et al., 2000). This environmental
and pathogenic promiscuity is in part due to the large and genetically diverse P. aeruginosa
genome. The common P. aeruginosa laboratory strain is PAO1 (Stover et al., 2000).
This strain was isolated from an infected burn/wound of a patient in Melbourne, Australia
(American Type Culture Collection ATCC 15692) (Hare et al., 2012). PAO1 is a moderately
virulent strain (Lee et al., 2006) and belongs to a relatively rare clonal group (Wiehlmann
et al., 2007). In contrast, UCBPP-PA14 is a highly virulent strain isolated from a burn
wound patient in the United States (Rahme et al., 1995) and represents the most common
clonal group worldwide (Figure 1.9) (Wiehlmann et al., 2007).
Figure 1.8: Widespread geographic distribution of major P. aeruginosa clones. UCBPP-
PA14 represents the most common clonal group worldwide. Clones are
depicted by uppercase letters and are arranged by decreasing frequency in
alphabetical order. Adapted from (Wiehlmann et al., 2007).
The UCBPP-PA14 genome shows a high degree of conservation compared to PAO1,
the difference in virulence seems to arise from two pathogenicity islands (PAPI-1 and
PAPI-2) that are absent in the PAO1 genome (Harrison et al., 2010). Harrisson and
coworkers showed that the deletion of one or both pathogenicity islands impacts the
virulence of PA14 in acute pneumonia and bacteremia murine models (Harrison et al.,
2010). The two pathogenicity islands were related to virulence factors that might promote
pathogen attachment to epithelial cells (He et al., 2004), and hence establish a successful
colonization of the host. The UCBPP-PA14 genome was sequenced ten years ago by
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Lee and coworkers and they predicted that the genome encodes 40 simple porins, 20
efflux pumps and 35 TBDTs (Table 1.1) (Lee et al., 2006; Winsor et al., 2016).
1.3.2 Porin-mediated resistance to antibiotics
P. aeruginosa UCBPP-PA14 encodes 40 simple porins, among which 19 belong to
the OprD family (Hancock and Brinkman, 2002). β-lactams carbapenems, such as
imipenem and meropenem, are antibiotics that interfere with the cell wall biosynthesis in
the periplasm and, exhibit high resistance against bacterial defence β-lactamases (Fig-
ure 1.1). Carbapenems have been shown to pass across P. aeruginosa outer membrane
through OprD (Trias and Nikaido, 1990a). Additionally, the porin has been described to
facilitate the diffusion of basic amino acids and small peptides, which is not surprising
as basic amino acids share structural similarities with carbapenem molecules (Trias and
Nikaido, 1990b; Lister et al., 2009).
Consequently, the loss of OprD significantly decreases the susceptibility of the pathogen
to carbapenems as shown by Sakyo and coworkers for imipenem, meropenem and
doripenem (Sakyo et al., 2006). Susceptibility of a strain is measured by changes in MIC.
OprD is a highly regulated protein at transcriptional and post-transcriptional levels by some
trace metals (Perron et al., 2004; Caille et al., 2007), amino acids (Ochs et al., 1999a),
and efflux pump regulators (Köhler et al., 1999; Muller et al., 2011). It has been shown
that OprD porin inactivation occurs via mutations that create frameshifts and premature
stop codons (Pirnay et al., 2002) and via disruption of the oprD structural gene by the
insertion of large insertion sequence (IS) elements (Evans and Segal, 2007; Wolter et al.,
2004).
Two intriguing studies revealed discordance between oprD expression and susceptibility
to imipenem. Imipenem-resistant strains showed a low level of oprD expression, or none
at all, as expected (Lister et al., 2009). However isogenic mutants, derived from the
parental imipenem-resistant strains, exhibited lower level of oprD expression, or still none
at all, but susceptibility to imipenem reverted back due to a not yet known mechanism
(Wolter et al., 2005; Wolter, 2008a; Lister et al., 2009). These two studies highlighted the
dynamic regulation and remarkable genetic versatility of P. aeruginosa, which makes P.
aeruginosa one of our greatest therapeutic challenges.
1.3.3 Eﬄux-mediated Resistance to Antibiotics
Decreasing the intracellular concentration of antibiotics can also be achieved through
active export by membrane-associated pumps. Efflux pump expression has been asso-
ciated with increased MIC values to antibiotics in clinical isolates (Sun et al., 2014). P.
aeruginosa is able to express ten RND pumps: MexAB-OprM, MexCD-OprJ, MexEF-OprN,
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MexXY, MexJK, MexGHI-OpmD, MexVW, MexPQ-OpmE, MexMN, and TriABC. Mex is an
acronym for Multiple efflux. Four RND efflux pumps have been discovered to be essential
for the survival, colonization and virulence of the bacteria during infection: MexXY–OprM,
MexCD–OprJ, MexEF–OprN and MexXY (Puzari and Chetia, 2017).
MexAB-OprM was the first multidrug efflux pump to be discovered (Poole et al., 1993).
MexAB-OprM is able to export several different classes of antibiotics (Li et al., 1995),
including fluoroquinolones, tetracyclines, chloramphenicol, β-lactams and β-lactamase
inhibitors (Li et al., 1998), macrolides, novobiocin, trimethoprim and sulfonamides (Köhler
et al., 1996; Lister et al., 2009). MexAB-OprM has the broadest substrate profile for the
β-lactam class (Srikumar et al., 1998). The pump is also constitutively expressed, thus
participating in the intrinsic resistance (Poole and Srikumar, 2001). Maximum expression
of the pump was reported in the late log phase/early stationary phase of bacterial growth
(Evans and Poole, 1999). As a result, the growth-phase-dependent expression was
suggested to participate in quorum sensing (Evans and Poole, 1999). The expression of
the pump is repressed by the negative transcriptional regulators MexR, NalC and NalD.
MexCD-OprJ is able to export a variety of antimicrobial agents (Gotoh et al., 1998;
Masuda et al., 1996), including fluoroquinolones, β-lactams (Srikumar et al., 1998), chlo-
ramphenicol, tetracycline, novobiocin, trimethoprim (Köhler et al., 1996) and macrolides
(Lister et al., 2009). Despite the high homology with MexAB-OprM (Poole et al., 1996),
MexCD-OprJ preferentially export the fourth-generation cephalosporins (Poole et al.,
1996; Masuda et al., 1996). MexCD-OprJ is present at very low levels in wild-type P.
aeruginosa, suggesting that this pump does not contribute to intrinsic resistance (Morita
et al., 2001). However, an increased expression of mexCD-oprJ is observed in a ∆mexAB-
∆oprM mutant (Li et al., 2000). mexCD-oprJ expression was not shown to be inducible by
clinically relevant antibiotics (Morita et al., 2001). Overexpression of MexCD-OprJ leads to
hypersusceptibility to aminoglycosides (Poole et al., 1996; Masuda et al., 1996) and other
β-lactams, including sulbenicillin, cefpodoxime, ceftriaxone, imipenem and biapenem
(Masuda et al., 2001), due to an unknown mechanism. Hypersusceptibility is defined as
an increase in susceptibility of fourfolds or more (Lister et al., 2009). Like MexAB-OprM,
MexCD-OprJ is negatively regulated by the negative transcriptional regulator NfxB.
MexEF-OprN is able to export fluoroquinolones, chloramphenicol, and trimethoprim, but
none of the currently available β-lactams (Michéa-Hamzehpour et al., 1997). Low levels
of mexEF-oprN expression was reported in wild-type (Li et al., 2000) and the disruption
of the pump did not affect the susceptibility of P. aeruginosa (Michéa-Hamzehpour et al.,
1997). This suggests that MexEF-OprN does not play a role in intrinsic resistance of
the pathogen. In contrast to MexAB-OprM and MexCD-OprJ, MexEF-OprN is positively
regulated by the global regulator MexT (Köhler et al., 1999), which also seems to have a
role in oprD regulation (Ochs et al., 1999b).
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MexXY can be associated with OprM, as well as with other outer membrane proteins,
such as OpmB, OpmG, OpmH, and OpmI (Mine et al., 1999; Chuanchuen et al., 2005)
and is able to export fluoroquinolones, specific β-lactams, aminoglycosides, tetracycline,
chloramphenicol, and erythromycin (Poole, 2002; Schweizer, 2003). mexXY expression
is induced by tetracycline, erythromycin, and gentamicin and, the pump was found to
contribute to intrinsic resistance of P. aeruginosa (Masuda et al., 2000; Morita et al.,
2001). MexXY is negatively regulated by the transcriptional regulator MexZ (Matsuo et al.,
2004).
Extensive efforts are made to discover efflux pumps inhibitors, i.e. agents that can inhibit
efflux by (i) altering the regulation of their expression, (ii) altering the functional assembly
of the efflux components, (iii) obstructing the outer membrane channels, (vi) destroying
the efflux energy and (v) inhibiting affinity sites of the efflux pumps with non-antibiotic
molecules (Puzari and Chetia, 2017). Two classes of inhibitors (the peptidomimetics and
the pyridopyrimidines) exhibited promising inhibitory activity against MexAB-OprM when
they were applied with ciprofloxacin and levofloxacin (Askoura et al., 2011; Sun et al., 2014;
Venter et al., 2015; Puzari and Chetia, 2017). Efflux pump inhibitors successfully compete
with the antibiotics for efflux, thus increasing the intracellular antibiotic concentration
(Hirakata et al., 2009).
The development of antibiotic resistance is a complex process that involves several
mechanisms, which are co-regulated in an uncharacterised manner. P. aeruginosa
carbapenem resistance involves downregulation of OprD, utilization of multiple efflux
systems and overproduction of the chromosomal AmpC β-lactamase (Lister et al., 2009).
Therefore, it is important to understand the contribution of efflux pumps to antibiotic
resistance during infection in order to assess the therapeutic success of their inhibitors.
1.3.4 Exploiting TBDTs for conjugates transport
P. aeruginosa UBCPP-PA14 genome encodes 35 TonB-dependent transporters (Table 1.1).
A comprehensive list of all TBDTs present in UPCBB-PA14 is presented in Table 1.2
(Winsor et al., 2016). These transporters are classified in different groups according to
their substrates:
• endogenous siderophore transporters, i.e. transporters of siderophore produced by
the pathogen;
• exogenous siderophore transporters, i.e. transporters of siderophore produced by
others microorganisms;
• heme transporters, i.e. transporters of heme or heme derivatives;
• metal transporters, i.e. transporters of heavy metals;
• others transporters, e.g. transporters of carbohydrates;
• unknown transporters, i.e. uncharacterized transport systems so far.
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In vivo studies in mice (Takase et al., 2000a), clinical and transcriptomic data (Son et al.,
2007; Bielecki et al., 2013; Ochsner et al., 2002; Schulz et al., 2015) have agreed on
an expression of TBDTs, which involved them in iron uptake, due to iron restriction in
infected tissues. Most of these TBDTs are associated with siderophores-mediated iron
or heme uptake. Several studies have suggested crucial roles of the TonB-dependent
siderophores and heme receptors during P. aeruginosa infection (Takase et al., 2000b;
Nguyen et al., 2014), but few have characterized the complete set of relevant TBDTs in
vivo (Schauer et al., 2008).
In contrast to efflux pumps or simple porins, the use of TBDTs as drug delivery systems
has two advantages:
• the transporters enable active transport, more powerful for an efficient drug delivery
than a passive diffusion;
• the transporters seem to play a major role during infection, especially those involved
in iron uptake.
Designing siderophore-antibiotic conjugates for relevant in vivo TBDT might be an efficient
way to circumvent the rapid development of antibiotic resistance.
So far, there have been three endogenous siderophores described in P. aeruginosa
UCBPP-PA14. The high-affinity siderophore systems pyoverdine and pyochelin have been
extensively studied in vitro and in vivo for over 50 years. Recently, a third endogenous
siderophore/metallophore, staphylopine (Ghssein et al., 2016) /nicotianamine was discov-
ered in P. aeruginosa and seems to have an important role in artificial lung conditions (Gi
et al., 2014).
1.3.4.1 Pyoverdine is the main siderophore of P. aeruginosa
Pyoverdine is the high-affinity siderophore of P. aeruginosa (1032 M-1) and is the reason for
the characteristic green fluorescence of P. aeruginosa (Hoegy et al., 2014). P. aeruginosa
can produce three different types of pyoverdine in a strain-specific fashion: type I, type
II and type III (Briskot et al., 1986; Meyer et al., 1997). Each one is characterized by a
different peptide chain. UCBPP-PA14 produces type I pyoverdine (Briskot et al., 1986;
Meyer et al., 1997). Pyoverdine biosynthesis is a complex process that starts in the
cytoplasm and ends in the periplasm with the maturation of the fluorescent pyoverdine
(Figure 1.10) (Hannauer et al., 2012a).
Pyoverdine production is regulated by the Ferric uptake regulator Fur and PvdS that is
in turn also regulated by Fur (Leoni et al., 1996). When the iron concentration is high,
Fur is bound to iron and represses the expression of pyoverdine biosynthesis (Leoni
et al., 1996). Upon iron starvation, Fur releases the sigma factor PvdS that initiates
pyoverdine biosynthesis (Leoni et al., 1996). Pyoverdine synthesis starts in the cytoplasm
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Figure 1.9: Pyoverdine type I, II and III structures (Visca et al., 2007). Each one is
characterized by a different peptide chain.
with the assembly of the peptide backbone in a multistep reaction done by four non-
ribosomal peptide synthetases (NRPSs) PvdL, PvdI, PvdJ and PvdD (Hannauer et al.,
2012a). NRPSs are very large enzymes organized in modules, where each module
catalyses the incorporation of one specific amino acid substrate into the peptide product
(Crosa and Walsh, 2002; Finking and Marahiel, 2004). Several enzymes produce the
necessary substrates for the assembly, such as the ornithine hydroxylase PvdA (Ge and
Seah, 2006), the hydroxyornithine transformylase PvdF (McMorran et al., 2001) and the
aminotransferase PvdH (Vandenende et al., 2004). Formation of the precursors occurs at
the siderophore-specific multi-enzymatic complexes, called siderosome, that is associated
with the inner leaflet of the inner membrane (Gasser et al., 2015). It was suggested that
this localization prevents the precursor from filling the periplasm and binding free iron
(Gasser et al., 2015). It also facilitates rapid secretion of pyoverdine (Imperi and Visca,
2013). The precursors are also bound to the inner membrane through a fatty acid chain
(myristoleic acid chain) during its assembly (Hannauer et al., 2012a).
The resulting peptide precursor is non-fluorescent and is transported across the inner
membrane and into the periplasm by PvdE, which is an ABC transporter specific to
pyoverdine (Yeterian et al., 2010b). The maturation of pyoverdine starts with the removal
of the myristoleic acid by the acylase PvdQ prior to the maturation of the chromophore
(Hannauer et al., 2012a). The generated precursor is called ferribactin. PvdM, PvdN,
PvdO and the tyrosinase PvdP are involved in the ferribactin maturation into pyoverdine
by a mechanism that remains unknown (Nadal-Jimenez et al., 2014; Ringel et al., 2016).
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PvdP and PvdN have been shown to be essential for pyoverdine production (Nadal-
Jimenez et al., 2014; Ringel et al., 2016). The newly synthesized pyoverdines are
secreted by the ATP-dependent efflux pump PvdRT-OpmQ (Figure 1.10) (Yeterian et al.,
2010a; Hannauer et al., 2012b; Schalk and Guillon, 2013). PvdRT-OpmQ is the second
siderophore efflux pump to be described (Hannauer et al., 2012b), AcrAB-TolC from E.
coli being the first (Sun et al., 2014).
Figure 1.10: Pyoverdine biosynthesis, secretion, transport and regulation.
Once iron Fe3+ has been chelated in the extracellular medium, ferripyoverdine is trans-
ported across the outer membrane via its two dedicated TBDTs: FpvA (Schalk et al., 1999)
and FpvB (Ghysels et al., 2004). The binding site of FpvA is highly specific for the ferripy-
overdine, with an affinity of 0.5 nM (Hannauer et al., 2012b). FpvB has been identified as
a ferripyoverdine transporter but its exact role remains unknown (Ghysels et al., 2004). In
the periplasm, the iron reductase FpvG releases iron from the siderophore by reduction
(Greenwald et al., 2007; Imperi et al., 2009). FpvH, FpvJ, and FpvK proteins probably act
as partners of FpvG by transferring iron to a chaperon protein FpvC (Ganne et al., 2017b).
FpvC has a higher affinity for Fe2+ than pyoverdine (Ganne et al., 2017b). FpvC, together
with another chaperon protein FpvF possibly bring Fe2+ to the ABC transporter FpvDE
for its translocation into the cytoplasm (Brillet et al., 2012). The apo-siderophore is then
recycled into the extracellular medium by PvdRT-OpmQ (Figure 1.10) (Schalk et al., 2002;
Imperi et al., 2009).
Depending on the strain, P. aeruginosa produces large amounts of pyoverdine: its concen-
tration is between 15 and 37 mM under iron-depleted culture conditions (Mislin and Schalk,
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2014). Pyoverdine is also able to efficiently chelate other metals: Ag+,Al3+,Cd2+,Co2+
,Cu2+ ,Fe3+ ,Ga3+ ,Hg2+ ,Mn2+ ,Ni2+ and Zn2+, but its highest affinity is for Fe3+ (Schalk
and Guillon, 2013). In contrast to Fe3+, these other metal ions are not released from
pyoverdine, but rather directly pumped out of the cell by PvdRT-OpmQ (Schalk and Guillon,
2013). The process has been proposed as a detoxification mechanism of the environment
in order to maintain metal homeostasis in P. aeruginosa and to prevent high intracellular
heavy metal concentration, carried by simple porin diffusion (Schalk and Guillon, 2013).
FpvA has been associated with a cell surface signalling (CSS) pathways (Llamas et al.,
2014). The binding of ferripyoverdine to FpvA initiates a signalling cascade through the
interaction between the signalling domain present on FpvA N-terminal domain and the anti-
sigma factor FpvR (Llamas et al., 2014). FpvR controls the activity of two extracytoplasmic
function (ECF) alternative sigma factors: PvdS and FpvI (Llamas et al., 2014). The FpvI
sigma factor recruits RNA polymerase to promote the expression of fpvA, while PvdS
promotes the expression of genes involved in pyoverdine biosynthesis (pvd) and virulence
factors such as exotoxin A (ToxA), proteases PrpL and AprA, and others (Figure 1.10)
(Beare et al., 2003; Tiburzi et al., 2008). Pyoverdine triggers a positive feedback loop
of its own expression and acts as a signalling molecule that controls the production of
virulence factors (Lamont et al., 2002; Minandri et al., 2016).
For decades, pyoverdine has been described as important for in vivo infections (Meyer
et al., 1996; Takase et al., 2000a; Takase et al., 2000b). Lately, a meta-analysis on
pyoverdine effects in vivo showed that different experimental conditions can lead to
divergent outcomes (Granato et al., 2016). A pyoverdine-deficient mutant showed lower
virulence in a wide range of hosts (Meyer et al., 1996; Takase et al., 2000a; Takase et al.,
2000b; Imperi et al., 2013; Lopez-Medina et al., 2015), potentially because of the absence
of pyoverdine-related virulence factors. This mutant showed reduced growth in vivo
compared to the wild-type, but was still able to colonize the host and trigger an infection in
the various infection models (Granato et al., 2016). Moreover, the mutation of pyoverdine
enyzme biosynthesis, PvdA, in clinical P. aeruginosa, associated with chronic lifestyle of P.
aeruginosa, is frequent in CF patients (De Vos et al., 2001; Jiricny et al., 2014; Andersen
et al., 2015). However the strains maintain the ability to take up pyoverdine (De Vos et al.,
2001; Jiricny et al., 2014; Andersen et al., 2015).
As a Trojan horse candidate, pyoverdine-antibiotic conjugates are challenging because the
structure of the pyoverdine is composed of a polycyclic moiety with asymmetric centers
of unnatural amino acids. Most of the Trojan horse pyoverdine-drugs that have been
developed, have been synthesized by hemisynthesis, i.e starting from chromopeptides
that were extracted from P. aeruginosa culture broth (Mislin and Schalk, 2014), making it
difficult to scale up to an industrial production level. Budzikiewicz and coworkers developed
two pyoverdine drug conjugates from pyoverdine that was isolated from P. aeruginosa
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ATCC 27853 and Pseudomonas fluorescens ATCC 13525 complexed with ampicillin
(PaTSebAmp and Pv9446SebAmp) (Kinzel et al., 1998; Kinzel and Budzikiewicz, 1999).
These pyoverdine-conjugates showed increased levels of antibacterial activity with very
low MIC, compared to ampicillin alone in vitro (Kinzel et al., 1998; Kinzel and Budzikiewicz,
1999). However, to our knowledge, there has been no follow up in vivo. Abdallah and
coworkers developed conjugates from pyoverdine that was extracted from P. aeruginosa
ATCC 15692 and fluoroquinolones (norfloxacin) (Hennard et al., 2001). The conjugates
showed antibacterial activity against E. coli, however when tested against several P.
aeruginosa strains, the compounds failed to exhibit any killing, presumably because the
fluoroquinolone moiety could not cross P. aeruginosa inner membrane (Fluoroquinolones
inhibit bacterial DNA gyrase) (Hennard et al., 2001). This study also highlighted the
complexity that arises from the three different types of pyoverdine, which would restrict
the spectrum of treatable Pseudomonas pathogens. (Mislin and Schalk, 2014).
1.3.4.2 Pyochelin is the second main P. aeruginosa siderophore
P. aeruginosa second main siderophore is pyochelin. Pyochelin is binding Fe3+ with a
lower affinity than pyoverdine (10−28.8 M-2 compared to 10−32 M-1) (Brandel et al., 2012).
The pyochelin molecule is smaller than pyoverdine (Figure 1.11) and the biosynthesis
is less energy-costly than the pyoverdine biosynthesis because it involves fewer steps
and enzymes. Pyochelin biosynthesis occurs in the cytoplasm (Serino et al., 1997). Two
operons, pchDCBA and pchEFGHI, are responsible for pyochelin biosynthesis (Gaille
et al., 2003). The first step involves the modification of the precursor salicylate by two
cytoplasmic enzymes: the isochorismate synthetase PchA (Gaille et al., 2003; Serino et
al., 1995) and the isochorismate pyruvate-lyase PchB (Gaille et al., 2002). The precursor
is then activated by PchD and further assembled by two NRPSs PchE and PchF. The
reduction of the precursor by the reductase PchG forms pyochelin (Figure 1.12) (Gasser
et al., 2015).
Figure 1.11: Pyochelin structure.
The regulatory gene PchR and the operon fptABCX that is responsible for the pyoche-
lin transport, are located next to the operons for pyochelin biosynthesis pchDCBA and
pchEFGHI (Reimmann, 2012). These three operons are repressed by Fur in the presence
of iron and activated by PchR complexed to ferripyochelin and pyochelin itself when
iron is scarce (Reimmann, 2012). The complexe ferripyochelin induces the expression
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Figure 1.12: Pyochelin biosynthesis, transport and regulation.
of pyochelin synthesis and transporters and represses the expression of pchR (Reim-
mann, 2012). FptA is the transporter involved in ferripyochelin transport across the
outer membrane (Ankenbauer and Quan, 1994). Once in the periplasm, the complex
ferripyochelin is transported across the inner membrane via the permease FptX (Cuív
et al., 2004). The mechanisms of the dissociation of the complex in the periplasm and the
secretion/potential recycling of pyochelin are not yet understood (Reimmann, 2012). Like
pyoverdine, pyochelin is able to bind to a wide spectrum of metals: Ag+, Al3+, Cd2+, Co2+,
Cr2+, Cu2+, Eu3+, Ga3+, Hg2+, Mn2+, Ni2+, Pb2+, Sn2+, Tb3+, Tl+, and Zn2+ but its affinity
for iron is the highest (Braud et al., 2009). When iron availability decreases, there is a
switch in P. aeruginosa that goes from pyochelin to pyoverdine production (Dumas et al.,
2013). This switch can also be triggered by changes in temperature and pH (Dumas et al.,
2013).
Pyochelin could be a promising candidate for the Trojan horse strategy because the
molecule is smaller than pyoverdine. Several groups tried to developed pyochelin conju-
gates and failed because of the lack of conjugate solubility under physiological conditions
and hydrolysis problem of the spacer arm in the extracellular medium (Mislin and Schalk,
2014). Furthermore, pyochelin has been shown to cause oxidative damages and inflam-
mation, especially in the presence of the pyocyanin toxin (Britigan et al., 1994). Pyochelin
production was increased in a synthetic CF sputum medium (Hare et al., 2011). However,
a contradictory study measured the concentration of pyochelin in 148 sputum samples
from 36 CF patients and could not detect any pyochelin (Martin et al., 2011). In chronic in-
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fections, such as in CF lungs, the production of pyochelin might contribute to the on-going
inflammatory response which is known to occur and cause damage to tissues (Cornelis
and Dingemans, 2013). Pyochelin is consequently not a good candidate for the Trojan
horse approach.
1.3.4.3 P. aeruginosa produces an endogenous metallophore
Recently, a third endogenous siderophore was reported in P. aeruginosa PAO1 (Gi et
al., 2014). In this study, they found that PA4834 (PA14_63910 in UCBPP-PA14) has
an important role in iron uptake in an artificial lung medium (Gi et al., 2014). PA4834
encodes a putative nicotianamine synthase (Winsor et al., 2016). Nicotianamine is a
metabolite that is essential in the homeostasis of iron, copper, nickel, and zinc (Curie
et al., 2009; Walker and Waters, 2011) in plants. Nicotianamine is the first precursor
of phytosiderophores, a family of molecules that shares functional characteristics with
siderophores (Hell and Stephan, 2003). Nicotianamine was first identified in leaves of
tobacco plants and was found, subsequently, in all naturally occurring plants (Noma et al.,
1971). Nicotianamine is present at varying concentrations, up to 400 µmol g−1 fresh mass
has been reported in growing tissues (Stephan et al., 1996). It forms strong complexes
with heavy metals (Beneš et al., 1983; Callahan et al., 2007; Ghssein et al., 2016; Zhou
et al., 2013), including Fe2+ and Fe3+ (Wirén et al., 1999) (Table 1.3). In the presence
of both Fe2+ and Fe3+, nicotianamine chelates preferentially Fe2+, suggesting that the
complex nicotianamine-Fe2+ is kinetically stable under aerobic conditions (Wirén et al.,
1999). By binding to Fe2+, the complex prevents the cell from oxidative damages (Wirén
et al., 1999).
PA4834 is organized in an operon that includes three other gene members: the two
hypothetical proteins PA4835 and PA4836, and one TBDT transporter PA4837 (respec-
tively PA14_63960) (Winsor et al., 2016). Gi and coworkers showed that the mutant
∆PA4834 exhibited growth defects in artificial lung sputum. These defects in growth were
restored by the addition of 100 µM iron or 100 µM nicotianamine, thus suggesting an iron
scavenging role for nicotianamine (Gi et al., 2014). Another recent study revealed the
presence of biosynthesis and trafficking pathways of a structurally related nicotianamine,
staphylopine, in Staphylococcus aureus (Figure 1.13) (Ghssein et al., 2016). Bioinformatic
analyses revealed that P. aeruginosa nicotianamine operon presents genes for putative
biosynthetic enzymes and transport proteins that are homologous to genes of the cnt
cluster, responsible for staphylopine synthesis (Ghssein et al., 2016; Neumann et al.,
2017). Ghessein and coworkers also confirmed the broad-spectrum of heavy metal
substrates for staphylopine as shown in previous studies (Callahan et al., 2007).
Nicotianamine synthase, the enzyme responsible for the biosynthesis of nicotianamine,
is conserved in P. aeruginosa, but the functions of the others genes present in the
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Figure 1.13: Nicotianamine vs. staphylopine structure.
Ka Ni2+ Zn2+ Fe3+ Fe2+ Cu2+ Co2+
Nicotianamine 16.1 14.7, 15.4 20.6 12.1–12.8 18.6 14.8
Table 1.3: Nicotianamine affinity constant Ka to different metals. Adapted from (Callahan
et al., 2007)
operon, need to be investigated. Applications of nicotianamine in plants and agriculture
have been widely exploited (Jones and Wildermuth, 2011). The molecule serves as an
antihypertensive substance in humans (Hayashi and Kimoto, 2007; Usuda et al., 2009).
Hence, it would be interesting to synthesize nicotianamine-based antibiotic conjugates as
Trojan horse.
1.3.4.4 P. aeruginosa benefits from host iron reservoir
P. aeruginosa can extract heme from hemoproteins via two TBDT-related systems Has and
Phu (Figure 1.14) (Ochsner et al., 2000). UCBPP-PA14 encodes for two other potential
heme uptake systems: HxuC (PA14_47380 ) which is similar to the transporter involved in
hemopexin utilisation of H. influenzae (Cope et al., 1994), and OptI (PA14_64710), which
is annotated as extracellular heme binding protein on UCBPP-PA14 (Winsor et al., 2016).
These last two candidates have not yet been studied in P. aeruginosa.
Pseudomonas heme uptake (Phu) system
The Pseudomonas heme uptake (Phu) system was identified in a screen for iron regulated
genes by Ochsner and coworkers (Ochsner and Vasil, 1996). PhuR is the TBDT that is
responsible for direct heme uptake (Ochsner et al., 2000). PhuS has been described as
the intracellular heme trafficking protein (Kaur et al., 2009). PhuR is negatively regulated
by Fur and phuSTUVW by three regulatory sRNA under the control of Fur (Oglesby-
Sherrouse and Vasil, 2010). Under iron-deficient conditions, heme is directly extracted by
PhuR from hemoglobin, haptoglobin-hemoglobin, hemopexin and myoglobin (Tong and
Guo, 2009).
Heme acquisition system (Has)
P. aeruginosa has an alternative system, which involves the secreted extracellular
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hemophore HasA, which captures free or haemoglobin-bound heme (Létoffé et al., 1999).
The hemophore-heme complex is then shuttled by another specific TBDT HasR (Létoffé
et al., 1999). HasR is able to transport free heme but this transport is less efficient than
the transport of the complexe heme-HasA. Indeed, the hemophore HasA has a higher
affinity for heme (10−11 M) than HasR (10−6 M) (Létoffé et al., 2001; Létoffé et al., 2004;
Tong and Guo, 2009).
Once in the periplasm, heme is bound by PhuT, a periplasmic binding protein (Tong and
Guo, 2007) and is then internalized through the inner membrane by the ATP-dependent
permeases PhuUVW, which transfer heme to PhuS, a cytoplasmic heme-binding protein
(Lansky et al., 2006). Afterwards, heme is delivered to the heme oxygenase HemO, where
it is degraded to form biliverdin, CO, and Fe2+(Cornelis and Dingemans, 2013). PhuR
and HasR might not be redundant, because it was suggested that HasR predominantly
plays a role in sensing heme in the environment, while PhuR achieves the heme uptake
and utilisation (Anzaldi and Skaar, 2010; Smith and Wilks, 2015).
Figure 1.14: Heme transport systems Phu and Has.
There has been research conducted on the use of the so-called non-iron metallopor-
phyrins, e.g. heme-mimetics. Some metalloporphyrins severely impaired the growth of
Gram-positive and Gram-negative pathogenic bacteria such as A. baumannii (Moriwaki
et al., 2011). The porphyrin coupled with gallium showed promising in vitro results, as
the Ga3+ ligand chemistry shares similarity with that of the Fe3+ for the metalloprophyrin
(Moriwaki et al., 2011). The compound inhibited the growth of a range of pathogens
(Stojiljkovic et al., 1999; Moriwaki et al., 2011). The compound is thought to exploit
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the heme uptake pathway of the pathogens, generating reactive oxygen species in the
cell, which lead to toxicity and cell death (Stojiljkovic et al., 1999; Moriwaki et al., 2011).
Few studies have investigated these non-iron metalloporphyrins as drug delivery targets
(Stojiljkovic et al., 1999; Moriwaki et al., 2011).
Following the example of metallo-conjugates, Trojan horse studies have been carried on
heme-mimetics. A recent example of this approach is GaPPIX [i.e., Ga3+ coupled with
the heme precursor protoporphyrin IX (Anzaldi and Skaar, 2010; Hijazi et al., 2017). This
compound showed good antibacterial activity against several bacterial species, including
Staphylococcus aureus and A. baumannii (Hijazi et al., 2017). GaPPIX was shown to
mainly exploit the Phu uptake pathway in order to enter bacterial cells, where it could
then substitute heme in heme-containing enzymes, including cytochromes, catalases,
and peroxidases, therefor resulting in the perturbation of bacterial respiration (Anzaldi
and Skaar, 2010; Hijazi et al., 2017). Clinical strains were sensitive to GaPPIX in vitro
and studies on human cell lines showed no cytotoxicity (Hijazi et al., 2017). In vivo
investigation should be carried out in order to conclude on the efficacy of this approach.
1.3.4.5 P. aeruginosa is involved in siderophore piracy
P. aeruginosa is able to utilize siderophores that are produced by other micro-organisms,
called the xenosiderophores (Cornelis and Dingemans, 2013). This siderophore piracy
confers to the pathogen a fitness advantage over its competitors in the environment (Luján
et al., 2015). P. aeruginosa saves the biosynthesis cost of producing siderophores and it
deprives its competitors from their iron source (Luján et al., 2015). P. aeruginosa metabolic
diversity allows the pathogen to colonize a wide range of niches with dynamic microbial
diversity. Consequently, the xenosiderophores play an important role in its iron acquisition
(Cornelis and Dingemans, 2013). Twelve transporters have been described in UCBPP-
PA14 (directly or inferred from homology) to transport xenosiderophore (Table 1.2).
Most of the TBDTs, including FepA, PiuA, PirA and BfrG, that are involved in xenosiderophore
uptake, have been studied in vitro, as part of the predicted translocation pathways for drug
transport using the Trojan horse approach (Köhler et al., in prep). Catecholates are among
the most common iron-chelating compounds used in synthetic siderophore-antibiotic con-
jugates (Gasser et al., 2016). Several studies have reported in vitro antibacterial activity
of the catechol-antibiotic conjugates, showing lower MIC than the antibiotic alone (Ghosh
and Miller, 1996; Poras et al., 1998; Heinisch et al., 2002; Ji et al., 2012; Fardeau et al.,
2014; Paulen et al., 2015; Gasser et al., 2016; Nairn et al., 2017). These studies reported
also that the antibacterial activity was measured under iron-deficient conditions, highlight-
ing the crucial role of xenosiderophore TBDTs in the uptake of the conjugates, particularly
of the enterobactin-related pathways such as PiuA and PirA. Enterobactin, produced by
E. coli is the tricatechol siderophore with the highest affinity for iron 1052 M-1 (Raymond
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et al., 2003). This value is even larger than pyoverdine 1032 M-1 or the strong synthetic
metal chelator EDTA (1025 M-1) (Walsh et al., 1990). For most of these conjugates, potent
in vivo antibacterial activity needs to be demonstrated.
Another interesting alternative that was proposed is the use of metallo-complex to increase
toxicity in bacteria. In this approach, metal properties are exploited instead of antibiotics
(Banin et al., 2008). Banin and coworkers attempted to replace Fe3+ by Ga3+ in the
ferriferrioxmine B siderophore, because Ga3+ shares similar properties with Fe3+ and could
interfere with iron metabolism. The galliferrioxamine complex acts by a “push and pull”
mechanism, releasing gallium in the cell and immediately sequestering iron at iron binding
sites of proteins (Banin et al., 2008). This compound showed inhibition of P. aeruginosa
growth and decrease in biofilm formation in vitro (Banin et al., 2008). In vivo applications
were not successful because the gallium complex seemed to reduce formation of reactive
oxygen species in P. aeruginosa, therefor contributing to the expansion of the infection
(Banin et al., 2008).
1.4 Motivation and problem statement
1.4.1 Failures of the Trojan horse approach
Hurdles associated with the development of new drugs arise from the remarkable versa-
tility of P. aeruginosa. Numerous siderophore-antibiotic conjugates based on the Trojan
horse strategy have been developed for over 50 years by both pharmaceutical indus-
tries and academics (Page, 2013; Mislin and Schalk, 2014). These past five years, five
promising siderophore-antibiotics conjugates were developed by different pharmaceutical
companies: the siderophore-conjugated monocarbam MC-1 (McPherson et al., 2012a)
and the siderophore-conjugated monobactam MB-1 (Tomaras et al., 2013) by Pfizer, the
siderophore monosulfactam BAL30072 by Basilea Pharmaceutica (Livermore, 2009), the
siderophore-conjugated monocarbam SMC-3176 by AstraZeneca (Kim et al., 2015a) and
the catechol-substituted siderophore cephalosporin S-649266 (Cefiderocol) by Shionogi
Pharmaceuticals (Kohira et al., 2016) (Figure 1.15). Out of these five conjugates, only
S-649266 and BAL30072 conjugates reached clinical trials (Tillotson, 2016). However,
Basilea Pharmaceutica recently announced that BAL30072 development program has
terminated (Basilea reports 2016 half-year results).
The four conjugates (MC-1, MB-1, SM-3176 and BAL30072) exhibited high in vitro
antibacterial activity measured by MIC changes for various clinical strains (McPherson
et al., 2012a; Tomaras et al., 2013; Kim et al., 2015a; Tillotson, 2016). The antibacterial
activity of the conjugates was increased under iron-deficient conditions, therefore MIC
studies were determined on iron-deficient media such as chelated MHB with subsequent
addition of essential non-iron metals (McPherson et al., 2012a; Tomaras et al., 2013; Kim
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Figure 1.15: Synthetic siderophore-drug conjugates. Molecular structures of the
siderophore-conjugated monocarbam MC-1 (McPherson et al., 2012a) and
the siderophore-conjugated monobactam MB-1 (Tomaras et al., 2013) by
Pfizer, the siderophore monosulfactam BAL30072 by Basilea Pharmaceutica
(Livermore, 2009; Page et al., 2010), the siderophore-conjugated mono-
carbam SMC-3176 by AstraZeneca (Kim et al., 2015a) and the catechol-
substituted siderophore cephalosporin S-649266 (Cefiderocol) by Shionogi
Pharmaceuticals (Kohira et al., 2016).
et al., 2015a; Tillotson, 2016). These studies also highlighted that the susceptibility of P.
aeruginosa (and A. baumannii for BAL30072) is mediated through PiuA and alternatively
PirA (to a lesser extent) which is not surprising because of the chemical similarities of
the four conjugates (McPherson et al., 2012a; Tomaras et al., 2013; Kim et al., 2015a;
Tillotson, 2016). Despite these encouraging in vitro results, the different studies exposed
a lack of correlation between in vitro MIC measurements and in vivo antibacterial efficacy
of the conjugates using neutropenic and septicemia mouse models (McPherson et al.,
2012a; Tomaras et al., 2013; Kim et al., 2015a). In the case of BAL30072, in vivo data
supported part of the in vitro antibacterial activity in A. baumannii (Moynié et al., 2017). It
was reported that the in vitro conditions were not predictive of the in vivo efficacy of the
conjugates against multiple strains of P. aeruginosa (McPherson et al., 2012a; Tomaras
et al., 2013; Kim et al., 2015a). Native siderophores such as pyoverdine or enterobactin
could attenuate the antibacterial efficacy by competing with the conjugates for iron. It
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was thus proposed to inactivate the biosynthesis of these siderophores in order to avoid
potentially adaptation-based resistance mechanism to conjugates (Kim et al., 2015a).
However, despite the development of new in vitro assays, none of the four conjugates
reached clinical trials (McPherson et al., 2012a; Tomaras et al., 2013; Kim et al., 2015a;
Tillotson, 2016).
In contrast, S-649266 has demonstrated potent in vitro and in vivo activity against
carbapenemase-producing MDR isolates (Ito et al., 2016; Kohira et al., 2016). S-649266
is also thought to exploit the bacterial iron active transport (Ito et al., 2016; Kohira et al.,
2016). However, the transporter involved in the translocation of the drug has not yet been
identified but PiuA, PirA and PfeA are suspected to transport this compound (Ito et al.,
2016; Kohira et al., 2016).
1.4 Motivation and problem statement 33
1.4.2 Problem Statement
Extensive research has been done on the development of new classes of antibiotics that
could target surface exposed proteins. The Trojan horse approach, targeting the bacterial
active transporters, seems to be a propitious approach to increase the antibiotics uptake
in the bacteria. However, the recent failures of the Trojan horse approach highlighted two
main issues:
(i) the gap of knowledge on P. aeruginosa physiology in vivo. In order to prevent
the rapid development of resistance, we need to have a broader understanding
of how porins are modulated according to their environment. Therefore, a better
understanding of bacterial transport specificities and of its importance in infected
hosts should guide a rational drug design for novel therapeutic approach to eradicate
P. aeruginosa.
(ii) the lack of correlation between in vitro and in vivo. We need better in vitro
conditions that can mimic in vivo situations for further conjugate developments in
order to prevent the attenuation of conjugates efficacy in vivo and the development
of resistance.
1.4.3 Goals of my PhD
This PhD project was part of the Translocation project, an Innovative Medicines Ini-
tiatives (IMI) antimicrobial resistance (AMR) program called New Drugs for Bad Bugs
(ND4BB). Translocation aims to increase the overall understanding of antibiotics translo-
cation and efflux mechanisms in multi-resistant Gram-negative bacteria such as the
ESKAPE pathogens (Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumo-
niae, Acinetobacter baumannii, Pseudomonas aeruginosa, and Enterobacter species).
This PhD project aims to strengthen the knowledge on porins expression and functions
during infection, with a main focus on TonB-Dependent Transporters (TBDTs). Under-
standing the contribution of porins during infection could bring insights on P. aeruginosa
physiology in vivo and could establish a basis for the development of rational therapeutic
options. To achieve the aim of my PhD, I addressed three specific questions:
1. Which TonB-dependent transporters are expressed in vivo, i.e. in different animal
models and human patients?
2. Which TonB-dependent transporters are essential for P. aeruginosa in vivo fitness?
3. What could be the implications of my results for the Trojan horse approach and the
development of future specific siderophore conjugates?
To accomplish this aim, we combined (i) ultrasensitive quantitative methods to determine
the absolute in vivo expression of Pseudomonas aeruginosa TBDTs in different hosts; and
(ii) competitive infections to assess individual TBDT mutant fitness against the wild-type,
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allowing for a better representation of the disease dynamic and the emergence of the
resistant clones.
1.5 Thesis Structure
This thesis is written in cumulative form. It includes a general introduction to introduce the
goals of my thesis, followed by a paper in preparation on my main project, and additional
papers to which I contributed: one paper in preparation, one submitted paper and two
published papers. The results are further discussed and brought into perspectives at the
end of the thesis.
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Part II
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State of the paper: Manuscript in preparation
2.1 Abstract of the paper
Poor compound penetration into bacteria is a key challenge for developing novel antibiotics.
The most advanced strategy to overcome this challenge exploits bacterial active uptake
of chelated iron, by coupling substrate analogs to bacterial inhibitors (“Trojan horse”
antimicrobials). However, incomplete understanding of bacterial iron transport in infected
tissues hampers further development. Here, we used ultra sensitive mass spectrometry
and extensive mutagenesis to comprehensively determine in vivo absolute abundance
and function of iron transporters of two key pathogens, Pseudomonas aeruginosa and
Acinetobacter baumannii. This analysis revealed similar P. aeruginosa iron transporter
patterns during pneumonia in human patients and rodent models, but clear discrepancies
to common in vitro conditions. Both pathogens primarily scavenged iron with endogenous
siderophores, but also expressed transporters for many other substrates including current
drug candidates. However, a P. aeruginosa mutant lacking 25 such transporters retained
wild-type in vivo fitness suggesting resistance risks. Together, the data reveal opportunities
and challenges for rational development of effectively penetrating antimicrobials, and
establish a reverse paradigm for antimicrobial development that starts with pathogen
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properties in human patients, validates animal infection models, and then uses these data
to establish suitable in vivo-like screening conditions.
2.2 Statement of my work
• Design of all the experiments;
• Development of the mutagenesis protocol that allows the generation of markerless
deletions in UCBPP-PA14;
• In vitro growth in different media;
• Development of the targeted proteomic methods (SRM mainly done by Dr. Christian
Schleberger and the PCF): Contribution in the peptides panel creation and set-up
of the PRM assay (together with Dr. Sandra Söderholm and the PCF);
• Proteomic sample preparation and data analysis;
• Development of an optimized intranasal model for UCBPP-PA14;
• Animal experimentation and data analysis.
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 Abstract 
Poor compound penetration into bacteria is a key challenge for developing novel antibiotics. 
The most advanced strategy to overcome this challenge exploits bacterial active uptake of 
chelated iron, by coupling substrate analogs to bacterial inhibitors (“Trojan horse” 
antimicrobials). However, incomplete understanding of bacterial iron transport in infected 
tissues hampers further development. Here, we used ultrasensitive mass spectrometry and 
extensive mutagenesis to determine in vivo absolute abundance and fitness contribution of 
iron transporters of two key pathogens, Pseudomonas aeruginosa and Acinetobacter 
baumannii. This analysis revealed similar P. aeruginosa iron transporter capabilities during 
pneumonia in human patients and rodent pneumonia models, but clear discrepancies to 
common in vitro conditions. Both pathogens primarily scavenged iron with endogenous 
siderophores, but also expressed transporters for many other substrates including current 
drug candidates. However, a P. aeruginosa mutant lacking 25 such transporters retained wild-
type fitness in vivo suggesting resistance risks. Together, the data reveal opportunities and 
challenges for rational development of effectively penetrating antimicrobials, and establish a 
reverse paradigm for antimicrobial development that starts with pathogen properties in human 
patients, and uses this to benchmark pre-clinical animal infection models and to establish 
suitable in vitro assay conditions. 
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 Multi-drug resistant pathogens are a major threat to human health worldwide 1. Novel drugs 
are urgently required, but their development has been difficult, especially for Gram-negative 
bacteria 2. These bacteria have outer membranes with low permeability, which hampers 
access of many inhibitors to their intracellular targets. On the other hand, Gram-negative 
bacteria actively transport nutrients such as iron siderophore complexes across the outer 
membrane using TonB-dependent transporters (TBDTs). Natural and synthetic siderophore 
analogs that are conjugated to antimicrobials can hijack these TBDTs, thereby boosting 
antimicrobial translocation and efficacy (‘Trojan horse’ strategy) 3,4. Based on extensive efforts 
in pharmaceutical companies and academia, two conjugate drug candidates have already 
entered human clinical trials making this the most advanced strategy to overcome the crucial 
outer membrane permeability barrier 2. However, conjugate efficacy depends on the 
respective TBDT abundance, and differential TBDT expression can cause inconsistencies 
between drug activities in vitro and in animal infection models 5-7. TBDT patterns might deviate 
even more in human patients due to difference in host genetics and siderophore-producing 
microbiota, which could put the whole strategy at risk. Yet a systematic characterization of iron 
transport of key pathogens in infected host tissues is currently lacking.  
As part of the Innovative Medicines Initiative project ND4BB-TRANSLOCATION, we 
focus on two pathogens with largely impermeable outer membranes, Acinetobacter baumannii 
and Pseudomonas aeruginosa, which WHO ranked first and second among the twelve 
bacteria that pose the greatest antimicrobial resistance threat to human health 8.  These 
pathogens encode a large diversity of TBDTs, most of which are involved in iron uptake 
(Pseudomonas aeruginosa 35 TBDTs, Acinetobacter baumannii 22 TBDTs; Tab. S1, S2). 
Almost all P. aeruginosa TBDTs are highly conserved among completely sequenced diverse 
clinical isolates (Tab. S1) suggesting that each of them confers fitness advantages in some 
relevant environments. However, in a particular mammalian host tissue probably only a TBDT 
subset is expressed 9, and this subset will determine if a specific Trojan horse antimicrobial is 
effectively transported. Analysis of bacterial gene expression in infected host tissues is 
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 challenging because of low numbers of bacteria (often 106 cells/ml or less) in a large excess 
of host proteins 10. To address these issues, we established ultrasensitive methods to 
determine absolute in vivo quantities of all potentially relevant TBDTs in P. aeruginosa and A. 
baumannii, using parallel reaction monitoring (PRM) on a high resolution and accurate mass 
instrument 11 (Fig. 1A; Tables S1, S2). We achieved attomole sensitivity indicating that in a 
sample containing 105 P. aeruginosa or A. baumannii cells, we could detect and quantify 
TBDTs that were present at only 10-50 molecules per cell, even in highly complex human 
sputum samples with an estimated 1millionfold excess of host proteins (Fig. 1A). We used 
these methods to quantify P. aeruginosa TBDTs in various samples directly taken from acutely 
infected human patients (urine, tracheal/broncheal secretions, bronchioalveolar lavage, 
sputum) (Fig. 1B).  
P. aeruginosa in urine from patients with urinary tract infections (UTI) had largely 
homogeneous TBDT patterns indicating that differences in host and P. aeruginosa genetics, 
or individual bladder microbiota, had limited impact on this aspect of P. aeruginosa physiology. 
P. aeruginosa expressed transporters for its endogenous siderophores pyoverdine 
(FpvA/FpvB, our methods detected FpvA I but not variants FpvA II and FpvA III that are 
present in many clinical isolates 12) and pyochelin (FptA), as well as heme (especially PhuR, 
but also HasR and HxuC). P. aeruginosa had low and variable levels of transporters for 
siderophores produced by other microbes (“xenosiderophores”), and commonly expressed 
the ferri-citrate transporter FecA consistent with high citrate content of urine in most patients 
13. Besides these iron transporters, P. aeruginosa had moderate levels of the putative copper 
transporter OprC 14, but no detectable zinc transporter ZnuD although zinc might be limiting 
for other UTI pathogens 15. A recent proteome study of P. aeruginosa biofilms on urine 
catheters from three patients also detected the endogeneous siderophore receptors FpvA, 
FpvB, and FptA, the heme receptors PhuR, HasR, the citrate transporter FecA, and the 
putative copper transporter OprC, while ZnuD were undetectable 16. Although absolute 
transporter abundances were not determined, these data were generally consistent with our 
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 findings, supporting rather homogeneous P. aeruginosa iron transport capabilities during UTI 
in human patients. 
Acute pneumonia is a major indication for current antimicrobial development against 
Gram-negative bacterial pathogens. Compared to UTI samples, lung secretions are much 
more challenging for P. aeruginosa analysis because of the typically low bacterial loads during 
acute infection (in contrast to chronic infection in cystic fibrosis patients) combined with a very 
large excess of host material. As a consequence, no data have been available for TBDT 
expression, and even in cystic fibrosis patients only very few TBDT transcripts could be 
detected 17,18. We found that ultrasensitive PRM methods could partially overcome this issue, 
at least for samples containing more than about 100’000 P. aeruginosa CFU per ml of 
secretion. Altogether, we could obtain seven such samples from acute pneumonia patients in 
two hospitals in Switzerland and Germany, respectively. The data revealed largely consistent 
TBDT patterns indicating that differences in host and P. aeruginosa genetics 19,20, or individual 
airway microbiota 21, had limited impact on this aspect of P. aeruginosa physiology. In lung P. 
aeruginosa expressed transporters for its endogenous siderophores pyoverdine (FpvB, the 
lack of FpvA I might be due to expression of variants FpvA II or III) and pyochelin (FptA), and 
in contrast to UTI, especially the mucin-inducible transporter OptC for the recently discovered 
third endogenous siderophore nicotianamine 22. P. aeruginosa had substantial levels of the 
heme transporter PhuR, and mostly low and variable numbers of transporter molecules for 
siderophores produce by other microbes (‘xensiderophores’), but not FecA in contrast to UTI. 
Besides these iron uptake systems, P. aeruginosa had moderate levels of the putative copper 
transporter OprC 14 and, again in contrast to UTI, high levels of the zinc transporter ZnuD 
consistent with zinc starvation 23. Together, the UTI and pneumonia data showed largely 
homogeneous, but tissue-specific P. aeruginosa TBDT patterns in human patients. 
For antimicrobial development, efficacy testing of drug candidates in pre-clinical animal 
infection models (usually rodent hosts) is mandatory prior to proceeding to human clinical 
trials. However, it has been unclear if rodent hosts are appropriate for testing Trojan horse 
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 antibiotics, which would require similar P. aeruginosa iron transport capabilities as in humans 
in spite of differences in innate immunity and airway microbiota 24 that might compete with P. 
aeruginosa for heavy metal uptake. To address this issue, we determined TBDT patterns of 
the virulent strain P. aeruginosa UCBPP-PA14 25 in three different rodent infection models 
(mouse/rat intratracheal instillation 26; mouse septicemia 27) with demonstrated predictive 
power for standard antibiotics. Both rodent pneumonia models showed good overall 
agreement with TBDT patterns in human pneumonia, while reproducing differences to human 
UTI (high OptC and ZnuD, but low FecA). By contrast, blood samples from the septicemia 
model showed generally lower TBDT levels and particularly less abundant transporters for 
endogenous siderophores, heme, and zinc, possibly reflecting higher heavy metal availability 
in this model. These animal model data suggest rather homogeneous, but lung-specific P. 
aeruginosa heavy metal physiology across different host species irrespective of host and P. 
aeruginosa genetics or competing airway microbiota, and support the use of rodent 
pneumonia models for efficacy testing of Trojan horse antibiotics.  
In contrast, commonly used in vitro conditions poorly reproduced TBDT patterns in 
human pneumonia or UTI (Fig. 1B). In iron-replete media, all TBDTs had rather low levels as 
expected. At low iron levels in CAA and chelexed CAA media many xenosiderophore 
transporter and particularly the potentially quorum sensing-associated 28 TBDT OptF were 
abnormally high, while TBDTs with substantial in vivo levels such as the dominant endogenous 
siderophore transporter OptC and the zinc transporter ZnuD were still poorly expressed. 
Human serum resulted in a TBDT pattern with similarities to P. aeruginosa in blood in the 
mouse septicemia model. Together, these data suggested that slightly increasing iron 
concentration in CAA, scavenging of zinc, addition of mucus for OptC induction 22, and 
lowering P. aeruginosa densities, might result in a medium more closely mimicking relevant 
conditions during human (and rodent) pneumonia.  
The discrepancies between in vitro and in vivo TBDT patterns also suggest an 
important change to current methods for drug efficacy testing in animal infection models. In 
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 such experiments, all Trojan horse candidates are administered already 1 to 2 hours post 
infection 5-7,29. TBDTs turnover strictly depends on bacterial growth and at least two divisions 
are required to deplete previously present TBDTs in at least half of the daughter cells 30. P. 
aeruginosa TBDT patterns early after infection will thus largely reflect the in vitro conditions 
that were used to grow the P. aeruginosa inoculum, instead of the quite different, but more 
relevant (and often less favorable) TBDT patterns that appear after the pathogen has fully 
adapted to the new in vivo conditions. Early drug administration thus exploits partially in vitro 
TBDT patterns and is not a realistic test for real in vivo efficacy, and should therefore be 
avoided in future studies. 
We also determined A. baumannii ATCC-19606 TBDT levels in the rodent pneumonia 
models that appeared to mimic human pneumonia based on our P. aeruginosa data (Fig. 2). 
A. baumannii expressed particularly transporters for its endogenous siderophores 
baumannoferrin (BfnH and possibly A1S_1667 encoded in close vicinity to the baumannoferrin 
gene cluster) and acinetobactin (BauA). In addition, multiple TBDTs for xenosiderophores 
were consistently expressed, often with higher levels in the rat model. The zinc transporter 
ZnuD had also high abundance, again consistent with zinc starvation in lung. In contrast to P. 
aeruginosa, heme transport capabilities were low based on poor A1S_1606 expression 
(A1S_1607 has been annotated as another heme-TBDT but its protein sequence is too short 
for a functional TBDT). Again, various in vitro media poorly reproduced A. baumannii in vivo 
TBDT patterns. Baseline conditions resulted in poor BauA expression, whereas iron depletion 
led to exaggerated TBDT abundances. Fine tuning of iron concentration and zinc scavenging 
in Iso-Sensitest broth at low A. baumannii densities, might enable more closely mimicking 
relevant in vivo conditions. 
Our data suggested in vivo presence of several TBDTs that might be exploitable for 
Trojan horse strategies. However, mutational inactivation of a specific TBDT can rapidly lead 
to resistance development 31, unless TBDT loss is associated with a fitness disadvantage, or 
multiple co-expressed TBDTs transport the same compound. Previous studies found a 
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 moderate, but consistent in vivo fitness defect in P. aeruginosa strains incapable of using 
pyoverdine 32-35, while data for heme uptake are contradicting 18,34,36. Individual studies 
reported large fitness contributions of nicotianamine transporter OptC 22, the 
ferrichrome/ferioxamine transporter FiuA 37, and the zinc transporter ZnuD 18, but these have 
not yet been confirmed. To comprehensively determine in vivo fitness contributions of 
potentially redundant TBDTs, we generated a series of strains lacking single, or up to 25 
different TBDT genes in the virulent strain P. aeruginosa UCBPP-PA14 (Fig. 3A). We tested 
these strains for in vivo fitness in an acute intranasal mouse pneumonia model (Fig. 3B). In 
contrast to previous studies, which all employed single-strain infections, we used mixed 
infections to assess mutant fitness in presence of competing wild-type, a scenario more 
closely mimicking emergence of resistant clones among wild-type bacteria. Under these 
conditions deletion of fpvA (strain “1”), but not the alternative pyoverdine TBDT gene fpvB 
(“2”), resulted in a significant fitness drop. A fpvA fpvB double mutant (“3”) showed no 
synergism arguing against an in vivo backup function of FpvB for pyoverdine uptake, 
consistent with low FpvB levels in rodent pneumonia (Fig. 1B). Additional inactivation of 
pyoverdine biosynthesis by deleting pvdA (“4”) ameliorated the fitness defect, which could 
reflect saving of futile biosynthesis costs and/or less local iron deprivation by its own ferri-
pyoverdine complexes (which the uptake mutant (“3”) generates but cannot scavenge). In 
contrast to pyoverdine, inactivation of uptake of pyochelin (“5”), or both uptake and synthesis 
of pyochelin (“6”), or uptake and synthesis of the nicotianamine-related compound (“8”) did 
not decrease in vivo fitness in our model, partially in agreement with previous observations 
33,34. However, simultaneous inactivation of uptake and synthesis of all three endogeneous 
siderophores (“9”) diminished in vivo fitness to levels below the pyoverdine-defective mutant 
(“4”). Additional deletion of feoB encoding an inner membrane transporter for ferrous iron 
(“10”), or another putative siderophore biosynthesis cluster present in a few P. aeruginosa 
strains including UCBPP-PA14 (“11”), had no further fitness effect. These data confirm the 
primary importance of pyoverdine, and partial compensation by pyochelin 33,34 and/or 
nicotianamine. To determine the fitness contributions of other in vivo expressed TBDTs, we 
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 deleted nine additional genes (“11”) but this did also not result in further fitness defects 
indicating that these TBDTs were unable to compensate for blocked utilization of endogenous 
siderophores. Finally, we constructed a P. aeruginosa strain lacking 25 different TBDT genes 
(but still carrying functional TBDTs for the endogenous siderophores) (“12”). This strain had 
wild-type in vivo fitness, indicating dispensability of transporters for heme and 
xenosiderophores, at least in this in pneumonia model. Together, these data suggested that 
P. aeruginosa primarily used its high-affinity siderophore pyoverdine for iron scavenging, 
whereas uptake capabilities for its other endogenous siderophores, xenosiderophores, heme-
associated substrates and possibly copper and zinc uptake were all dispensable for in vivo 
fitness in our acute pneumonia model. Low fitness contributions of xenosiderophore receptors 
might reflect limited delivery of microbiota-produced siderophores to P. aeruginosa infection 
foci in the lung.  
The only available data for A. baumannii 38 indicate that inactivation of the TBDT BauA 
specific for the endogenous siderophore acinetobactin, decreased in vivo fitness in strain 
ATCC-19606 (which is defective for biosynthesis of the other, possibly more potent 
endogenous siderophore baumannoferrin 39).  These data suggest that A. baumannii ATCC-
19606 cannot compensate blocked uptake of endogenous siderophores using its abundantly 
expressed ferri-xenosiderophore TBDTs (Fig. 2, data shown were obtained with the same 
strain) suggesting at most supportive roles for these TBDTs. 
The in vivo expression and fitness data could provide a rational basis to guide further 
development of Trojan horse antibiotics for treating Pseudomonas and Acinetobacter 
infections (Fig. 4; Supplemental Text). Xenosiderophore TBDTs are especially attractive for 
the Trojan horse strategy because of the extended pathogen spectrum compared to species-
specific siderophores. Indeed, all four most advanced siderophore conjugates exploit P. 
aeruginosa TBDTs PirA, PiuA (or its paralog PiuD), and BfrG (also called OptJ; Köhler et al. 
in prep.), or A. baumannii TBDTs PirA and PiuA 40. P. aeruginosa all three relevant TBDTs 
had rather low abundance compared to other TBDTs in human patients and rodent infection 
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 models, and this might in part explain the variable in vivo efficacy of these compounds 5,6. 
Siderophores can induce the expression of their transporters 41, and this is also true for PirA 
induction by the advanced drug candidate BAL30072 (Köhler et al., in prep.). However, 
induction ratios are typically moderate (less than 10fold), and this does not always 
substantially increase susceptibility (e.g., PirA-dependent activity of BAL30072 is still weak 
42).  
P. aeruginosa expresses at least two or all three TBDTs PiuA, PirA, and BfrG in all 
tested common in vitro conditions including cation-adjusted Müller Hinton broth (MHB), the 
favored medium for antimicrobial testing and development. This homogeneous expression 
might contribute to the promising activity and slow resistance development in vitro 42 (and in 
vivo efficacy when administrating drug candidates early after infection, see above). Pathogens 
often encounter severe iron starvation in mammalian tissues 43, but common methods for iron 
depletion to mimic such conditions in vitro lead to overshooting P. aeruginosa TBDT 
abundances well above levels observed in vivo (Fig. 1B). Under such condition, all three 
crucial TBDTs PiuA, PirA, and BfrG are present in levels of at least a few hundred molecules, 
which could explain the increased activity of drug candidates 7,44. However, these attractive 
properties might not always translate to in vivo conditions where P. aeruginosa often 
expresses only one, and sometimes none, of these TBDTs at detectable levels.  
In contrast to P. aeruginosa, A. baumannii consistently expressed low to moderate 
levels of both PirA and PiuA in the rat model (and low but consistent levels in the mouse 
model), suggesting a potentially more reliable efficacy of these compounds against A. 
baumannii. Again, iron-depleted in vitro conditions might be exaggerating drug efficacy due to 
untypically high PiuA and PirA levels.  
Both P. aeruginosa and A. baumannii expressed additional xenosiderophore TBDTs 
but except for the A. baumannii receptors A1S_1725 and A1S_3339 with unknown ferri-
siderophore substrates, abundance levels of these TBDTs were rather variable. 
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 TBDT expression and fitness contributions would favor employment of endogenous 
siderophores that are required for in vivo fitness such as pyoverdine, baumannoferrin and 
acinetopbactin, but challenging chemistry and small potential spectrum would limit their utility. 
All other substrates for P. aeruginosa showed a risk for facile resistance development. Either 
only a single specific TBDT with no detectable fitness contribution transports such a substrate; 
or multiple TBDTs could transport the same substrate, but their low-level, scattered expression 
and low fitness contribution fail to provide robust redundancy for preventing resistance 
development. Based on these considerations, no TBDT substrate appeared to pass stringent 
suitability criteria as a basis for mono-therapy against P. aeruginosa. However, Trojan horse 
conjugates to heme analogs targeting PhuR, respectively, might be suitable for combination 
therapy with another antimicrobial (as previously proposed for BAL30072 29). If both small 
spectrum and combination therapy would be acceptable, pyochelin and nicotianamine 
transporters FptA and OptC could also be attractive choices.  
All these considerations were based on our data for acute infections. The issue is even 
more complex for chronic Pseudomonas infections in cystic fibrosis patients in which TBDT 
diversifies and changes over time 45-47. In contrast to these challenging conditions in P. 
aeruginosa, current advanced compounds exploiting A. baumannii PirA and PiuA appear to 
target already the most suitable TBDT targets in this pathogen.  
In conclusion, comprehensive in vivo analysis of TBDT abundance and fitness 
contributions provides a rational basis to prioritize specific strategies for implementing the 
Trojan horse approach. More generally, our study shows how current antimicrobial 
development paradigms that optimize drug candidates under in vitro conditions and in animal 
infection models with unknown relevance for conditions in human patients, might cause 
subsequent failures. Instead, we propose a reverse paradigm for antimicrobial development 
that first determines relevant pathogen properties in human patients, uses these data as 
benchmark to validate and improve testing methods in animal infection models, and then 
employs in vitro assay conditions that most closely reproduce the relevant pathogen in vivo 
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 properties. Ultrasensitive, high-resolution direct analysis of infected patient material as used 
in this study, might pave the way for broad application of this reverse paradigm to better control 
human infections.  
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 Methods  
 
Bacterial strains, growth conditions, and mutagenesis 
For all animal infections and in vitro work with Pseudomonas aeruginosa, we used strain 
UBCPP-PA14 25. P. aeruginosa was routinely grown on lysogeny broth (Lennox-LB) or cation-
adjusted Müller-Hinton broth. Clean gene deletions were generated by two-step allelic 
exchange using gentamicin and sucrose for positive and negative selection respectively 48, 
and confirmed by sequencing. Strains with multiple deletions were confirmed for all atered loci 
using PCR.  
For all animal infections and in vitro work with Acinetobacter baumannii, we used strain 
ATCC 19606 49. This strain was routinely grown on cation-adjusted Müller-Hinton broth. 
  
Human samples 
Urine, sputum, tracheal secretions, and bronchioalveolar lavage samples from infected 
patients were obtained from material obtained for medical microbiology diagnostics. All 
samples were anonymized and freshly processed upon arrival at the in-house diagnostic 
laboratory (irrespective of having culture confirmation for P. aeruginosa). Samples not 
containing P. aeruginosa were subsequently discarded.  
 
Animal infection models 
Intratracheal instillation model: specific pathogen free (SPF) immunocompetent male 
Sprague-Dawley rats weighing 100 - 120 g or male CD-1 mice weighing 20 - 25 g were infected 
by depositing an agar bead containing around 107 colony-forming units P. aeruginosa UCBPP-
PA14 or Acinetobacter baumannii ATCC 19606, deep into the lung via nonsurgical 
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 intratracheal intubation 26. At 24 h post infection, animals were sacrificed and lung was 
homogenized in sterile saline using a lab blender. All procedures are in accordance with 
protocols approved by the GSK Institutional Animal Care and Use Committee (IACUC), and 
meet or exceed the standards of the American Association for the Accreditation of Laboratory 
Animal Care (AAALAC), the United States Department of Health and Human Services and all 
local and federal animal welfare laws. 
Septicemia model: male CD-1 mice were infected by intraperitoneal injection of around 105 
colony-forming units P. aeruginosa UCBPP-PA14 in 750 μl 0.9 % NaCl, 3.3% porcine stomach 
mucin (Sigma, M-2378) 27. Animals were observed carefully and euthanized when the surface 
body temperature dropped under 25°C and/or the general health score reached predefined 
termination criteria. The animals were killed with pentobarbital (200 mg/kg) and the blood was 
taken via heart puncture in heparine coated vials. All procedures were approved (license 1927, 
Kantonales Veterinäramt Basel) and performed according to local guidelines (Tierschutz-
Verordnung, Basel) and the Swiss animal protection law (Tierschutz-Gesetz). 
Intranasal model: Female BALB/c mice were exposed to 2.5% isoflurane delivered in O2 (2 
l/min) within a 1 liter induction chamber until a state of areflexia was reached. Mice were then 
removed from the induction chamber and instillation was performed immediately by pipetting 
by pipetting 25 μl of PBS containing 5x106 colony-forming units P. aeruginosa UCBPP-PA14 
from exponentially growing cultures 50 onto the outer edge of each nare of the mice 51. Mice 
were euthanized at 10 h post infection by intraperitoneal injection of 300 μl water containing 6 
mg xylazine and 15 mg ketamine. The lungs were recovered and homogenized in 2 ml PBS 
using a cell strainer. For competitive fitness determination, various mutants were mixed with 
wild-type P. aeruginosa and administrated together. Lungs from sacrificed mice were plated 
on LB plates. Colonies were typed using multiplex PCR. Competitive indices were calculated 
as (outputmutant/outputwild-type)/(inputmutant/inputwild-type). Competitive indices were log-normally 
distributed permitting parametric testing for statistical significance after log-transformation. All 
procedures were approved (license 2746, Kantonales Veterinäramt Basel) and performed 
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 according to local guidelines (Tierschutz-Verordnung, Basel) and the Swiss animal protection 
law (Tierschutz-Gesetz). 
 
Sample workup for proteomics 
The sample workup protocol was optimized to deplete host material while maintaining P. 
aeruginosa viability until lysis. All buffers and equipment were used at 0 to 4°C to minimize 
proteome changes during sample workup. The sample volume (maximum of 1 ml) was 
estimated and an equal volume of 1% Tergitol in PBS was added followed by vigorous 
vortexing for 30 s. After centrifugation at 500xg for 5 min, the supernatant was transferred to 
a fresh tube, and the pellet was extracted again with 2 ml 0.5% Tergitol in PBS. The 
supernatant was combined with the first supernatant and centrifuged at 18’000xg for 5 min. 
The pellet was washed with 2 ml and again centrifuged at 18’000xg for 5 min.  
The supernatant was removed, and the pellet was resuspended in 100 µL 5% sodium 
deoxycholate, 5 mM Tris(2-carboxyethyl)phosphine hydrochloride, 100 mM NH4HCO3. The 
sample was incubated at 90°C for 1 min. and then stored at -80 °C. Samples were thawed 
and sonicated for 2x20 s (1 s interval, 100% power). Proteins were alkylated with 10 mM 
iodoacetamide for 30 min in the dark at room temperature. Samples were diluted with 0.1M 
ammonium bicarbonate solution to a final concentration of 1% sodium deoxycholate before 
digestion with trypsin (Promega) at 37°C overnight (protein to trypsin ratio: 50:1). After 
digestion, the samples were supplemented with TFA to a final concentration of 0.5% and HCl 
to a final concentration of 50 mM. Precipitated sodium deoxycholate was removed by 
centrifugation at 4°C and 14’000 rpm for 15 min. Peptides in the supernatant were desalted 
on C18 reversed phase spin columns according to the manufacturer's instructions (Macrospin, 
Harvard Apparatus), dried under vacuum, and stored at −80°C until further processing. 
 
Parallel reaction monitoring 
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 Heavy proteotypic peptides (JPT Peptide Technologies GmbH) were chemically synthesized 
for P. aeruginosa and A. baumannii TBDTs and P. aeruginosa OprF (Tables S1, S2). Peptides 
were chosen dependent on their highest detection probability and their length ranged between 
7 and 20 amino acids. Heavy proteotypic peptides were spiked into each sample as reference 
peptides at a concentration of 20 fmol of heavy reference peptides per 1 µg of total 
endogenous protein mass. For spectrum library generation, we generated parallel reaction-
monitoring (PRM) assays 11 from a mixture containing 500 fmol of each reference peptide. The 
setup of the μRPLC-MS system was as described previously 52.  Chromatographic separation 
of peptides was carried out using an EASY nano-LC 1000 system (Thermo Fisher Scientific) 
equipped with a heated RP-HPLC column (75 μm x 37 cm) packed in-house with 1.9 μm C18 
resin (Reprosil-AQ Pur, Dr. Maisch). Peptides were separated using a linear gradient ranging 
from 97% solvent A (0.15% formic acid, 2% acetonitrile) and 3% solvent B (98% acetonitrile, 
2% water, 0.15% formic acid) to 30% solvent B over 60 minutes at a flow rate of 200 nl/min. 
Mass spectrometry analysis was performed on Q-Exactive HF mass spectrometer equipped 
with a nanoelectrospray ion source (both Thermo Fisher Scientific). Each MS1 scan was 
followed by high-collision-dissociation (HCD) of the 10 most abundant precursor ions with 
dynamic exclusion for 20 seconds. Total cycle time was approximately 1 s. For MS1, 3e6 ions 
were accumulated in the Orbitrap cell over a maximum time of 100 ms and scanned at a 
resolution of 120,000 FWHM (at 200 m/z). MS2 scans were acquired at a target setting of 1e5 
ions, accumulation time of 50 ms and a resolution of 30,000 FWHM (at 200 m/z). Singly 
charged ions and ions with unassigned charge state were excluded from triggering MS2 
events. The normalized collision energy was set to 35%, the mass isolation window was set 
to 1.1 m/z and one microscan was acquired for each spectrum.  
The acquired raw-files were converted to the mascot generic file (mgf) format using 
the msconvert tool (part of ProteoWizard, version 3.0.4624 (2013-6-3)). Converted files (mgf 
format) were searched by MASCOT (Matrix Sciences) against normal and reverse sequences 
(target decoy strategy) of the UniProt database of Pseudomonas aeruginosa UCBPP-PA14 
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 and 3 additional proteins (PiuD, FpvA II, FpvA III) from other P. aeruginosa, or Acinetobacter 
baumannii strains ATCC 19606 and ATCC 17978, as well as commonly observed 
contaminants. The precursor ion tolerance was set to 20 ppm and fragment ion tolerance was 
set to 0.02 Da. Full tryptic specificity was required (cleavage after lysine or arginine residues 
unless followed by proline), three missed cleavages were allowed, carbamidomethylation of 
cysteins (+57 Da) was set as fixed modification and arginine (+10 Da), lysine (+8 Da) and 
oxidation of methionine (+16 Da) were set as variable modifications.  
 For quantitative PRM experiments the resolution of the orbitrap was set to 30,000 
FWHM (at 200 m/z) and the fill time was set to 50 ms to reach a target value of 1e6 ions . Ion 
isolation window was set to 0.7 Th and the first mass was fixed to 100 Th. Each condition was 
analyzed in biological triplicates.  All raw-files were imported into Spectrodive (Biognosys AG) 
for protein and peptide quantification. To control for variation in injected sample amounts, three 
peptides belonging to the abundant, constitutively expressed protein OprF were also included 
in the quantification and used for normalization using a value of 26’000 copies per cell as 
determined from in vitro cultures under diverse culture conditions. 
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 FIGURE LEGENDS 
 
Figure 1: Detection of P. aeruginosa proteins in patient material, animal infection models, and 
in vitro cultures. A, Detection of two different peptides using parallel reaction monitoring in 
tracheal secretions of a human pneumonia patients. Fragmentation products of endogeneous 
light peptides (upper part) and heavy isotope-labelled internal reference peptide (lower part) 
are shown in the same colors (e.g., fragment y1 in red, etc.). The amounts are calculated 
based on the added heavy peptide concentration (fmol, femtomole; amol, attomole). B, Copy 
numbers for P. aeruginosa TonB-dependent transporters (TBDTs) in various in vivo and in 
vitro conditions. Each column represents an independent sample (MHB, cation-adjusted 
Müller-Hinton broth; LB, lysogeny broth; BM2, BM2 minimal medium; CAA, casamino acid 
minimal medium; chCAA, chelex-treated casamino acid medium; M9, m) minimal medium; 
hSerum, heat-inactivated human serum). Substrate classes are shown on the left (ES, 
endogeneous siderophores; XS, xenosiderophores; H, heme; oM, metals other than iron; un, 
unknown). Among xenosiderophores, known substrate classes are shown on the right 
(Hydroxamat., hydroxamate siderophores). TBDTs that transport advanced Trojan horse 
conjugates are marked with the dashed line. 
 
Figure 2: Copy numbers for A. baumannii TonB-dependent transporters (TBDTs) in various 
in vivo and in vitro conditions. Each column represents an independent sample (MHB, cation-
adjusted Müller-Hinton broth; ZnMgCA, re-adjusted ions after chelex treatment; apoTF, 
addition of apo-Transferrin; ISB, iso-sensitest broth). Substrate classes are shown on the left 
(ES, endogeneous siderophores; XS, xenosiderophores; H, heme; oM, metals other than iron; 
un, unknown). TBDTs that transport advanced Trojan horse conjugates are marked with the 
dashed line. 
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 Figure 3: In vivo fitness contributions of P. aeruginosa TonB-dependent transporters. A, 
Genotype of various P. aeruginosa mutants. Black boxes indicate deleted genes. B, 
Competitive indices of various P. aeruginosa mutants in a mouse pneumonia model. A log10 
value of “0” indicates a wild-type fitness level. Some affected siderophore classes or 
transporters are labelled (NA, nicotianamine). Statistical significance for divergence from wild-
type fitness, or differences between two groups were analyzed using t-test (n.s., P> 0.05; *, 
P< 0.05; **, P< 0.01; ***, P< 0.001).  
 
Figure 4: Predicted suitability of P. aeruginosa TonB-dependent transporters for targeting with 
Trojan horse conjugate antibiotics. Various criteria were analyzed to obtain a final score for 
treatment with a single drug, or using a combination of antimicrobials (red, suitable; yellow, 
partially suitable; white, no-suitable).  
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aeruginosa porins in
nutrient uptake and
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Thomas Bock2, Scott Sucoloski3, Jennifer Hoover3, Josh West3, Klaus Gebhardt4, Mal-
colm Page4, Michael Hogardt5, Dominik Vogt6, Adrian Egli6, Dirk Bumann1
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legeville, PA, USA; 4 Basilea, CH-4056 Basel, Switzerland; 5 University Hospital, Frankfurt,
Germany; 6 University Hospital Basel, CH-4056 Basel, Switzerland
State of the paper: In preparation
3.1 Abstract of the paper
Pseudomonas aeruginosa is a major threat to human health because of its increasing
multi-drug resistance. A major roadblock for development of novel drugs is the poor perme-
ability of the P. aeruginosa outer membrane. Several molecules can actually penetrate this
barrier and this could provide hints for improving drug candidates, but physico-chemical
constraints and underlying molecular mechanisms remain largely unclear. Here, we
determined the expression and function of 40 different P. aeruginosa porins that can
form water-filled channels in the outer membrane. Our proteome analysis revealed that
during infection in human patients and rodent models, P. aeruginosa expressed only
a subset of some 12 porins, that together contributed to P. aeruginosa in vivo fitness.
Another key pathogen with low envelope peremabiltiy, Acinetobacter baumannii, showed
comparable in vivo expression patterns. To determine transport substrates for each porin,
we deleted all 40 porin genes to obtain a porin-free P. aeruginosa ∆40 strain, and then
complemented this strain with single-porin expression constructs. Growth and nutrient
uptake experiments revealed a crucial role of porins for uptake of many but not all nutri-
ents. Several porins had large, overlapping substrate spectra and seemed to discriminate
solutes primarily based on size instead of charge, dipole, or hydrophobicity. Surprisingly,
the porin-free ∆40 strains had unaltered susceptibility against diverse classes of antibi-
73
otics except for the well-known slight OprD-dependency of carbapenems. These data
indicated unexpected porin-independent translocation pathways for diverse antimicrobials.
On the other hand, forced expression of cryptic porins sensitized P. aeruginosa to some
otherwise ineffective antimicrobials such as fosfomycin and aztreonam. Together, these
data challenge key dogmas about a crucial barrier for novel antimicrobials and suggest
new opportunities for overcoming this barrier.
3.2 Statement of my work
• Development of the mutagenesis protocol that allows the generation of markerless
deletions in UCBPP-PA14;
• Development of the targeted proteomic methods (SRM mainly done by Dr. Christian
Schleberger and the PCF): Contribution in the peptides panel creation;
• Overexpression of selected simple porins as inclusion bodies;
• In vivo growth competition assays using septicemia and intranasal models to
evaluate the fitness of selected simple porins mutants. Basilea Pharmaceutica
performed the speticemia infections.
3.3 Theoretical background on targeted proteomics
In order to determine the abundance of porins in preclinical and clinical samples, we
needed a robust technique that overcomes the problem of the background complexity in
our in vivo samples. Most in vivo studies used transcriptomics thanks to the advances
in microarray technologies. Microarrays detect gene expression profiles by measuring
mRNA. However, this approach is subject to some limitations, since there is a poor
correlation between mRNA and protein abundance.
Mass spectrometry has progressively become the method of choice for analysis of
complex protein samples (Aebersold and Mann, 2003). In such approach, proteins are
solubilized, denatured and digested into peptides by trypsin. The peptide mix is then
fractionated and subjected to the mass spectrometric analysis. In the mass spectrometer,
the peptides are ionized into precursor ions, the precursors are subsequently fragmented
by collisional activation and the resulting product-ion mass spectra are recorded and used
to identify the amino acids sequence of the selected peptides by database comparison.
The discovery-based or shotgun mass-spectrometry-based proteomic approach has been
the most widely used method and has generated the vast majority of proteomic data
available today. It measures the most abundant peptides, giving a relative quantification
of proteins depending on the samples. Although shotgun proteomics can achieve high-
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throughput screenings, the limitation of the technique lies in the lack of reproducibility and
sensitivity for complex samples (Domon and Aebersold, 2010). Recent advances in mass
spectrometry instrumentation favoured the use of targeted proteomics over the common
shotgun proteomics.
Selective Monitoring Reaction (SRM), the gold standard of targeted proteomics, allows
a higher reproducibility and sensitivity than shotgun approach and enables absolute
quantification of proteins, by selecting predefined precursors ions and its subsequent
predefined product-ions (also called transition). Recently, the Parallel Monitoring Reaction
(PRM) has been developed thanks to increased advances in high resolution and accurate
mass instruments. PRM is the same as SRM, except that all the product-ions of the
selected precursors are measured, enabling a higher resolution and sensitivity in detection
of trace proteins and discrimination of host proteins background (Domon and Aebersold,
2010; Aebersold and Mann, 2003).
3.4 Identification of simple porins in vivo
GFP-labelled P. aeruginosa were used to infect mice in a septicemia model. After an
infection time of 24 to 48h, the bacteria were purified from the lungs and the blood by
flow cytometry and further analysed by proteomics. To be able to measure quantitative
protein abundance with high sensitivity, mass spectrometry-based proteomics is used. P.
aeruginosa membrane were solubilized with 5% sodium deoxycholate and digested with
trypsin to obtain peptides. The mixture was separated by nano Liquid chromatography
and then analyzed by mass spectrometer. Ion precursors were selected according to
our list of porins of interest for further fragmentation, giving spectra that could then be
compared to a genome database. This results in the proteins identification with their
relative abundance.
The intensities of the porins varied widely, low abundant porins and their peptides could
be easily missed among hundreds of abundant proteins. To target the mass spectrometer
to these low abundant peptides, we over-expressed the respective proteins and measured
their peptides in simple mixtures. We started with the simple porins. In total, we cloned the
9 porins that we had not been able to see in the MS of complex samples and expressed
them in E. coli as inclusion bodies (Figure 3.1). They were then added to the membrane
preparation and analysed as explained. Based on these data, we could clearly identify
the previously undetectable simple porins.
OprF is the most abundant porins of P. aeruginosa. We included this protein in our
experiment because the shotgun analysis could not detect reliable peptides for OprF
identification.
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Figure 3.1: SDS-PAGE of simple porins fraction after inclusion bodies washing.
SDSPAGE (12 %) analysis of fractions after inclusion bodies washing, sol-
ubilization and purification of selected simple porins. M corresponds to the
marker. Lane 1: OprB3; Lane 2: OprF; Lane 3: FadL3; Lane 4: AlgE; Lane 5:
OccD7; Lane 6: OccD8; Lane 7: OccK4; Lane 8: OprO; Lane 9: OprP
3.5 In-silico digestion of proteins for rapid and robust panel
generation
Based on empirical evidences, we then developed an algorithm that performed an in-
silico enzymatic digestion of proteins and a pre-selection of the "best flying" peptides
according to the following criteria: (i) the peptides should be short and the priority is given
to those containing proline residues, because they are better targets for SRM; (ii) three
peptides should be selected per protein to get a reliable quantification and avoid incorrect
detection due to post-translational modifications; (iii) we should avoid targeting peptides
with a high propensity for artifactual modifications, i.e. avoid methionine and glutamate
at the N-terminus; (iv) neighbouring cleavage site (at R or K) should also be avoided;
(v) we selected conserved peptides among different strains to have universal set up but
discriminate against the proteomes of diverses hosts (mouse, rat and human).
In order to set up the targeted proteomic assays, we ordered heavy isotope labelled
peptides from proteins of interest, according to detected peptides from previous shotgun
datasets and in silico digestion. The heavy isotope labelled peptides were then measured
by the mass spectrometer to refine our panel of proteins with the most reliable peptides
for identification. These panels were further used for quantification of our proteins of
interest in various samples.
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3.6 Quantification of simple porins in vivo
The expression level of simple porins was determined in various human patients samples
and in different rodents samples (Figure 3.2). Overall, the data revealed a constant
expression pattern among the different samples with a dominant subset of simple porins,
which included the major porin OprF (Nestorovich et al., 2006; Rawling et al., 1998;
Sugawara et al., 2006), OprD family porins (Ochs et al., 1999b; Ochs et al., 1999a;
Tamber and Hancock, 2006), the cation-selective channel OprG (McPhee et al., 2009;
Touw et al., 2010) and the long-chain fatty acid porin FadL (Hancock and Brinkman,
2002).
Figure 3.2: Expression level of simple porins in human patients and rodent models. Tar-
geted proteomics (SRM) on urine and lavage samples from human patients
that were acutely infected with P. aeruginosa; and lung and blood samples
from rat and mice in pneumonia and septicemia model. The simple porins
are ordered according to their expression in vitro in Mueller-Hinton broth.
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4Limited impact of the eﬄux
on clinical multi-drug
resistance of Escherichia
coli and Pseudomonas
aeruginosa
Olivier Cunrath1∗, Julien Buyck1∗, Dominik Meinel2, Pamela Saint Auguste1, Vincent
Trebosc4, Jonas Körner1, Christoph Dehio1, Christian Kemmer4, Adrian Egli2,3, Dirk
Bumann1
1 Focal Area Infection Biology, Biozentrum; 2 Clinical Microbiology, University Hospital
Basel; 3 Applied Microbiology Research, Department of Biomedicine, University of Basel,
Basel, Switzerland. 4 BioVersys AG, Basel, Switzerland.
∗ These authors contributed equally to the work.
State of the paper: Manuscript submitted to Nature Medicine.
4.1 Abstract
Extensive efforts have been devoted to develop efflux inhibitors for combatting multi-drug
resistant (MDR) bacterial pathogens. However, we show here using a versatile strategy
for genetic inactivation that major efflux systems make only limited contributions to high-
level resistance against old and new antimicrobials in MDR clinical isolates of two key
pathogens causing major threats to human health worldwide, Escherichia coli expressing
extended spectrum β-lactamases (ESBL) and Pseudomonas aeruginosa. Novel control
strategies for MDR pathogens are urgently needed, but efflux inhibition might have limited
impact.
4.2 Statement of my work
Design the original markerless deletion method in Pseudomonas aeruginosa.
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ABSTRACT 
Extensive efforts have been devoted to develop efflux inhibitors for combatting multi-drug resistant 
(MDR) bacterial pathogens. However, we show here using a versatile strategy for genetic 
inactivation that major efflux systems make only limited contributions to high-level resistance 
against old and new antimicrobials in MDR clinical isolates of two key pathogens causing major 
threats to human health worldwide, Escherichia coli expressing extended spectrum β-lactamases 
(ESBL) and Pseudomonas aeruginosa. Novel control strategies for MDR pathogens are urgently 
needed, but efflux inhibition might have limited impact.  
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Multi-drug resistant (MDR) Gram-negative bacterial pathogens represent a major global threat to 
human health. MDR pathogens drive clinical usage of last-resort antibiotics such as carbapenems 
and colistin further amplifying resistance development and emergence of pan-resistant pathogens 
1. As a consequence, deaths attributable to antimicrobial resistance may rise sharply, although 
the global burden of MDR remains difficult to estimate 2. Resistance is multi-factorial but one 
promiscuous mechanism covering diverse antibiotic classes is the expression of so-called 
resistance-nodulation-division (RND) superfamily exporters, which mediate active efflux of small 
molecules including many antibiotics 3-6. In laboratory strains of various Gram-negative bacterial 
pathogens, upregulation of RND efflux systems increases resistance to diverse antibiotics, while 
genetic inactivation of such systems renders mutants hypersensitive. Over-expression of RND 
efflux systems is observed in many multi-drug resistant (MDR) clinical isolates suggesting that 
efflux might be involved in increasing resistance 7. Based on these observations, academia and 
industry have devoted major efforts to develop efflux inhibitors, hoping that such inhibitors could 
broadly restore sensitivity to old antimicrobials, and/or brake the intrinsic resistance of Gram-
negative bacteria against drugs that are efficacious against Gram-positive bacteria lacking RND 
efflux systems.  
Surprisingly, however, the foundation for these efforts has been rather weak. Almost all 
evidence for the impact of efflux comes from non-representative laboratory strains, while the 
quantitative contribution of efflux to clinical multi-drug resistance remains unclear due to technical 
difficulties. Methods for genetically inactivating efflux remain ineffective for MDR clinical strains. 
Efflux inhibitors are widely used to assess efflux contributions in clinical strains, but currently 
available inhibitors are hampered by pleiotropic effects on cell envelope integrity and overall 
bacterial physiology, impairing conclusive interpretation 5. Efflux system gene expression and 
sequences can be readily determined, but overexpression and sequence polymorphisms poorly 
correlate with resistance levels in clinical isolates 8,9.  
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 As part of the IMI Translocation project 10, we developed in this study a method that 
enables generation of genetically defined efflux mutants in diverse MDR clinical isolates. We 
employed a suicide plasmid (Figure 1a) and selection for two consecutive single cross-overs using 
a positive selection marker (thiopurine-S-methyltranferase Tpm conferring resistance to tellurite 
11) that works even in MDR isolates, and a negative selection marker (levan sucrase SacB 
conferring susceptibility to sucrose) for gene deletion events (see ONLINE METHODS). We 
employed this method to study the role of efflux in two major MDR pathogens that represent 
particularly serious threats 1, Escherichia coli expressing extended-spectrum β-lactamases 
(ESBL-E. coli) 12, and multi-resistant Pseudomonas aeruginosa 13. We selected several highly 
resistant P. aeruginosa isolates from four different Belgian hospitals 14 that had divergent efflux 
pump expression patterns (Figure 1b) and resistance patterns (Figure 2a). In addition, we obtained 
ESBL-E. coli clinical isolates that were obtained at the University Hospital Basel from patient 
blood, sputum, surface swabs, urine, or fecal samples. Whole genome sequencing revealed that 
these isolates are genetically highly diverse with hundreds to over thousand allelic differences 
covering a large variety of E. coli lineages (Figure 1b), and carry various β-lactamases and other 
highly heterogeneous acquired resistance genes (Figure 1c), resulting in divergent antimicrobial 
resistance patterns (Figure 2a).  
In P. aeruginosa we deleted oprM encoding the outer membrane channel of major efflux 
systems MexAB and MexXY (except for rare isolates of the taxonomic outlier PA7 group 15, in 
which MexXY uses OprA), as well as minor systems MexMN, MexVW, and partially MexJK. In 
ESBL-E. coli we deleted tolC encoding the outer membrane channel of all known E. coli RND 
efflux systems. For several strains, we could obtain clean deletions of oprM or tolC, respectively, 
within three days. However, for many others we had to screen hundreds of clones to obtain the 
desired mutants (see ONLINE METHODS). For some extensively multi-drug resistant P. 
aeruginosa isolates, there was a high background growth even at 200 mg l-1 tellurite hampering 
positive selection for ex-conjugants. Altogether, we managed to obtain oprM mutants for seven 
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out of 12 P. aeruginosa isolates (all of which were non-susceptible to agents in three or more 
antipseudomonal antimicrobial categories thus fulfilling the standard definition for MDR status 16). 
In addition, we obtained tolC mutants for 17 out of 24 ESBL-E. coli isolates (all of which had MDR 
status). We are aware of genetically defined efflux mutants for a single clinical MDR P. aeruginosa 
isolate (from the rare outlier PA7 group 17) and none for ESBL-E-coli clinical isolates in previous 
literature. 
 We tested these mutants and their parental strains for susceptibility to therapeutically 
relevant antimicrobials according to EUCAST breakpoints (v 6.0; available at 
http://www.eucast.org/clinical_breakpoints/) using a commercial phenotyping system (Vitek 2, bio-
Mérieux Suisse SA, Geneva, Switzerland) and E-tests. We represent the data as minimal 
inhibitory concentrations that prevent growth (MIC) (Figure 2). High MIC values indicate strong 
resistance. MIC ranges corresponding to probable clinical treatment failures are shown in red, 
while likely efficacious treatment is represented by the blue regions. If RND efflux would represent 
a major contribution to clinical antimicrobial resistance, we would expect our efflux mutants to 
show markedly decreased MIC values, compared to their parental clinical isolates. Deletion of 
oprM in P. aeruginosa, or tolC in ESBL-E. coli, had indeed some impact on MIC values in various 
isolates, in some cases similar to what has been observed in fully susceptible laboratory strains 3-
6. However, such changes were almost always too small to convert highly resistant strains into 
susceptible ones (i.e., moving from the red to the blue areas), and sometimes occurred even in 
the opposite direction (i.e., getting more resistant) as previously reported 18. The only exceptions 
were a single P. aeruginosa isolate that converted from amikacin resistant to sensitive upon oprM 
deletion (red arrow in Figure 2a), and a single ESBL-E. coli isolate that became susceptible to the 
aminoglycosides tobramycin and amikacin as well as cotrimoxazol upon tolC deletion (red arrows 
in Figure 2a). The residual high resistance of many mutants was the consequence of other potent 
resistance mechanisms (such as those mediated by identified acquired resistance genes of our 
ESBL-E. coli isolates shown in Figure 1c).  
84 Chapter 4 Limited impact of the eﬄux on clinical multi-drug resistance of
Escherichia coli and Pseudomonas aeruginosa
Efflux has been proposed to have an especially important role during initial encounters 
with new drugs, at a time when other resistance mechanisms might yet not have evolved 3-6. 
Indeed, deletion of oprM had in some cases remarkable effects on P. aeruginosa susceptibility to 
aztreonam (which is rarely used against this pathogen) and a ceftazidime / avibactam combination 
that was approved in 2015, after the P. aeruginosa strains of this study had been isolated 14 (Figure 
2b). However, several mutants still retained resistance suggesting the presence of potent 
alternative resistance mechanisms.  
We also tested two drugs, tigecycline and azithromycin, that cannot be used 
therapeutically against P. aeruginosa because of high intrinsic resistance. In laboratory strains, 
this intrinsic resistance can largely be overcome by inactivating just one OprM-dependent efflux 
pump, MexAB 5. As expected based on these data, oprM deletion very strongly increased 
sensitivity to both drugs also in several of our clinical isolates (Figure 2c, left). Susceptibility 
breakpoints for these two drugs have not been established for P. aeruginosa but using EUCAST 
breakpoints for other bacterial pathogens as tentative first approximations, several oprM mutants 
might indeed have become susceptible to clinically achievable tigecycline concentrations (hatched 
blue area). On the other hand, several mutant strains retained high resistance against tigecycline 
and no mutant became susceptible to azithromycin.  
The orpM deletion inactivated the clinically most relevant RND efflux systems in P. 
aeruginosa, MexAB and MexXY 19,  which represent the primary targets for efflux inhibitor 
development programs against MDR P. aeruginosa. However, P. aeruginosa encodes various 
other RND efflux systems that are independent of OprM 5. It is possible that such other efflux 
systems masked the effect of oprM deletion in some of our mutants (as has been shown for one 
single isolate of the rare PA7 group 17), but the most important alternative pumps, MexCD-OprJ 
or MexEF-OprN, were not overexpressed in our most refractory strains 142 and 256 (Figure 1b). 
In general, it might be challenging to develop promiscuous but safe inhibitors/inhibitor 
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combinations for all relevant P. aeruginosa efflux systems given the toxicity of several otherwise 
promising inhibitors 3-6. In addition, highly resistant clinical isolates likely carry already alternative 
efflux-independent resistance mechanisms. 
We also tested erythromycin and fusidic acid, two drugs that are ineffective against E. coli 
laboratory strains because of RND efflux-mediated intrinsic resistance 5. Indeed, tolC deletion 
(which disrupts all E. coli RND efflux systems) greatly increased sensitivity to these drugs in 
several MDR ESBL-E. coli clinical isolates (Figure 2c, right). However, no mutant passed 
estimated breakpoints for sensitivity, and a sizable fraction showed no or only weak sensitization. 
These data show that even for “new” drugs, several MDR clinical isolates already carry potent 
alternative resistance mechanisms limiting the contribution of efflux. 
Together, our direct experimental data using genetically defined mutants show that major 
RND efflux systems contribute to the MDR phenotype and intrinsic resistance of many clinical P. 
aeruginosa and ESBL-E. coli strains, but the effect size is often limited due to potent alternative 
resistance mechanisms. A limited contribution of efflux to high-level resistance has been 
previously postulated based on observations with laboratory strains 5 and three Salmonella 
isolates from pigs 20. Our data indicate that efflux inhibitors might have limited impact on 
therapeutic success with old or even new antimicrobials against human MDR pathogens, arguing 
against the main motivation for the extensive past and current development programs for such 
inhibitors. Efflux might have a bigger relative role in strains with only low-level resistance (which 
we did not include in this study), but this would have probably little relevance for solving the urgent 
MDR crisis. However, further research on RND efflux systems and their substrate selectivity is still 
essential to obtain a rational basis for developing efficacious novel drugs that escape efflux. 
Moreover, efflux systems can contribute to pathogen virulence 21 suggesting a potential role of 
efflux inhibitors in anti-virulence strategies.  
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We have investigated diverse clinical MDR isolates of two major bacterial pathogens that 
have been at the focus of RND efflux research. Future studies could determine the role of these 
and other efflux systems in clinical multi-drug resistance in additional pathogens using the 
methods developed in this study. 
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METHODS 
Methods, including statements of data availability and any associated accession codes and 
references, are available in the online version of the paper. 
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FIGURE LEGENDS 
 
Figure 1:  Gene deletion plasmid and diversity of clinical Escherichia coli strains.  
(a) Plasmid for deleting genes in MDR bacterial pathogens. The plasmid carries the R6K γ origin 
of replication which depends on the replication protein π (encoded by pir) which is absent in almost 
all clinical strains; tpm encoding thiopurine-S-methyltranferase conferring resistance to tellurite 
(even MDR strains are mostly sensitive to tellurite); the origin of conjugational transfer oriT; traJ 
encoding the transcriptional activator for conjugational transfer genes; sacB encoding levan 
sucrase conferring sensitivity to sucrose. The hooked arrows represent promoters. 
(b) Strain characteristics of highly resistant Pseudomonas aeruginosa clinical isolates (n.d., not 
detected).  
(c,d) Analysis of clinical Escherichia coli strains expressing extended-spectrum β-lactamases by 
whole genome sequencing. (c) Minimum-spanning tree illustrating the phylogenetic relationship 
based on the cgMLST allelic profiles of 17 strains for which we could obtain tolC mutants. The 
scale bar represents 500 allelic differences. (d) Occurrence of acquired antimicrobial resistance 
genes as detected by ResFinder 22 and inspection of gyrA alleles. 
 
Figure 2:  Impact of genetic inactivation of efflux on antimicrobial sensitivity.  
(a,b,c) Minimal inhibitory concentrations that prevent growth (MICs) of clinical isolates of 
Pseudomonas aeruginosa (left) or ESBL-expressing Escherichia coli (right). Data are shown for 
common therapeutically used antimicrobials (a), for rarely used or just recently approved drugs 
(b) (Ceft. / Avib., Ceftazidime / Avibactam), and for drugs that are ineffective against wild-type 
strains (c). Crosses represent values for parental isolates. The impact of oprM (P. aeruginosa) or 
tolC (ESBL-E. coli) deletion is represented by arrows. If there is no arrow, mutant MIC remained 
at the parental level. MIC values corresponding to clinical resistance (red) or susceptibility (blue) 
according to EUCAST breakpoints are also shown. Breakpoints for Ceftazidime / Avibactam (b) 
were based on values for Ceftazidime. In (c) breakpoints have been estimated based on values 
for other bacterial pathogens. The thick red arrows mark conversion of clinical resistance to 
susceptibility as a result of genetic inactivation of major efflux systems. MIC values outside the 
measurement range are shown above the highest labeled tick, or below the lowest labeled tick, 
respectively.  
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5.1 Abstract of the paper
Previous studies have suggested that antibiotic vectorization by siderophores (iron
chelators produced by bacteria) considerably increases the efficacy of such drugs.
The siderophore serves as a vector: when the pathogen tries to take up iron via the
siderophore, it also takes up the antibiotic. Catecholates are among the most common
iron-chelating compounds used in synthetic siderophore-antibiotic conjugates. Using re-
verse transcription polymerase chain reaction and proteomic approaches, we showed that
the presence of catecholate compounds in the medium of Pseudomonas aeruginosa led
to strong activation of the transcription and expression of the outer membrane transporter
PfeA, the ferri-enterobactin importer. Iron-55 uptake assays on bacteria with and without
PfeA expression confirmed that catechol compounds imported iron into P. aeruginosa
cells via PfeA. Uptake rates were between 0.3 × 103 and 2 × 103 Fe atoms/bacterium/min
according to the used catechol siderophore in iron-restricted medium, and remained as
high as 0.8 × 103 Fe atoms/bacterium/min for enterobactin, even in iron-rich medium.
Reverse transcription polymerase chain reaction and proteomic approaches showed that
in parallel to this switching on of PfeA expression, a repression of the expression of
95
pyochelin (PCH) pathway genes (PCH being one of the two siderophores produced by P.
aeruginosa for iron acquisition) was observed.
5.2 Statement of my work
Shotgun proteomic samples preparation and data analysis of PAO1 exposed to enter-
obactin, two synthetic catechols bis-catechol vector (BCV) or tris-catechol vector (TCV) in
casamino acid medium (CAA).
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Summary
Previous studies have suggested that antibiotic
vectorization by siderophores (iron chelators pro-
duced by bacteria) considerably increases the effi-
cacy of such drugs. The siderophore serves as a
vector: when the pathogen tries to take up iron via
the siderophore, it also takes up the antibiotic.
Catecholates are among the most common iron-
chelating compounds used in synthetic siderophore–
antibiotic conjugates. Using reverse transcription
polymerase chain reaction and proteomic
approaches, we showed that the presence of
catecholate compounds in the medium of
Pseudomonas aeruginosa led to strong activation
of the transcription and expression of the outer
membrane transporter PfeA, the ferri-enterobactin
importer. Iron-55 uptake assays on bacteria with and
without PfeA expression confirmed that catechol
compounds imported iron into P. aeruginosa cells via
PfeA. Uptake rates were between 0.3 × 103 and 2 × 103
Fe atoms/bacterium/min according to the used
catechol siderophore in iron-restricted medium, and
remained as high as 0.8 × 103 Fe atoms/bacterium/min
for enterobactin, even in iron-rich medium. Reverse
transcription polymerase chain reaction and
proteomic approaches showed that in parallel to this
switching on of PfeA expression, a repression of the
expression of pyochelin (PCH) pathway genes (PCH
being one of the two siderophores produced by P.
aeruginosa for iron acquisition) was observed.
Introduction
The emergence of resistant and, in some cases pan-
resistant (resistant to all the antibiotics currently available)
bacteria has led to an urgent need to discover new bacte-
ricidal molecules with different targets and innovative strat-
egies for preserving or increasing the efficacy of known
antibiotics. In recent years, a number of reviews have
highlighted the possible use of bacterial iron uptake path-
ways as a Trojan horse strategy for promoting the transport
of drugs into bacteria, thereby increasing their efficacy (Ji
et al., 2012b; Rebuffat, 2012; Page, 2013; Mislin and
Schalk, 2014). Iron is a cofactor in many important biologi-
cal processes, and it is therefore an essential nutrient for
bacterial growth and infectious processes (Ratledge and
Dover, 2000). One of the most common strategies for
obtaining iron used by bacteria involves siderophores,
small organic iron chelators [molecular weight between
200 and 2000 Da (Hider and Kong, 2011)]. These mol-
ecules are synthesized by bacteria and have a high affinity
for iron. They are released into the environment, where
they scavenge iron highly efficiently before being taken up
again by the bacteria, resulting in the transport of the iron
they carry to the bacterial cytoplasm (Schalk et al., 2012;
Schalk and Guillon, 2013). Antibiotics can be attached to
siderophores in a Trojan horse strategy resulting in the
delivery of the conjugates to the bacterial cytoplasm via
siderophore-mediated iron uptake pathways.
In Gram-negative bacteria, the ferrisiderophore com-
plexes formed in the environment surrounding the bacte-
rium are transported back across the bacterial outer
membrane by specific TonB-dependent transporters
(TBDTs). The uptake activity of these transporters is regu-
lated by the inner membrane protein TonB (Schalk et al.,
Received 13 November, 2015; revised 20 December, 2015; accepted
23 December, 2015. For correspondence. *E-mail isabelle.schalk@
unistra.fr; Tel. 33 3 68 85 47 19; Fax 33 3 68 85 48 29. **E-mail
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2012). They are further transported across the inner mem-
brane by specific ABC transporters or proton-motive
force-dependent permeases (Schalk and Guillon, 2013).
The iron is generally then released from the siderophores
in the bacterial cytoplasm, through a process involving
both iron reduction and an enzymatic degradation or
modification of the siderophores (for a review see Schalk
and Guillon, 2013). In some siderophore pathways, a
different sequence of events occurs: for example, during
iron uptake via pyoverdine (PVD) or citrate in
Pseudomonas aeruginosa, the iron is released from the
siderophore in the periplasm, and only the iron is trans-
ported further into the cytoplasm, by an ABC transporter
(Greenwald et al., 2007; Marshall et al., 2009; Brillet
et al., 2012; Schalk and Guillon, 2013).
Most bacteria acquire iron by producing their own
siderophores, but they can also use siderophores
from other microorganisms (siderophore piracy).
Pseudomonas aeruginosa, an opportunist pathogen,
used as a model organism in this study, produces two
major siderophores, PVD and pyochelin (PCH). However,
it can also use many xenosiderophore (not produced by
the bacterium itself) like PVDs from other pseudomonads,
enterobactin (Poole et al., 1990), cepabactin (Mislin et al.,
2006), mycobactin and carboxymycobactin (Llamas et al.,
2008), desferrichrysin, desferricrocin, coprogen (Meyer,
1992), vibriobactin, aerobactin, fungal siderophores
[ferrichrome (Llamas et al., 2006) and deferrioxamines
(Vasil and Ochsner, 1999; Llamas et al., 2006)] and
natural chelators, such as citrate (Cox, 1980; Harding and
Royt, 1990), (for reviews see Poole and McKay, 2003;
Cornelis and Dingemans, 2013).
Many studies have shown that siderophore iron uptake
pathways can be used to transport antibiotics into bacteria
(Mollmann et al., 2009; Ji et al., 2012b; Page, 2013; Mislin
and Schalk, 2014). Microorganisms have themselves
developed siderophore–antibiotic conjugates known as
sideromycins (Braun and Braun, 2002; Braun et al., 2009;
Mislin and Schalk, 2014), in which the antibiotic moiety is
connected to the siderophore via a spacer arm. The
archetypal conjugates of this type are albomycins (Benz
et al., 1982; Braun and Braun, 2002; Mislin and Schalk,
2014), ferrimycins (Bickel et al., 1965), danomycins
(Tsukiura et al., 1964), salmycins (Tsukiura et al., 1964)
and certain microcins (de Lorenzo, 1984; de Lorenzo
et al., 1984; Thomas et al., 2004; Destoumieux-Garzon
et al., 2006; Nolan and Walsh, 2008). These natural
siderophore–antibiotic conjugates can chelate iron(III)
and are then transported into the target bacterium via the
siderophore-dependent iron uptake pathways. This
energy-coupled transport across the bacterial mem-
branes greatly increases the antibiotic efficacy of
sideromycins: their minimal inhibitory concentration is
often at least two orders of magnitude lower than that of
the antibiotic without the siderophore, which enters the
cell by diffusion (Braun et al., 2009). Trojan horse strate-
gies based on the use of bacterial iron uptake pathways
are, therefore, currently considered to be a promising
approach for the treatment of infection. Several research
teams have developed different synthetic siderophore–
antibiotic conjugates (Rivault et al., 2007; Page et al.,
2010; Noel et al., 2011; Ji et al., 2012a,b; Milner et al.,
2013; Page, 2013; Wencewicz and Miller, 2013;
Wencewicz et al., 2013; Fardeau et al., 2014; Zheng and
Nolan, 2014; Ji and Miller, 2015), some of which have
potentially useful antibiotic activities.
However, for such Trojan horse strategies to be
effective, the target bacteria must prefer to use
xenosiderophores present in their environment rather
than producing their own siderophores to obtain iron. In
this context, it is vital to have a precise understanding of
the ability of bacteria to sense the presence of
xenosiderophores (or sideromycins in a Trojan horse
strategy) in their environment and to switch from one
siderophore pathway to another for iron acquisition.
Catecholate siderophores are the iron-chelating com-
pounds most frequently tethered to various antibiotics (Ji
et al., 2012a; Wencewicz and Miller, 2013; Fardeau et al.,
2014; Zheng and Nolan, 2014; Chairatana et al., 2015). In
this study, we therefore evaluated the capacity of P.
aeruginosa to use several catechol xenosiderophores in
conditions of iron limitation: enterobactin (a well known
siderophore produced by Escherichia coli, used here as a
reference), protochelin and azotochelin [siderophores
produced by Azotobacter vinelandii (Knosp et al., 1984;
Cornish and Page, 2000)] and two synthetic chelators [the
tris-catechol vector, TCV and the bis-catechol vector, BCV
(Baco et al., 2014)], which could potentially be used for
the vectorization of antibiotics for transport into P.
aeruginosa cells (Fig. 1). We show here that when P.
aeruginosa cells are grown in the presence of catechol
compounds, the expression of the TBDT PfeA (the
enterobactin outer membrane transporter) is highly acti-
vated, and the expression of the genes encoding for pro-
teins involved in the endogenous PCH iron uptake
pathway is repressed. Using 55Fe uptake assays, we
show that iron is transported by these catechol com-
pounds via PfeA, into P. aeruginosa cells.
Results
Enterobactin, azotochelin, protochelin, BCV and TCV
induce the expression of the outer membrane
transporter PfeA
Pseudomonas aeruginosa is known to be able to sense
xenosiderophores in its extracellular environment, and the
detection of these molecules leads to an upregulation of
the genes encoding the corresponding ferrisiderophore
2 V. Gasser et al.
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uptake proteins (Dean and Poole, 1993; Llamas et al.,
2008; 2014). We used reverse transcription quantitative
polymerase chain reaction (RT-qPCR) and proteomic
approaches to investigate whether the presence of
catecholate chelators in the growth medium activated the
transcription of one or more siderophore TBDTs in P.
aeruginosa. For both approaches, experiments were
carried out with PAO1 ATCC15692 and the corresponding
PVD and PCH-deficient ΔpvdFΔpchA strain (Table S1)
grown in LB or iron-deficient casamino acid medium
(CAA) medium, with or without supplementation with
10 μM of enterobactin (the reference compound),
azotochelin, protochelin, BCV or TCV.
We studied 10 genes in RT-qPCR experiments: seven
genes corresponding to TBDTs (piuA, pirA, pfeA, cirA,
fvbA, pfuA and PA0434) potentially involved in iron acqui-
sition via catechol chelators according to the annotation of
the P. aeruginosa PAO1 genome (Winsor et al., 2011), the
fpvA and fptA genes to assess changes in the transcrip-
tion of the genes encoding the PVD and PCH TBDTs, and
the housekeeping gene uvrD, which was used for normali-
zation. Reverse transcription qPCR demonstrated a large
increase in transcript levels for pfeA (Fig. 2) but not for
any of the other TBDT genes tested (fold changes of less
than seven for these other genes; Fig. S1) in the presence
of enterobactin and the other four catecholate chelators
tested. In the iron-deficient CAA medium, all five mol-
ecules tested strongly activated the transcription of pfeA,
even in the wild-type strain PAO1, which produced and
secreted large amounts of the endogenous siderophores,
PVD and PCH (Cunrath et al., 2015a). Tris-catechol
vector and protochelin were the most effective activators
of pfeA transcription (3000 and 4500-fold changes in
PAO1 and ΔpvdFΔpchA, respectively), followed by
enterobactin (1400-fold change) and azotochelin, with
BCV the least effective molecule (520 and 810-fold
changes in PAO1 and ΔpvdFΔpchA respectively). In
Luria–Bertani (LB) medium [containing about 4 μM
iron (Cunrath et al., 2015a)], TCV, protochelin and
enterobactin were able to promote pfeA transcription in
both strains tested, with fold changes of between 100 and
700 for TCV (Fig. 2F). In LB medium, TCV was again the
most effective compound for the activation of pfeA tran-
scription. This activation of pfeA transcription in LB
medium strongly suggested that P. aeruginosa made use
of the enterobactin pathway to acquire iron even in iron-
rich media, such as LB, if tris-catechol siderophores were
present. The proteomic investigation was carried out on
the wild-type PAO1 strain grown in CAA medium in the
presence of enterobactin, BVC or TCV (Fig. 3). It clearly
demonstrated an activation of expression for the PfeA
gene but for no other TBDT gene (Fig. 3A).
In conclusion, RT-qPCR and proteomic investigations
showed strong induction of the transcription and expres-
sion of pfeA in the presence of catechol chelators in
iron-deficient and iron-rich media.
Enterobactin, azotochelin, protochelin, BCV and TCV
can transport iron into P. aeruginosa cells via the TBDT
PfeA
The activation of pfeA transcription and expression in the
presence of the various catechol siderophores strongly
suggests that these chelators transport iron into P.
aeruginosa cells via this TBDT. We therefore assessed
the ability of a mutant with a pfeA deletion to transport and
accumulate 55Fe in the presence of the various catechol
siderophores.
In the first experiment (Fig. 4A–E), we prevented iron
uptake by the endogenous siderophores by using the
PCH and PVD-negative P. aeruginosa mutant
ΔpvdFΔpchA and its pfeA deletion mutant derivative
Fig. 1. Structures of enterobactin (ENT),
azotochelin (BCS), protochelin (TCS), BCV
and TCV.
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ΔpvdFΔpchAΔpfeA, grown in the presence of 10 μM
enterobactin to induce PfeA expression. We also repeated
all the 55Fe uptake experiments with cells subjected to
pretreatment with the protonophore carbonyl cyanide
m-chlorophenylhydrazone (CCCP; Fig. 4A–E), which
inhibits the proton-motive force of the bacteria, thereby
preventing any TonB-dependent uptake (Clément et al.,
2004). Iron-55 uptake was observed in ΔpvdFΔpchA cells
(shown in black in Fig. 4A–E) in the presence of the five
molecules tested, but not in cells that had been treated
with CCCP (shown in green in Fig. 4A–E). Thus, none of
the five catechol–55Fe complexes tested were able to
diffuse across the outer membrane: the iron uptake
observed was mediated exclusively by TBDTs. A complete
inhibition of iron uptake was also observed for the pfeA
mutant in the presence of enterobactin-55Fe, protochelin-
55Fe and TCV-55Fe (shown in red in Fig. 4A, C and E), as
shown by comparison with the ΔpvdFΔpchA strain
expressing PfeA, indicating that these three compounds
transport iron into P. aeruginosa cells via PfeA only, with
no other TBDT able to perform this function. In the pres-
ence of BCV and, to a lesser extent, azotochelin (Fig. 4D
and B), the inhibition of 55Fe uptake in ΔpvdFΔpchAΔpfeA
cells was incomplete, suggesting the involvement of
another TBDT, in addition to PfeA, in iron acquisition by
these two bis-catechol compounds. Iron uptake was
restored by the complementation of ΔpvdFΔpchAΔpfeA
with pMMB190pfeA, a pMMB derivative carrying the pfeA
gene for all five catecholate compounds tested (shown in
blue in Fig. 4A–E).
As all the 55Fe uptake assays with the different catechol
siderophores were carried out with enterobactin as the
inducer of pfeA expression, the expression levels of this
protein are equivalent in all the uptake assays using PAO1
in Fig. 4A–E. Therefore, the 55Fe transport efficiency of
the different catecholate compounds can be compared:
uptake rates of 2 × 103 Fe atoms/bacterium/min were
recorded in the presence of enterobactin as siderophore,
Fig. 2. Analysis of changes in the
transcription of the pfeA gene. Reverse
transcription quantitative PCR was performed
on RNA from P. aeruginosa PAO1 and the
corresponding PVD and PCH-deficient
ΔpvdFΔpchA cells grown in CAA or LB
medium, with and without supplementation
with 10 μM enterobactin, azotochelin,
protochelin, BCV or TCV. The data are
normalized relative to the reference gene
uvrD and are representative of three
independent experiments performed in
triplicate (n = 3).
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1.3 × 103 Fe atoms/bacterium/min in the presence of
azotochelin, 0.6 × 103 in the presence of protochelin or
BCV and 0.3 103 Fe atoms/bacterium/min for TCV. In
these experimental conditions, TCV appears about seven
times less efficient than enterobactin for 55Fe uptake in P.
aeruginosa.
We then compared these uptake rates obtained with
PVD and PCH-deficient ΔpvdFΔpchA cells grown in con-
ditions of iron limitation with those obtained when
siderophore-producing PAO1 cells were grown in iron-rich
media (Fig. 5 and Table 1). The idea here was to compare
55Fe uptake by catecholate compounds in more favour-
able (iron-restricted growth conditions with a strain unable
to produce any endogenous siderophore) and less favour-
able conditions (iron-rich growth conditions with a strain
able to produce two endogenous siderophores). In addi-
tion, we also investigated the effect of (i) a lack of induc-
tion of PfeA expression (black bares in Fig. 5), (ii)
induction with the siderophore enterobactin (gray bares in
Fig. 5) and (iii) induction with the catechol chelator used in
the 55Fe uptake assays (white bares in Fig. 5), which lead
to the induction of the transporter with different efficien-
cies according to Fig. 2.
A significant 55Fe uptake via PfeA was observed only
when the bacteria were grown in the presence of a
catechol chelator inducing PfeA expression (Fig. 5), con-
firming again that this TBDT must be expressed to
observe any 55Fe uptake in the presence of such com-
pounds. However, this rule was not respected in the case
PAO1 cells grown in LB with protochelin and TCV used as
siderophores. The second interesting point is an efficient
iron transport via enterobactin, azotochelin and BCV even
in PVD and PCH-producing P. aeruginosa cells grown in
iron-rich medium. At last, iron uptake rates did not differ
significantly between cells in which PfeA expression was
induced with enterobactin and cells in which PfeA expres-
sion was induced with the siderophores used for 55Fe
uptake assays, despite the high capacity of compounds
such as TCV to induce PfeA expression (Fig. 2F). This
apparent absence of connection between the level of
PfeA expression and iron uptake rates may be due to
differences in siderophores recognition efficiencies with
the different proteins of the enterobactin iron uptake
pathway in P. aeruginosa.
Thus, all the five catechol compounds transported iron
into P. aeruginosa cells via PfeA, with enterobactin being
the more efficient. The uptake rates could reach with
enterobactin 1306 ± 220 Fe atoms/bacterium/min in P.
aeruginosa cells unable to produce siderophores grown in
iron-deficient medium, and it remained as high as
827 ± 64 Fe atoms/bacterium/min, even in a PVD and
PCH-producing strain grown in iron-rich medium (Fig. 5
and Table 1).
Enterobactin, azotochelin, protochelin, BCV and TCV
repress the expression of the PCH pathway, but not that
of the PVD pathway
In parallel with the induction of PfeA expression,
proteomic analyses on P. aeruginosa cells grown in iron-
deficient medium in the presence of 10 μM enterobactin,
BCV or TCV showed a repression of the expression of the
genes involved in PCH biosynthesis (pchA, pchB, pchC,
pchD, pchE, pchF and pchG), the genes encoding the
outer and inner membrane importers of PCH-Fe (fptA and
fptX, respectively) and the pchH and pchI genes of the
PCH locus, the functions of which are unknown (Fig. 3B).
Fig. 3. Analysis of expression changes for TBDTs (A) and proteins
of the PVD (B; green, blue and red crosses) and PCH (B; green,
blue and red triangles) pathways. Proteomic analyses were
performed on P. aeruginosa PAO1 cells grown in CAA
supplemented or not with 10 μM enterobactin, BCV or TCV.
Median values measured in CAA in the absence of any
supplementation with catechol compounds were plotted against
median values measured in CAA supplemented with either
enterobactin (green symbols in panel A and B), BCV (blue symbols
in panel A and B) and TCV (red symbols in panel A and B).
Median values represent the median of the relative intensity of
each protein, normalized against all detected proteins during
shotgun analyses (n = 3).
Ability of P. aeruginosa to acquire iron via catechols 5
© 2015 Society for Applied Microbiology and John Wiley & Sons Ltd, Environmental Microbiology
Ability of P. aeruginosa to acquire iron via catechols 823
VC l il y ons Ltd, Environ ental Microbiology, 18, 819–832
5.3 Published paper 101
No effect on the expression of the genes of the PVD locus
was observed. Since P. aeruginosa cells produce no PVD
and PCH in LB [an iron-rich medium; (Cunrath et al.,
2015a)], the repression of PCH pathway genes in the
presence of catecholate compounds was observed only in
conditions of iron limitation (CAA medium). Reverse tran-
scription qPCR experiments confirmed that, in conditions
of iron limitation, the presence of catechol compounds in
the growth medium of P. aeruginosa clearly repressed the
transcription of pchE (a non-ribosomal peptide synthetase
involved in PCH biosynthesis), fptA and fptX (Fig. 6A),
with an 80% decrease in the fold changes recorded.
Again, no repression of transcription was observed for the
genes of the PVD pathway (fpvA, encoding the TBDT;
fpvF, encoding a periplasmic binding protein involved in
ferri-PVD import and pvdJ, encoding an enzyme involved
in PVD biosynthesis; Fig. 6B).
We investigated the timing of this repression using P.
aeruginosa cells expressing mCherry-tagged PchE or
FptX (pchEmcherry and fptXmcherry, Table S1). The con-
structions of these strains have been described previously
(Cunrath et al., 2015b; Gasser et al., 2015). Chromo-
somal insertion of mcherry was chosen to obtain physi-
ological protein expression levels. The insertion of
mcherry, by allelic exchange, into wild-type PAO1 pro-
duced strains expressing mCherry fused to the
C-terminus of either FptX (fptXmcherry strain) or PchE
(pchEmcherry strain). We monitored the growth of these
two strains in iron-depleted CAA medium after addition of
200 μM enterobactin, BCV or TCV, by measuring optical
density at 600 nm upon time (Fig. 7). These two strains
carrying the fusion proteins grew as well as the parental
strains PAO1 and the addition of the catechol compounds
stimulated bacterial growth, a feature commonly observed
with siderophores (Youard et al., 2007). After 8 h culture,
PchE-mCherry and FptX-mCherry were already
expressed in P. aeruginosa cells, and a clear repression of
PchE-mCherry and FptX-mCherry expression was
observed, beginning about 1 h after the addition of
catechol chelators to the growth medium. This repression
was most effective with TCV and least effective with BCV,
and persisted over about 20 h of culture.
This switching off of the PCH pathway was confirmed
by carrying out PCH–55Fe uptake assays (Fig. 4F) on P.
Fig. 4. A–E. Time-dependent 55Fe assimilation in P. aeruginosa cells in the presence of 55Fe-loaded enterobactin, azotochelin, protochelin,
BCV and TCV. The PVD and PCH-deficient ΔpvdFΔpchA strain, its corresponding pfeA mutant (ΔpvdFΔpchAΔpfeA) and the complemented
ΔpvdFΔpchA (pME3088ΔpvdF) strain were grown in CAA medium in the presence of 10 μM enterobactin to induce PfeA expression. The
bacteria were then washed with 50 mM Tris-HCl (pH 8.0), and transport assays were initiated by adding 200 nM enterobactin-55Fe (A),
azotochelin-55Fe (B), protochelin-55Fe (C), BCV-55Fe (D) or TCV-55Fe (E). Samples (100 μl) of the suspension were taken at various time points
and filtered; the radioactivity retained was measured. The results are expressed as atoms of 55Fe transported per bacterium. For A–E, the
black and red lines correspond to 55Fe uptake assays with ΔpvdFΔpchA and ΔpvdFΔpchAΔpfeA cells, respectively, both grown in the presence
of enterobactin; in green: 55Fe uptake assay with ΔpvdFΔpchA cells grown in the presence of enterobactin and then treated with 200 μM
CCCP (a protonophore), preventing TBDT-dependent transport; in blue: 55Fe uptake assay with ΔpvdFΔpchA(pME3088ΔpvdF) cells grown in
the presence of enterobactin. F. Time-dependent 55Fe assimilation in P. aeruginosa cells in the presence of PCH. ΔpvdFΔpchA cells were
grown in CAA medium in the absence of chelator (grey) or in the presence of 10 μM BCV (dark blue) or TCV (purple), to induce PfeA
expression. As above, the bacteria were then washed with 50 mM Tris-HCl (pH 8.0) and transport assays were initiated by adding 200 nM
PCH-55Fe. The experiments were repeated with the protonophore CCCP at a concentration of 200 μM (light blue and pink: ΔpvdFΔpchA cells
treated with CCCP after culture in the presence of 10 μM BCV and TCV respectively). All the experiments in A–F were carried out three times,
with similar results obtained in each case.
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aeruginosa cells grown in the presence or absence of
BCV or TCV. Iron-55 uptake via PCH was observed for
bacteria grown in the presence of BCV or TCV, indicating
that the repression of the PCH pathway documented by
proteomic and RT-qPCR studies was not total, with the
bacteria still able to acquire iron via PCH. However, 55Fe
uptake was clearly slower in cells grown in the presence
of BCV or TCV (no plateau reached after more than
15 min, Fig. 4F curve in blue and red) than in cells grown
in the absence of these compounds (plateau reached in
about 3 min, Fig. 4F curve in black).
These data show that the presence of catechol
chelators in the growth medium of P. aeruginosa cells
strongly represses the proteins of the PCH pathway. This
repression occurred after about 1 h of growth in plank-
tonic conditions in CAA medium and was maintained
throughout the rest of the culture period (20 h). This
repression was not total, with the bacterium still able to
acquire iron via the PCH siderophore.
Discussion
In addition to its own siderophores, PVD and PCH, P.
aeruginosa can use many siderophores produced by
other microorganisms (Poole and McKay, 2003; Cornelis
and Dingemans, 2013), consistent with the presence in
the genome of this pathogen of more than 30 genes
encoding TBDTs (Cornelis and Bodilis, 2009), which act
as gates allowing the various ferrisiderophore complexes
to enter bacteria. All these siderophore-dependent iron
uptake pathways, indicating a high potential of this bac-
terium to adapt to different conditions of iron limitation,
may be also considered as possible gates for the entry
of siderophore-antibiotic conjugates in Trojan horse
strategies.
We show here that the presence in the growth medium
of catechol xenosiderophores (azotochelin and
protochelin) or two synthetic chelators (BCV and TCV)
that can be linked to antibiotics by click chemistry induced
the expression of PfeA in P. aeruginosa, as previously
reported for enterobactin (Dean and Poole, 1993). By
contrast, no other TBDT was induced (Figs 2 and 3A).
The efficiency of PfeA induction was highest for TCV,
followed by protochelin, enterobactin, azotochelin and,
finally BCV. Dean and Poole have shown that two genes,
pfeS and pfeR (located immediately upstream from pfeA),
encode the sensor kinase and response regulator,
respectively, of a two-component system involved in regu-
lating pfeA expression in response to enterobactin (Dean
and Poole, 1993; Rodrigue et al., 2000). It is tempting to
hypothesize that this two-component system is also
involved in the regulation of pfeA expression in response
to other catechol compounds. The sequence of PfeS sug-
gests that it is an inner membrane protein (Dean and
Poole, 1993), and further studies are required to gain
insight into the mechanism of stimulus perception by this
protein: do the catechol compounds interact with this
Fig. 5. 55Fe assimilation in P. aeruginosa PAO1 and ΔpvdFΔpchA
cells in the presence of 55Fe-loaded enterobactin, azotochelin,
protochelin, BCV and TCV. PAO1 was grown in LB and the
corresponding PVD and PCH-deficient ΔpvdFΔpchA strain in CAA
medium. Cells were grown without enterobactin supplementation to
ensure an absence of PfeA expression (black bars) or with 10 μM
enterobactin (gray bars) or 10 μM of the catechol compound used
for 55Fe uptake (white bars) to induce PfeA expression. The
bacteria were then washed with 50 mM Tris-HCl (pH 8.0) and
transport assays were initiated by adding the various catechol
compounds loaded with 55Fe to a concentration of 200 nM.
Samples (100 μl) were taken from the suspensions at various time
points and filtered; the radioactivity retained was measured. The
results are expressed as atoms of 55Fe transported per bacterium
per min. Data of Fig. 5 are presented as well in Table 1.
Table 1. 55Fe assimilation in P. aeruginosa PAO1 and ΔpvdFΔpchA cells in the presence of 55Fe-loaded enterobactin, azotochelin, protochelin,
BCV and TCV.
55Fe atoms/bacterium/min
Enterobactin Azotochelin Protochelin BCV TCV
PAO1 in LB 827 ± 64 299 ± 33 98 ± 4 661 ± 32 145 ± 14
ΔpvdFΔpchA in CAA 1306 ± 220 712 ± 126 273 ± 62 372 ± 68 363 ± 36
PAO1 was grown in LB and the corresponding PVD and PCH-deficient ΔpvdFΔpchA strain in CAA medium. Cells were grown with 10 μM of the
catechol compound used for 55Fe uptake to induce PfeA expression. The bacteria were then washed with 50 mM Tris-HCl (pH 8.0), and transport
assays were initiated by adding the various catechol compounds loaded with 55Fe to a concentration of 200 nM. Samples (100 μl) were taken from
the suspensions at various time points and filtered; the radioactivity retained was measured. The results are expressed as atoms of 55Fe
transported per bacterium per min (n = 3).
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protein only after their transport into the bacterial
periplasm or is another mechanism involved?
Despite the current lack of information concerning the
molecular mechanisms underlying this stimulation of PfeA
expression, the findings presented here already have
interesting implications for the development of
siderophore conjugates for Trojan horse strategies. First,
the induction of PfeA expression (or switching on of the
enterobactin pathway) was even significant in a wild-type
PAO1 strain, indicating that, in the presence of catechol
compounds, P. aeruginosa makes use of these molecules
to obtain iron, despite its ability to produce the highly
Fig. 6. A. Analysis of changes in transcription for the genes of the
PCH pathway. fptA and fptX encode the outer and inner membrane
transporters of PCH-Fe, respectively, and pchE encodes an
nonribosomal peptide synthetase involved in PCH biosynthesis.
Reverse transcription qPCR was performed on P. aeruginosa
PAO1 grown in CAA medium with or without 10 μM enterobactin,
azotochelin, protochelin, BCV or TCV (NI for not induced).
B. Analysis of changes in the transcription of genes of the PVD
pathway. fpvA encodes the TBDT of PVD-Fe, fpvF encodes a
periplasmic binding protein involved in PVD-Fe uptake, pvdI
encodes an non-ribosomal peptide synthetases involved in PVD
biosynthesis. As for panel B, RT-qPCR was performed on P.
aeruginosa PAO1 cells grown in CAA medium with or without
10 μM enterobactin, azotochelin, protochelin, BCV or TCV (NI for
not induced). For both panels, the data were normalized relative to
the reference gene uvrD and are representative of three
independent experiments performed in triplicate (n = 3).
Fig. 7. Monitoring of PchE-mCherry (A) and FptX-mCherry (B)
fluorescence during bacterial growth in the presence and absence
of enterobactin, BCV or TCV. Fresh CAA medium was inoculated
with pchEmcherry and fptXmcherry cells grown in the same
medium, and the resulting suspension was dispensed into the wells
of a 96-well plate. For both panels, after 8 h of growth, 200 μM
enterobactin (●), BCV (■) or TCV (▲) was added; the control
experiment with no siderophore addition is shown in black (black
line with no symbols). OD600nm measurements were used to assess
growth over time. The fluorescence of mCherry was measured by
excitation at 570 nm, with monitoring of the emission of
fluorescence at 610 nm. These measurements were performed at
30 min intervals, in a Tecan microplate reader incubated at 30°C,
with shaking. Each curve corresponds to the mean of three
replicates.
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efficient siderophores PVD and PCH. In addition, the
enterobactin pathway was switched on even in iron-rich
medium (LB), leading to efficient iron uptake via this
siderophore: 827 ± 64 Fe atoms/bacterium/min (Fig. 5
and Table 1). The total iron content of bacteria in this
medium is in the range of 810 000 Fe atoms/bacterium
(Cunrath et al., 2015a).
This switching on of the enterobactin pathway was
accompanied by a clear repression of the expression of
the PCH pathway. However, the PCH pathway was not
totally switched off (Fig. 3F), the bacteria were still able to
gain access to iron via PCH at any moment. This repres-
sion occurred as long as the bacteria were in contact with
catechol chelators (Fig. 7). No repression of the PVD
pathway was observed. Interestingly, this hierarchy of iron
uptake pathway expression reflects the affinity of the
siderophores for ferric iron (1052 M−1, 1030.8 M−1 and
1028.8 M−2 for enterobactin, PVD and PCH respectively
(Carrano and Raymond, 1979; Albrecht-Gary et al., 1994;
Brandel et al., 2012). Moreover iron chelation needs only
one molecule of enterobactin or PVD per iron ion, but two
molecules of PCH (2:1 -PCH : Fe- stoichiometry) to get an
octahedral coordination. This suggests that, when several
siderophores are present in the bacterial environment, the
siderophore most successful at chelating the available
iron will scavenge it and deliver it to the microorganism.
Consequently, the bacterium will specifically upregulate
the expression of all the proteins required to obtain iron
via this specific siderophore. In the presence of tris-
catechol chelators, PCH, which has a lower affinity for iron
and chelates, this metal with a 2:1 (PCH : Fe)
stoichiometry, is probably not competitive for the chelation
of this metal. Consequently, fewer PCH–Fe complexes
are formed and transported into P. aeruginosa cells for
activation of the PCH pathway via the cytoplasmic regu-
lator PchR. By contrast, the presence of catechol–Fe
complexes in the bacterial environment leads to the
enterobactin pathway being switched on. Accordingly, in
the development of siderophore-antibiotic conjugates, it
may be important to design a siderophore moiety with a
high enough affinity for iron to compete with the natural
siderophores produced by the pathogen. Consequently, it
is not surprising that compounds like siderophore conju-
gate monocarbams are poorly efficient in a Trojan horse
strategy in P. aeruginosa infections (Tomaras et al., 2013;
Kim et al., 2015). Such compounds have certainly affini-
ties for iron lower than that of PCH and will not be com-
petitive with the endogenous siderophores to provide iron
to P. aeruginosa cells. Moreover, the iron chelation
stoichiometry of such compounds is not 1:1
(siderophore : Fe) as for many natural siderophores;
therefore iron loaded monocarbam conjugates may have
complex tridimensional structures, which may be poorly
recognized by TBDT for uptake.
Iron-55 uptake assays demonstrated that P. aeruginosa
cells used the TBDT PfeA to assimilate iron complexed
with catechol compounds (Fig. 4). Deletion of the PfeA
gene abolished completely iron uptake by these com-
pounds, with the exception of BCV, for which another, as
yet unidentified TBDT must be involved in BCV–Fe
assimilation. Previous studies have suggested that TBDTs
are highly specific for iron transport via one specific
siderophore or structurally related siderophores, but
never siderophores with very different chemical structures
(for a review see (Schalk et al., 2012). In P. aeruginosa,
PfeA recognizes the ferric forms of the tris-catechol com-
pounds enterobactin, protochelin and TCV, but also the
bis-catechol compounds azotochelin and BCV at the bac-
terial cell surface and transports them across the outer
membrane. Consequently, PfeA should be able to take up
BCV–antibiotic and TCV–antibiotic conjugates.
In all conditions tested, enterobactin was the most effi-
cient siderophore for iron uptake into P. aeruginosa,
whereas protochelin with TCV were the least efficient
(Figs 4 and 5 and Table 1): 1306 ± 220 Fe atoms/
bacterium/min for enterobactin and 273 ± 62 Fe atoms/
bacterium/min for protochelin, for cells grown in iron-
deficient conditions. Surprisingly, the uptake rates of the
different catechol chelators did not reflect the ability of
these compounds to induce PfeA expression. This appar-
ent absence of connection between the level of PfeA
expression and the rates of iron uptake mediated by
catechol siderophores may be due to differences in the
recognition and interaction efficiencies between these
catecholate compounds and the different protein partners
involved in iron acquisition via enterobactin in P.
aeruginosa.
The iron uptake rates of enterobactin (1306 ± 220 Fe
atoms/bacterium/min in iron-deficient medium and
827 ± 64 Fe atoms/bacterium/min in LB – Fig. 5 and
Table 1) indicate that this siderophore should be able to
transport large amounts of antibiotics in a Trojan horse
strategy. The lower uptake rate of protochelin and TCV
probably reflects difficulties interacting with one of the
proteins involved in enterobactin uptake pathway: PfeA or
another, unidentified partner. Iron uptake via enterobactin
has been studied in detail in E. coli and involves transport
across the outer membrane by the TBDT FepA, across
the inner membrane by the ABC transporter FepBCD and
the release of the metal from the siderophore in the cyto-
plasm, via a mechanism involving iron reduction and
siderophore hydrolysis (Raymond et al., 2003; Schalk and
Guillon, 2013). This scenario does not seem to apply to P.
aeruginosa, particularly as the operon containing pfeA in
this bacterium contains only the PA2689 gene (down-
stream from pfeA) encoding a putative esterase (Winsor
et al., 2011) with a typical signalling sequence, suggesting
a periplasmic distribution. No gene coding for an inner
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membrane transporter is present on the genome in the
vicinity of pfeA, strongly suggesting that, as for iron acqui-
sition via PVD, iron may be released from enterobactin
and other catechol chelators in the periplasm of P.
aeruginosa rather than in the cytoplasm as in E. coli.
However, further studies are required to obtain insight into
the enterobactin pathway in P. aeruginosa, to identify the
various protein partners and molecular mechanisms
involved and to improve our understanding to facilitate the
design of optimal catechol–antibiotic conjugates trans-
ported into P. aeruginosa cells with the same efficiency as
for the natural siderophore enterobactin.
In conclusion, the development of Trojan horse strat-
egies involves considering different parameters to
ensure the design of siderophore–antibiotic compounds
with a high probability of ensuring effective drug delivery.
It involves the synthesis of siderophore–antibiotic conju-
gates having a very high affinity for iron, able to
compete for this nutrient with the endogenous
siderophores produced by the target bacterium. Moreo-
ver, it is crucial that the siderophore–antibiotic conju-
gates once loaded with iron can still be recognized by
TBDTs with good affinities. Consequently, vectors having
structural homologies with natural siderophores will be
vectors with the highest probability to transport efficiently
antibiotics into bacteria. At last, the development of
such Trojan horse strategies also requires an excellent
knowledge of the molecular mechanisms involved in
ferrisiderophore uptake.
The data presented here indicate that enterobactin–
antibiotic conjugates should have a high potential for acti-
vating PfeA transcription, facilitating the transport of large
amounts of antibiotic into the bacteria (the transport of
800 to 2000 molecules of antibiotic might be predicted).
The high potential of TCV to activate the transcription of
PfeA is also of potential interest in such a study, to ensure
that the catechol–antibiotic conjugates remain close to the
bacterial cell surface, ready to be transported. An ideal
catechol vector for the transport of antibiotics into bacteria
would be a compound able to activate the transcription of
PfeA, like TCV, but able to ensure transport with the
uptake rate of enterobactin.
Materials and methods
Chemicals
The pyochelin (PCH) used for 55Fe uptake assays was
synthesized and purified as previously described (Zamri
and Abdallah, 2000; Youard et al., 2007). Enterobactin
was purchased from Sigma-Aldrich. Azotochelin (BCS),
BCV and TCV were synthesized as previously described
(Baco et al., 2014). The syntheses of protochelin (TCS) is
described in the Supplementary Material.
Bacterial strains, plasmids and growth conditions
The P. aeruginosa and Escherichia coli strains and
plasmids used in this study are listed in Table S1.
Escherichia coli strains were routinely grown in LB (Difco)
at 37°C. Pseudomonas aeruginosa strains were first
grown overnight at 30°C in LB broth and were then
washed, re-suspended and cultured overnight at 30°C in
iron-deficient CAA medium (composition: 5 g l−1 low-iron
CAA (Difco), 1.46 g l−1 K2HPO4 3H2O, 0.25 g l−1 MgSO4
7H2O. Carbenicillin was added at a concentration of
150 μg ml−1 when required.
Mutant construction
All enzymes for deoxyribonucleic acid (DNA) manipulation
were purchased from Fermentas and were used in accord-
ance with the manufacturer’s instructions. Escherichia coli
strain TOP10 (Invitrogen) was used as the host strain for all
plasmids. The DNA fragments from P. aeruginosa used for
cloning were amplified from the genomic DNA of the PAO1
strain with Phusion High-Fidelity DNA polymerase
(ThermoFisher Scientific). The primers used are listed in
Table S2. As previously described (Guillon et al., 2012),
the general procedure involved the insertion of the 700 bp
flanking sequences on either side of the gene to be deleted
into the pME3088 suicide vector (Voisard et al., 1994).
Mutations in the chromosomal genome of P. aeruginosa
were generated by transferring the suicide vector from E.
coli TOP10 strains into the PAO1 strain and allowing the
plasmid to integrate into the chromosome, with selection
for tetracycline resistance. A second crossing-over event
excising the vector was achieved by enrichment for
tetracycline-sensitive cells to generate the corresponding
mutants (Ye et al., 1995). All gene-deletion mutants were
verified by PCR and sequencing.
For construction of the complementation plasmid
encoding pfeA under the control of its own promoter, the
gene was amplified from the chromosomal DNA of P.
aeruginosa PAO1 by PCR with the pfeAatg-104F and
pfeAstop+31R primers (Table S2). The PCR fragment
was trimmed by digestion with EcoRI and HindIII and
inserted between the sites for these enzymes in
pMMB190 (Morales et al., 1991) and bacteria trans-
formed with this vector.
Growth and quantification of fluorescence intensity
The cells were cultured overnight in CAA medium,
pelleted by centrifugation and re-suspended in fresh CAA
medium, and the resulting suspension was diluted so as
to obtain an optical density at 600 nm of 0.01 units. We
dispensed 200 μl of the suspension per well into a 96-well
plate (Greiner, U-bottomed microplate). The plate was
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incubated at 30°C, with shaking, in a Tecan microplate
reader (Infinite M200, Tecan) for measurements of
OD600nm and mCherry (excitation/emission wavelengths:
570 nm/610 nm) fluorescence at 30 min intervals, for
40 h. After 8 h of culture, we added 200 μM enterobactin,
BCV or TCV and continued measurements of OD600nm and
mCherry fluorescence. We calculated the mean of three
replicates for each measurement.
Quantitative real-time PCR
Specific gene expression was measured by RT-qPCR, as
previously described (Gross and Loper, 2009). Briefly,
overnight cultures of strains grown in LB or CAA medium
were pelleted, re-suspended and diluted in fresh medium
to obtain an OD600nm of 0.1 units. The cells were then
incubated in the presence or absence of 10 μM
enterobactin, azotochelin, protochelin, BCV and TCV, with
vigorous shaking, at 30°C for 3 h (LB medium) or 8 h
(CAA medium). An aliquot of 2.5 × 108 cells from this
culture was added to two volumes of RNAprotect Bacteria
Reagent (Qiagen). Total RNA was extracted with an
RNeasy Mini kit (Qiagen), treated with DNase (RNase-
Free DNase Set, Qiagen) and purified with an RNeasy
Mini Elute cleanup kit (Qiagen). We then reverse-
transcribed 1 μg of total RNA with a High-Capacity RNA-
to-cDNA Kit, in accordance with the manufacturer’s
instructions (Applied Biosystems). The amounts of spe-
cific complementary DNAs were assessed in a StepOne
Plus instrument (Applied Biosystems) with Power Sybr
Green PCR Master Mix (Applied Biosystems) and the
appropriate primers (Table S1), with the uvrD messenger
RNA used as an internal control. The transcript levels for
a given gene in a given strain were normalized with
respect to those for uvrD and are expressed as a ratio
(fold change) relative to the reference conditions.
Proteomics analysis
For the digestion and cleanup steps, 109 P. aeroginosa
cells were lysed in 50 μl lysis buffer (2% sodium
deoxycholate, 0.1M ammoniumbicarbonate) and dis-
rupted by two cycles of sonication for 20 s (Hielscher
Ultrasonicator). Protein concentration was determined by
BCA assay (Thermo Fisher Scientific) using a small
sample aliquot.
Proteins were reduced with 5 mM TCEP [Tris
(2-Carboxyethyl) phosphine hydrochloride] for 10 min at
95°C, alkylated with 10 mM iodoacetamide for 30 min in
the dark at room temperature. Samples were diluted with
0.1M ammonium bicarbonate solution to a final concen-
tration of 1% sodium deoxycholate before digestion with
trypsin (Promega) at 37°C overnight (protein to trypsin
ratio: 50:1). After digestion, the samples were supple-
mented with TFA to a final concentration of 0.5% and HCl
to a final concentration of 50 mM. Precipitated sodium
deoxycholate was removed by centrifugation (15 min at
4°C at 14,000 rpm). Then, peptides were desalted on C18
reversed phase spin columns according to the manufac-
turer’s instructions (Macrospin, Harvard Apparatus),
dried under vacuum and stored at −80°C until further
processing.
For the shotgun proteomics assays, 1 µg of peptides of
each sample were subjected to liquid chromatography-
mass spectrometry (LC-MS) analysis using a dual pres-
sure LTQ-Orbitrap Elite mass spectrometer connected to
an electrospray ion source (both Thermo Fisher Scientific)
as described recently (Glatter et al., 2012) with a few
modifications. In brief, peptide separation was carried out
using an EASY nLC-1000 system (Thermo Fisher Scien-
tific) equipped with a reversed-phase high-performance
liquid chromatography column (75 μm × 45 cm) packed
in-house with C18 resin (ReproSil-Pur C18–AQ, 1.9 μm
resin; Dr. Maisch GmbH, Ammerbuch-Entringen,
Germany) using a linear gradient from 95% solvent A
(0.15% formic acid, 2% acetonitrile) and 5% solvent B
(98% acetonitrile, 0.15% formic acid) to 28% solvent B
over 120 min at a flow rate of 0.2 μl min−1. The data acqui-
sition mode was set to obtain one high-resolution MS
scan in the Fourier Transform part of the mass spectrom-
eter at a resolution of 240 000 full width at half-maximum
(at m/z 400) followed by tandem mass spectrometry (MS/
MS) scans in the linear ion trap of the 20 most intense
ions using rapid scan speed. The charged state screening
modus was enabled to exclude unassigned and singly
charged ions and the dynamic exclusion duration was set
to 30s. The ion accumulation time was set to 300 ms (MS)
and 25 ms (MS/MS).
For label-free quantification, the generated raw files
were imported into the PROGENESIS LC-MS software (Non-
linear Dynamics, Version 4.0) and analysed using the
default parameter settings. Tandem mass spectrometry
data were exported directly from PROGENESIS LC-MS in
mgf format and searched against a decoy database the
forward and reverse sequences of the predicted proteome
from P. aeruginosa (NCBI, http://www.ncbi.nlm.nih.gov/,
11985 protein sequences, downloaded 2014/01/10) using
MASCOT (version 2.4.0). The search criteria were set as
follows: full trypsic specificity was required (cleavage after
lysine or arginine residues); three missed cleavages were
allowed; carbamidomethylation (C) was set as fixed modi-
fication; oxidation (M) as variable modification. The mass
tolerance was set to 10 ppm for precursor ions and 0.6 Da
for fragment ions. Results from the database search were
imported into PROGENESIS, and the final peptide feature
list and the protein list containing the summed peak areas
of all identified peptides for each protein, respectively,
were exported from PROGENESIS LC-MS. Both lists were
further statically analysed using an in-house developed R
Ability of P. aeruginosa to acquire iron via catechols 11
© 2015 Society for Applied Microbiology and John Wiley & Sons Ltd, Environmental Microbiology
Ability of P. aeruginosa t cquire iron via c techols 829
VC l il y ons Ltd, Environ ental Microbiology, 18, 819–832
5.3 Published paper 107
script (SafeQuant) and the peptide and protein false dis-
covery rate was set to 1% using the number of reverse
hits in the dataset (Glatter et al., 2012).
Iron uptake
The protonophore CCCP was purchased from Sigma.
Obtained was 55FeCl3 from Perkin Elmer Life andAnalytical
Sciences (Billerica, MA, USA), in solution, at a concentra-
tion of 71.1 mM, with a specific activity of 10.18 Ci/g.
Siderophore–55Fe complexes were prepared at 55Fe con-
centrations of 20 μM, with a siderophore : iron (mol : mol)
ratio of 20:1. Iron uptake assays were carried out as
previously described for PVD–Fe transport (Schalk et al.,
2001; Hoegy and Schalk, 2014), except that bacteria were
grown in CAAmedium in the presence or absence of 10 μM
enterobactin or catechol chelator, to induce PfeA expres-
sion. The bacteria were then washed with 50 mM Tris-HCl
pH 8.0, to eliminate the siderophores used to induce PfeA
expression, and diluted to an OD600nm of 1. Bacteria were
then incubated in the presence of 200 nM chelator-55Fe,
and the incorporation of radioactivity into the bacteria over
time was monitored by filtration (Schalk et al., 2001; Hoegy
and Schalk, 2014). The experiments were repeated with
cells pretreated with 200 μM CCCP. This compound inhib-
its the proton-motive force across the bacterial cell mem-
brane, thereby inhibiting TonB-dependent iron uptake
(Clément et al., 2004). For the data presented in Table 1,
the radioactivity incorporated into the bacteria was moni-
tored after 15 min of incubation with the chelator–55Fe
complexes. Iron-55 uptake assays in the presence of
PCH-55Fe (200 nM) were carried out as for enterobactin
except that the bacteria were harvest by centrifugation, as
previously described (Hoegy et al., 2009; Hoegy and
Schalk, 2014), and not by filtration to avoid an adsorption of
PCH-55Fe on the GFB filters (Whatman).
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6.1 Abstract of the paper
The conjugation of siderophores to antimicrobial molecules is an attractive strategy to
overcome the low outer membrane permeability of Gram-negative bacteria. In this Trojan
horse approach, the transport of drug conjugates is redirected via TonB-dependent
receptors (TBDR), which are involved in the uptake of essential nutrients, including
iron. Previous reports have demonstrated the involvement of the TBDRs PiuA and PirA
from Pseudomonas aeruginosa and their orthologues in Acinetobacter baumannii in the
uptake of siderophore-beta-lactam drug conjugates. By in silico screening, we further
identified a PiuA orthologue, termed PiuD, present in clinical isolates, including strain
LESB58. The piuD gene in LESB58 is located at the same genetic locus as piuA in strain
PAO1. PiuD has a similar crystal structure as PiuA and is involved in the transport of
the siderophore-drug conjugates BAL30072, MC-1, and cefiderocol in strain LESB58.
To screen for additional siderophore-drug uptake systems, we overexpressed 28 of the
111
34 TBDRs of strain PAO1 and identified PfuA, OptE, OptJ, and the pyochelin receptor
FptA as novel TBDRs conferring increased susceptibility to siderophore-drug conjugates.
The existence of a TBDR repertoire in P. aeruginosa able to transport siderophore drug
molecules potentially decreases the likelihood of resistance emergence during therapy.
6.2 Statement of my work
Shotgun proteomic samples preparation and data analysis of PAO1 cells grown in Mueller-
Hinton broth (MHB) and in MHB treated with Chelex. Different TonB-defficient mutants
constructions and related proteomic analysis.
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ABSTRACT The conjugation of siderophores to antimicrobial molecules is an attrac-
tive strategy to overcome the low outer membrane permeability of Gram-negative
bacteria. In this Trojan horse approach, the transport of drug conjugates is redi-
rected via TonB-dependent receptors (TBDR), which are involved in the uptake of es-
sential nutrients, including iron. Previous reports have demonstrated the involve-
ment of the TBDRs PiuA and PirA from Pseudomonas aeruginosa and their
orthologues in Acinetobacter baumannii in the uptake of siderophore-beta-lactam
drug conjugates. By in silico screening, we further identiﬁed a PiuA orthologue,
termed PiuD, present in clinical isolates, including strain LESB58. The piuD gene in
LESB58 is located at the same genetic locus as piuA in strain PAO1. PiuD has a simi-
lar crystal structure as PiuA and is involved in the transport of the siderophore-drug
conjugates BAL30072, MC-1, and ceﬁderocol in strain LESB58. To screen for addi-
tional siderophore-drug uptake systems, we overexpressed 28 of the 34 TBDRs of
strain PAO1 and identiﬁed PfuA, OptE, OptJ, and the pyochelin receptor FptA as
novel TBDRs conferring increased susceptibility to siderophore-drug conjugates. The
existence of a TBDR repertoire in P. aeruginosa able to transport siderophore-
drug molecules potentially decreases the likelihood of resistance emergence dur-
ing therapy.
KEYWORDS Pseudomonas aeruginosa, TonB-dependent receptor, siderophore-drug
conjugate
With the shortage of novel classes of antimicrobials, alternative approaches aimingto increase antimicrobial penetration into Gram-negative bacteria have gained
widespread interest. Such approaches include the inhibition of broad-spectrum efﬂux
pumps (1), adjuvants that increase cell permeability (2), and the redirection of drug
uptake through speciﬁc nutrient transport systems (3). The most prominent example of
the latter approach is the hijacking of essential bacterial iron transport systems by
linking antimicrobial molecules to siderophores in a Trojan horse strategy. The recent
development of such compounds by all major pharmaceutical companies historically
involved in antimicrobial drug development highlights the increasing interest in this
appealing concept (4–7). So far, most of the efforts have focused on the design and
study of beta-lactam-siderophore conjugates. Since their targets are located in the
periplasmic space, the conjugates do not require further translocation across the inner
membrane. Moreover, the conjugates are designed such that the siderophore moiety
does not interfere with the drug target interaction and does not require prior cleavage
(8). The beta-lactam scaffolds used for the design of such conjugates include penicillins
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(9), cephalosporins (KP736 and ceﬁderocol) (7, 10), and monobactams (BAL30072 and
MC-1) (4, 5). The iron-binding moiety of these beta-lactam conjugates is either a
catechol-type siderophore such as dihydroxypyridone or a mixed catechol/hydroxam-
ate (11). Both the monobactam (5, 12–14) and the cephalosporin conjugates (15)
showed potent activity against the Gram-negative nonfermenters Pseudomonas aerugi-
nosa and Acinetobacter baumannii.
Two TonB-dependent receptors (TBDRs), PiuA and PirA, have been shown to be
responsible for the uptake of BAL30072, MC-1, and ceﬁderocol in P. aeruginosa (5, 16,
17). We previously observed that some P. aeruginosa isolates did not carry the piuA
gene, although they were susceptible to BAL30072 (16). Therefore, we suspected that
other TonB-dependent receptors (TBDRs) might be present in these strains or that their
expression differs with respect to the PAO1 reference strain. Furthermore, the expres-
sion of TBDRs is often regulated by sigma/anti-sigma factors or two-component
systems (18) and is induced by the presence of the corresponding siderophore (19, 20).
These receptors could potentially participate in siderophore-drug uptake, but their
contribution is masked under standard noninducing conditions. Therefore, we per-
formed an in silico screen for PiuA orthologues in the P. aeruginosa genome database,
and we additionally expressed from plasmids 28 of the 34 TBDRs of PAO1. This enabled
us to identify a novel TBDR, termed PiuD, sharing 60% amino acid identity with PiuA,
as well as ﬁve additional TBDRs of PAO1, potentially involved in the uptake of three
different siderophore-drug conjugates, including the most recent catechol-based com-
pound, ceﬁderocol (21).
RESULTS
piuD and piuA encode homologous proteins and are mutually exclusive in P.
aeruginosa genomes. We and others (5) previously identiﬁed the TonB-dependent
receptors (TBDR) PiuA and PirA as transporters for the uptake of siderophore-drug
conjugates BAL30072 and MC-1 (Fig. 1) both in P. aeruginosa (16) and in A. baumannii
(22). When performing PCR ampliﬁcations of piuA from P. aeruginosa clinical isolates, we
noticed the absence of a piuA signal in 54% of genotypically nonredundant isolates
FIG 1 Siderophore-drug conjugates used in this study. BAL30072 and MC-1 contain a dihydroxypyridone
as a siderophore, while ceﬁderocol contains a chlorinated catechol group.
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collected from intensive care unit patients (data not shown). We performed a homology
search for potential orthologues of PiuA in the genome of LESB58, a strain that we
previously showed lacks the piuA gene (16). The BLAST algorithm identiﬁed an open
reading frame (ORF) of 766 amino acids in strains LESB58 (PALES_48941) and 39016
(PA39016_000870080), showing 60% amino acid identity with PiuA of PAO1 (753 amino
acids). The highest sequence identity was observed in the N terminus (99% amino acid
identity in the ﬁrst 84 residues, including the signal sequence) and the putative
substrate binding loops (NL1 to NL3) (see Fig. S1 in the supplemental material). We
termed this PiuA orthologue PiuD. The piuD gene has a GC content of 59%, which is
below the average of 66% for P. aeruginosa. To determine whether piuD would be
present in strains from which piuA could not be ampliﬁed, we performed a multiplex
PCR with piuA and piuD primer sets on the same set of genetically distinct clinical
isolates tested above for piuA. The multiplex PCR conﬁrmed our hypothesis, showing a
PCR band either for piuA or for piuD, suggesting that both genes are mutually exclusive
in P. aeruginosa genomes (see Fig. S2A). The piuD gene was found to be embedded in
the same genomic context as piuA (16), since the gene products of piuB (PA4513)
located downstream of piuA and those of the two genes piuC (PA4515) and piuE
(PA4516), transcribed in an opposite direction, shared 98% amino acid identities with
their homologues in LESB58 (Fig. S2B).
Contribution of PiuD and PirA to the activity of siderophore-beta-lactam
conjugates. We compared the contributions of PiuA and PiuD with that of PirA,
conserved in PAO1 and LESB58, to the activity of various siderophore-drug conjugates.
To this end, we constructed deletion mutants in the piuD (PALES_48941) and pirA
(PALES_43851) genes of LESB58. We tested the monobactam drugs BAL30072 (4) and
MC-1 (5), conjugated to a hydroxypyridone siderophore, as well as the cephalosporin
derivative ceﬁderocol, linked to a catechol siderophore (7) (Fig. 1). In the PAO1
background, both types of conjugates were strongly affected by the deletion of piuA (8-
to 32-fold increase in MICs) but not by a pirA deletion. Surprisingly, the deletion of the
pirA gene in the LESB58 background showed a stronger effect on the activities of the
hydroxypyridone conjugates (8- to 16-fold increase in MICs) than on the catechol
conjugate ceﬁderocol (2-fold increase in MICs). Conversely, the deletion of piuD in-
creased ceﬁderocol MICs 32-fold, while MICs for MC-1 and BAL30072 increased by only
2- and 4-fold, respectively (Table 1). This could reﬂect the different expression levels of
these receptors and/or the different afﬁnities for the two types of siderophore-drug
conjugates.
To address this question, we extracted RNA from PAO1 and LESB58 from late
exponential-phase cells grown under the same conditions as for the MIC assays and
measured by reverse transcription-quantitative PCR (qRT-PCR) the expression of piuA
and piuD in comparison to that of pirA. As shown in Fig. 2, pirA was expressed 3-fold
less than piuA in PAO1, while the relative expression levels between pirA and piuD were
comparable in strain LESB58. The low basal expression level of pirA might therefore not
be sufﬁcient to contribute to siderophore-drug uptake in PAO1, as highlighted by the
TABLE 1 Susceptibility of piuD and pirA deletion mutants of P. aeruginosa PAO1 and
LESB58
Strain
MIC (mg/liter)a
BAL MC-1 ATM CFD CAZ
PAO1 1 0.5 4 0.5 2
PAO1ΔpiuA 8 8 4 8 2
PAO1ΔpirA 1 0.5 4 0.5 2
PAO1ΔpiuAΔpirA 16 16 4 16 2
LESB58 1 1 16 0.06 4
LESB58ΔpiuD 4 2 16 2 4
LESB58ΔpirA 16 8 16 0.125 4
LESB58ΔpiuDΔpirA 32 32 16 4 4
aMICs were determined in MHB-Chelex. BAL, BAL30072; ATM, aztreonam; CFD, ceﬁderocol; CAZ, ceftazidime.
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identical MIC values of the pirA mutant and the wild-type strain PAO1 (Table 1). In
contrast, in LESB58, PirA seemed to transport preferentially the hydroxypyridones
BAL30072 and MC-1, while ceﬁderocol uptake occurred mainly via PiuD. Since PirA
amino acid sequences from PAO1 and LESB58 (PALES_43851) are 99% identical, this
difference was not due to altered substrate afﬁnities.
Crystal structure of PiuD from P. aeruginosa. We previously determined the
crystal structure of PiuA from P. aeruginosa and its orthologue from A. baumannii (22).
Here, we determined the structure of PiuD from strain 39016, which shows 99.6%
amino acid identity with PiuD (PALES_48941) from LESB58. The obtained PiuD structure
was similar to that of PiuA from PAO1. The crystallographic asymmetric unit has two
monomers (denoted A and B). PiuD comprised two domains, a 22-stranded transmem-
brane -barrel and an N-terminal plug domain (residues 27 to 156) folded inside the
barrel (Fig. 3). The plug domain has two -sheets and two -helices, which together,
occluded the central pore. As often occurs in the TBDR structures, some of the
extracellular loops were not experimentally located in the PiuD structure. In the B
monomer, these regions, namely, NL1 (83 and 84), NL3 (113 and 114), the loop 138
to 141 of the plug domain, L7 (504 to 530), L8 (564 to 572), and L9 (609 to 624), were
presumed to be disordered. The closest structural relatives were PiuA of A. bau-
mannii (root mean square deviation [RMSD] of 1.1 Å over 701 residues) and P.
FIG 2 Expression analysis of pirA and piuA in PAO1 and pirA and piuD in LESB58. RNA was extracted from
cells grown to late exponential phase in MHB. qPCR was performed using target-gene-speciﬁc primers.
Expression of pirA is 3-fold lower than piuA in a PAO1 background, while piuD and pirA expression levels
are comparable in strain LESB58. Values are the expression ratios of the target gene divided by the rpsL
housekeeping gene. The expression of piuA and piuD was set to 1 (100%) in the respective strain. Values
show the means from three independent experiments performed in duplicates. Error bars indicate
standard deviations. *, P  0.05 by Student t test; ***, P  0.001 by analysis of variance (ANOVA); ns, not
signiﬁcant.
FIG 3 Crystal structure of PiuD from P. aeruginosa. Side (A) and extracellular (B) views of PiuD. The 22-stranded
transmembrane -barrel is colored in green. -Sheets of the plug domain are colored in yellow, loops in green, and
helices in red. (C) Structural comparison between PiuA (light blue) and PiuD (green).
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aeruginosa (1.1 Å over 656 residues) and the pyochelin receptor FptA from P.
aeruginosa (1.8 Å over 655 residues) (23). As a consequence of the disorder, one side
of the extracellular -barrel was absent. A “belt” of outward facing hydrophobic
residues (Trp 445, 486, 541, and 594, Phe 157, 180, 217, 350, 648, and 731, and Tyr
645 and 685), sits at the periplasmic end of the barrel, a characteristic of outer
membrane proteins.
Proteomic analysis under Fe chelation. To identify further siderophore-drug
transporters, we reasoned that under iron-limiting conditions, the expression of Fe-
repressed TBDRs would be upregulated and could potentially contribute to the trans-
port of siderophore-drug conjugates. Therefore, we performed a proteome analysis
using PAO1 cells grown in Mueller-Hinton broth (MHB) and in MHB treated with Chelex,
which complexes ferric iron but also divalent metal cations. The TBDRs for the endog-
enous siderophores pyochelin (FptA) and pyoverdin (FpvA and FpvB) showed the
strongest induction in the Chelex-treated medium (40- to 130-fold increases) (Fig. 4).
We also observed an induction of the heme receptors PhuR and HasR, as well as of the
Zn transporter ZnuD. The expression of the known siderophore-drug transporters PiuA
and PirA increased 2- and 10-fold, respectively, upon iron chelation. Among the TBDRs
expected or reported to transport xenosiderophores, 11 showed a 2-fold increase in
expression. CirA was below the 2-fold induction threshold, and six xenosiderophore
receptors were not expressed or were expressed below the detection limit.
Constitutive expression of TonB-dependent receptors in PAO1. To assess the
possible involvement of these receptors in siderophore-drug uptake, we cloned 26 of
the 34 TBDR genes from PAO1 (see Table S1), including the Chelex-induced TBDRs
(FiuA, FemA, FoxA, OptJ, OptN, ChtA, and CirA) and those that were undetectable. We
cloned the corresponding genes into a vector harboring a constitutively expressed
promoter in P. aeruginosa and transferred the resulting plasmids into strain PAO1. We
excluded the heme/hemophore transporters (PhuR, HasR, HxuC, and OptI), the cobal-
amin transporter BtuB (PA1271), and the citrate receptor FecA. For comparison, we
included the previously identiﬁed receptor genes piuA and pirA, as well as the newly
identiﬁed piuA orthologue piuD. The susceptibility data clearly showed that six TBDRs,
namely, PiuD, OptJ, FemA, OptE, PfuA, and FptA, increased by at least 4-fold the
susceptibility of PAO1 to the three siderophore-drug conjugates tested (shown in bold
in Table 2). The strain harboring pPA0151 showed a 4-fold increase in susceptibility only
FIG 4 Proteomic analysis of TBDRs from P. aeruginosa PAO1. Protein expression levels were compared
between cells grown for 20 h in MHB or Chelex-treated MHB. The dashed line indicates the 2-fold
induction threshold level.
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for the dihydroxypyridone-containing drugs BAL30072 and MC-1, and the strain har-
boring ChtA only showed increased susceptibility for the catechol-based ceﬁderocol.
Surprisingly, the overexpression of PfuA, which was undetectable by proteome analysis,
produced the largest increase in susceptibility (32-fold for BAL30072). With the
exception of a 4-fold-decreased MIC for ceftazidime (pPA0151), we observed no
signiﬁcant changes in MICs for the nonsiderophore drugs aztreonam and ceftazidime.
Since OptJ was induced to a similar level as PirA under Chelex treatment (Fig. 4), we
constructed deletions in optJ in PAO1 and its piuA and pirA deletion mutants. As for a
pirA deletion in PAO1, optJ deletion had no effect on siderophore-drug conjugate MICs
(see Table S4). However, a consistent 2-fold increase in BAL30072 MICs in a piuA
deletion background suggests a minor contribution of OptJ under uninduced condi-
tions in a PAO1 background.
To assess whether the observed changes in susceptibility could result from indirect
effects on the expression level of the main siderophore-drug transporter PiuA, we
introduced the relevant constructs in a PAO1ΔpiuA deletion mutant and tested the
drug susceptibilities. PiuA, PirA, and PiuD expression decreased the MICs of all three
siderophore-drug conjugates by 8- to 32-fold (Table 3). Interestingly, PirA overex-
pression produced only a 4- to 8-fold MIC decrease for ceﬁderocol compared to that of
the vector control, while PiuD expression resulted in a32-fold MIC decrease (Table 3).
This ﬁnding is in agreement with the susceptibilities of pirA and piuD mutants in strain
LESB58 (Table 1), which suggested preferential transport of ceﬁderocol via PiuD. The
overexpression of PfuA showed MIC changes exceeding those conferred by PiuA and
TABLE 2 Effect of overexpression of TonB-dependent receptors on P. aeruginosa
susceptibilities to three siderophore-drug conjugates
Strain or plasmida
MIC (mg/liter)b
BAL MC-1 ATM CFD CAZ
PAO1 1 0.25 4 0.5 1
pIApX2 (vector) 1 0.25 4 0.5 1
ppiuA1.1 0.06–0.125 0.06 4 0.03–0.06 1
ppirA1.1 0.06–0.125 0.06 4 0.03–0.06 1
ppiuD 0.06–0.125 0.03 4 0.03 1
poptJ (PA0434) 0.06–0.125 0.03 4 0.03–0.06 1
pfemA (PA1910) 0.125 0.06 2 0.06 1
poptE (PA2911) 0.25 0.06 2 0.125 1
ppfuA (PA1322) 0.03 0.03 2 0.03 1
pfptA 0.125 0.06 2 0.125 0.5
pPA0151 0.25 0.06 2 0.25 0.25
pchtA (PA4675) 0.5 0.125 2 0.125 NDc
pﬁuA (PA0470) 0.5 ND 4 0.25 1
pfoxA (PA2466) 1 0.125 2 0.25 1
ppfeA (PA2688) 1 0.25 4 0.5 ND
pcirA (PA1922) 1 0.25 4 0.25–0.5 1
poptN (PA1365) 1 0.25 4 0.5 ND
poptF (PA2590) 1 ND 4 0.5 0.5
poptQ (PA2289) 1 ND 2 0.25 0.5
poptR (PA3268) 1 0.25 2 0.5 1
pznuD (PA0781) 1 ND 2 ND ND
optO (PA2335) 0.5 0.25 2 0.5 1
poptP (PA0192) 1 0.25 2 0.5 1
poptL (PA2089) 1 0.25 4 0.5 1
poptC (PA4837) 1 0.125 2 0.5 1
pPA1613 1 0.125 4 0.5 1
poptM (PA2070) 1 0.25 4 0.5 1
psppR (PA2057) 0.5 0.25 4 0.5 2
pfvbA (PA4156) 0.5 0.125 4 0.5 0.5
pfpvA 2 0.5 8 0.5 1
pfpvB 1 0.25 4 1 1
aPlasmids in boldface font conferred a 4-fold increase in susceptibility to all siderophore-drug conjugates
compared to the vector control.
aBAL, BAL30072; ATM, aztreonam; CFD, ceﬁderocol; CAZ, ceftazidime.
cND, not done.
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PirA, suggesting efﬁcient siderophore-drug transport independent of PiuA. Similar
results were obtained in a piuA-pirA double mutant (data not shown). On the other
hand, FptA and OptE expression produced 2- to 8-fold decreases for MC-1 and
ceﬁderocol, and OptJ produced a decrease only for MC-1. Finally, FemA and PA0151
expression showed no signiﬁcant MIC changes in a piuA deletion mutant, suggesting an
indirect effect on PiuA expression, when overexpressed in a PAO1 wild-type strain.
To further evaluate if additional TBDRs would be involved in the uptake of
siderophore-drug conjugates, we determined the susceptibilities under iron-limited
growth conditions in MHB Chelex and in a minimal Casamino Acids medium. We
observed 2-fold decreases in MICs of BAL30072 and MC-1 in PAO1 and the pirAmutant,
and a 4- to 8-fold drop in the piuA mutant backgrounds. The increase in susceptibility
was even more pronounced for ceﬁderocol (8- to 64-fold decreases) for the strains
tested. MICs for the nonsiderophore drugs aztreonam and ceftazidime were not
affected (see Table S5). The MICs were comparable or even lower than those obtained
by the overexpression of the individual receptors from the plasmids in the piuA mutant
background (Table 3), suggesting a simultaneous expression of several TBDRs besides
PiuA and PirA for the uptake of siderophore-drug conjugates in P. aeruginosa under
iron-limited conditions.
DISCUSSION
The Trojan horse strategy has recently gained renewed interest, as illustrated by the
development of novel siderophore-beta-lactam conjugates by pharmaceutical compa-
nies (4, 12) and academic research groups (9, 24). These differ in the beta-lactam
scaffolds (penicillins, monobactams, and cephems) as well as the attached siderophore
moieties (mono-, tris-catechols and mixed catechol-hydroxamates). Initial investiga-
tions have identiﬁed two TBDR proteins, PiuA and PirA, in P. aeruginosa (5, 16) and their
orthologues in A. baumannii (22). These are the main transporters for BAL30072 and
MC-1. While the deletion of these TBDRs affected the activity of these compounds
under standard MIC determination conditions, it remained unclear whether additional
TBDRs expressed under iron deﬁciency or upon substrate-induced expression can
contribute to drug susceptibility.
We have addressed these questions by screening for orthologues of PiuA in clinical
strains and by overexpressing 28 of the 34 TBDRs from P. aeruginosa PAO1, thereby
mimicking induction under speciﬁc physiological conditions or by natural substrates.
An in silico screen identiﬁed PiuD in LESB58 and other clinical isolates as a homologue
of PiuA, sharing 60% amino acid identity. The piuD gene was located in the same
genetic environment as piuA, including the conserved intergenic promoter region (see
Fig. S2 in the supplemental material). The lower GC content of the piuD gene (59%
compared to 66% for PAO1) suggests an acquisition by horizontal gene transfer. The
TABLE 3 Effect of overexpression of TonB-dependent receptors on siderophore-drug
conjugates activities in a piuA deletion mutant of P. aeruginosa
Strain or plasmid
MIC (mg/liter)a
BAL MC-1 ATM CFD CAZ
PAO1ΔpiuA 8 2 8 8 2
pIApX2 (vector) 8 4 4 8 2
ppiuA 0.25 0.03 4 0.06 2
ppirA 0.25 0.06 4 1–2 2
ppiuD 0.125 0.03 8 0.03–0.125 2
ppfuA 0.03 0.03 4 0.03 2
pfptA 4 0.5 2 0.25 2
poptE 4 0.5 4 2 2
poptJ 4 1 4 4–8 2
pfemA 8 2 4 8 2
pPA0151 8 4 2 8 1
aMIC changes of 4-fold compared to the vector control are shown in boldface font. BAL, BAL30072; ATM,
aztreonam; CFD, ceﬁderocol; CAZ, ceftazidime.
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natural substrates of PiuA and PiuD are unknown, but the presence of conserved genes
within the piu locus, including the oxidoreductase genes piuC and piuB and the ORF
PA4516 (piuE), suggests that the metabolic fates of the natural substrates of these
receptors are similar.
The amino acid similarity between PiuA and PiuD (Fig. S1) results in very similar
crystal structures (Fig. 3). Like PiuA, PiuD also has a distinctive cluster of aromatic and
positively charged residues located inside the pore at the extracellular face (see Fig. S3).
This cluster is formed by Trp residues 311 and 327, Tyr 309, 710, and 714, Phe 94 (from
the plug domain), His 713, and Arg 329 and 333 (Fig. S3). In PiuA, Trp 239, Tyr 307, 325,
and 697, Phe 94, His 700, Lys 329, and Arg 331 form a cluster in the same position (Fig.
S3). In the pyoverdin (FpvA) and pyochelin (FptA) receptors, this cluster is directly
involved in the recognition of siderophores (23, 25). So far, there is no cocrystal
structure available for a TBDR with its siderophore-drug conjugate, and only two
cocomplexes between natural siderophores and their corresponding receptors have
been solved (26–28). However, several binding and mutation studies regarding sidero-
phore receptors and their cognate substrates have been reported (29–31), and their
results are compatible with biphasic binding kinetics involving an initial binding in the
loop extremities and a secondary binding at a site deeper inside the barrel, leading
eventually to substrate translocation.
Our proteomic analysis revealed that divalent metal cation chelation induced the
expression of 18 of the 34 TBDRs in PAO1. These include receptors for the endogenous
siderophores pyoverdin (FpvA and FpvB), pyochelin (FptA), and nicotianamine (OptC)
(32), as well as the heme (PhuR and HasR) and zinc (ZnuD) transporters. The other
induced receptors could transport xenosiderophores that P. aeruginosa may encounter
in the environment or during polymicrobial infections. A subset of these likely requires
the cognate siderophore as an inducer. One example is PfeA from PAO1, sensing the
presence of the exogenous siderophore enterobactin from Escherichia coli via the
two-component system PfeR-PfeS (33). Similarly, the siderophore mycobactin from
Mycobacterium smegmatis induces by 30-fold the expression of FemA in P. aeruginosa
(19). Strikingly, the overexpression of PfuA resulted in the largest increase in suscep-
tibility to all three siderophore-drug conjugates tested. The closest homologues of PfuA
turned out to be PiuA in PAO1 and PiuD in LESB58, both sharing a 39% amino acid
identity (57% similarity). The natural substrate of PfuA is unknown. A Fur binding site
precedes the pfuA gene (34), suggesting iron repression; however, additional regulators
and the presence of the substrate are likely required for induction of this TBDR in PAO1.
Its closest orthologue in E. coli is Fiu, a TBDR also involved in the transport of BAL30072
(our unpublished data). Other receptors, undetectable by mass spectrometry (MS)
analysis, may respond to other organic compounds or metal ions. Importantly, we
identiﬁed the pyochelin receptor FptA as a candidate for the uptake of siderophore-
drug conjugates. This receptor is the most highly induced receptor under iron limita-
tion, as highlighted by our proteome analysis. FptA is also strongly expressed in lung
and blood samples from mice and rats infected with P. aeruginosa and in human urine
and respiratory samples (D. Bumann, unpublished results). The identiﬁcation of the
natural substrates of xenosiderophore receptors, as for instance PfuA, should provide
an elegant way to induce speciﬁcally the expression of a receptor for the uptake of
siderophore-drug conjugates. It also remains to be determined if siderophore-drug
conjugates can act as inducers of their own transport, although this would require
conjugate analogues deprived of antibiotic activity. The increased susceptibility to all
three siderophore-drug conjugates under iron-limited conditions supports our ﬁndings
on the plasmid-mediated expression of the individual TBDRs.
In summary, we have provided evidence for an overlapping subset of TBDRs in P.
aeruginosa able to transport three different siderophore-drug conjugates, presenting
two different types of iron-complexing substituents and on the basis of two classes of
beta-lactams. The redundancy of TBDR recognition proﬁles should be an advantage
during therapeutic treatments, since it should limit the risk of resistance emergence to
these novel drug conjugates.
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MATERIALS AND METHODS
Bacterial strains and growth conditions. The strains and plasmids used in this study are listed in
Table S1 in the supplemental material. E. coli and P. aeruginosa were grown in lysogeny broth (LB) at 37°C
with shaking (250 rpm). E. coli DH10B was used as the cloning host and E. coli SM10 as the donor for
biparental matings. Gentamicin (15 g/ml for E. coli and 50 g/ml for P. aeruginosa) or carbenicillin (200
g/ml) was added for plasmid -carrying strains. MICs were determined in Mueller-Hinton broth (MHB)
according to CLSI guidelines (35) and were repeated at least on three different occasions. Cation-
depleted MHB was prepared by dissolving 11 g of Chelex (C7901; Sigma-Aldrich) in 100 ml MHB. After
stirring for 6 h, the suspension was ﬁltered and the ﬁltrate autoclaved at 115°C for 15 min. The
Chelex-treated MHB was supplemented with 2 mM MgSO4 and 0.2 mM CaCl2 (ﬁnal concentrations). The
M9 Casamino Acids medium contained 1 M9 salts, supplemented with 0.5% Casamino Acids (ﬁlter
sterilized), and 2 mM MgSO4.
PCR ampliﬁcations and DNA modiﬁcations. PCR primers are listed in Table S2. All primer se-
quences were based on the sequences from the pseudomonas.com website (36). For screening PCRs,
bacterial cells were boiled at 95°C for 5 min and subsequently pelleted at 13,000 rpm for 1 min. Phusion
DNA polymerase (Thermo Scientiﬁc) was used for high-ﬁdelity PCRs (supplemented with 5% dimethyl
sulfoxide [DMSO]). Restriction digestions were performed according to the manufacturer’s instructions at
the appropriate temperature. All ligation reactions were carried out at room temperature using T4 DNA
ligase (Promega). DNA preparations were performed using the GeneJET PCR puriﬁcation or the GeneJET
gel extraction kit (Thermo Scientiﬁc).
Construction of knockout mutants. The generation of unmarked knockout mutants was based on
the protocol described by Hoang et al. (37). Brieﬂy, DNA fragments of 500 to 700 bp were PCR-ampliﬁed
using primer pairs A1/A2 and B1/B2, respectively. For the deletion of pirA in strain LESB58, the up- and
downstream regions ﬂanking the gene were PCR ampliﬁed. For the knockout of piuD in strain LESB58,
the ampliﬁed fragments were located in the 5= and 3= regions of the genes. After ampliﬁcation, the
obtained A and B fragments were gel puriﬁed, and approximately 40 ng of each fragment was used in
a PCR fusion ampliﬁcation with primers A1 and B2, which share an 18-bp homologous region. The
resulting fusion products were gel puriﬁed and further cloned into the suicide vectors pEX18Gm via
HindIII/EcoRI restriction sites (pirA) and pEX18Gm via SalI/EcoRI (piuD). The cloned knockout fragments
were veriﬁed by sequencing. The replacement vectors were mobilized into P. aeruginosa via biparental
conjugation, and the generation of the unmarked mutants was carried out as previously described (38).
The deﬁned gene knockouts were veriﬁed by PCR ampliﬁcation using the external primers and subse-
quent Sanger sequencing.
Construction of expression plasmids. The coding regions, including at least 50 nucleotides (nt)
upstream of the ATG initiation codon and 20 nt downstream of the STOP codon, were ampliﬁed by PCR
from genomic DNA of P. aeruginosa 39016 (piuD) or PAO1. The piuD coding region was ampliﬁed with
primers piuD-Xba and piuD-Hind and cloned as a 2,526-bp XbaI-HindIII DNA fragment into the expres-
sion vector pIApX2, yielding plasmid ppiuD. All other constructs were prepared in a similar way using the
primers shown in Table S2. The Q5 high-ﬁdelity DNA polymerase (NEB) was used for all ampliﬁcations.
PCR conditions were as follows: denaturation at 98°C for 2 min, followed by 27 cycles of 98°C for 20 s,
57°C for 30 s, and 72°C for 2 min, and a ﬁnal extension at 72°C for 4 min. The plasmids were transferred
into P. aeruginosa by electroporation, and cells were spread on LB agar supplemented with carbenicillin
at 200 mg/liter. All constructs were veriﬁed by Sanger sequencing.
Quantitative real-time PCR. Overnight cultures of strains grown in LB were diluted and inoculated
into fresh MHB and grown in microtiter plates (200 l/well) until reaching late exponential phase. Three
wells were combined to form one sample. RNA was extracted using the RNeasy kit (Qiagen, Germany),
according to the manufacturer’s protocol. Residual genomic DNA was removed by treatment with
RNase-free DNase (Promega). One microgram of RNA was reverse transcribed using ImProm-II reverse
transcriptase (Promega). Gene-speciﬁc primers were used for PCRs using the Rotor-Gene SYBR green PCR
kit (Qiagen). qPCRs were performed in a Rotor-Gene 3000 (Corbett Research, Australia) using the
following conditions: 2 min at 95°C, followed by 35 cycles of 20 s at 95°C, 30 s at 60°C, and 30 s at 72°C,
followed by a ﬁnal extension at 72°C for 3 min. The ribosomal rpsL gene was used as a housekeeping
reference gene (39).
Cloning, overexpression, and puriﬁcation of PiuD from P. aeruginosa. The signal peptide of the
proteins was predicted with Signal P4.0 (40) and excluded from cloning. The coding sequence of the
mature protein was ampliﬁed from the genomic P. aeruginosa strain 39016 using KOD DNA polymerase
(Novagen) and the primers piuD-39016-F and piuD-39016-R. The PCR product was digested by BspHI and
XhoI restriction enzymes and cloned into the pTAMACHis6 vector using restriction sites NcoI and XhoI.
The construct results in an expressed protein with an N-terminal TamA signal sequence for the outer
membrane localization and a noncleavable C-terminal His6 tag. The pTAMACHis6 expression vector was
obtained by replacing the PelB signal peptide of pEPELBCHIS (courtesy of Huanting Liu, University St
Andrews) with the TamA signal peptide (41). PiuD was overexpressed in E. coli C43(DE3) cells. The
expression and puriﬁcation steps were as described for PiuA (22). The fractions were pooled and loaded
on a Superdex S200 gel ﬁltration column (GE Healthcare) equilibrated with 10 mM Tris (pH 8), 150 mM
NaCl, and 0.45% (vol/vol) tetraethylene glycol monooctyl ether (C8E4). Protein fractions were pooled and
concentrated to 10 mg/ml.
Crystallization and structure determination. Crystals of PiuD appeared at 20°C after a few days by
mixing 2 l of protein solution (10 mg/ml) with 1 l of reservoir solution containing 14% poly(ethylene
glycol) methyl ether (PEG MME 5000) and 0.1 M bicine (pH 9). Crystals were frozen with the same solution
containing 35% PEG MME 5000. The data were collected at ID23-1 at the ESRF. The data were processed
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with GrenADES (42–46). The structure of PiuD was solved by molecular replacement using P. aeruginosa
PiuA coordinates (PDB code 5FOK) as a model, with the program PHASER (47). The models were adjusted
with Coot (48), and the reﬁnement was carried out using REFMAC in the CCP4 program suite with TLS
parameters (49). The quality of all structures was checked with MolProbity (50). The ﬁgures were drawn
using PyMOL (version 1.8; Schrödinger, LLC). The ﬁnal reﬁnement statistics are given in Table S3.
Proteomics analysis. Sample preparation and MS analysis were performed as described previously
(33). Brieﬂy, P. aeruginosa was grown in MHB or MHB treated with Chelex (Sigma-Aldrich, Switzerland)
under standard MIC determination conditions in microtiter plates without shaking at 37°C for 18 h. The
cells from three wells were combined to yield sufﬁcient material for proteome analysis. Three replicate
samples were lysed, and the proteins were reduced with 5 mM Tris (2-carboxyethyl) phosphine
hydrochloride and alkylated with iodoacetamide. The samples were diluted before digestion with trypsin
at 37°C overnight. The peptides were desalted on a C18 reversed-phase column and dried under vacuum.
One microgram of peptide was injected into a liquid chromatography-mass spectrometer (LTQ-Orbitrap
Elite). The peptides were separated using an EASY nLC-1000 system (Thermo Fisher scientiﬁc) using a C18
high-performance liquid chromatography (LC) column. Tandem mass spectrometry data were exported
from Progenesis LC-MS and searched against a protein decoy database of P. aeruginosa.
Statistics. Data were analyzed and plotted using GraphPad Prism (ver 7.02).
Accession number(s). Atomic coordinates and structure factors for PiuD have been deposited in the
Protein Data Bank (accession no. 5NEC).
SUPPLEMENTAL MATERIAL
Supplemental material for this article may be found at https://doi.org/10.1128/AAC
.00097-18.
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Part IV
General discussion and
perspectives

7General Discussion
Antimicrobial resistance is a serious public health threat worldwide. Last resort antibiotics
are failing, threatening patients and the healthcare systems (ECDC., 2017). Developing
new antibiotics is a considerable challenge because of the rapid emergence of resistance
in bacteria through the genetic changes upon antibiotics exposure and the misuses
of antibiotic treatment by hospitals (ECDC., 2017). Gram-negative bacteria possess a
bacterial envelope composed of an outer membrane, a peptidoglycan layer and an inner
membranes that delimit a periplasmic space. The outer membrane plays a crucial role
due to its dual function as a protective layer against toxic compounds and as an interface
for nutrient exchange with the environment (Hancock and Brinkman, 2002). The outer
membrane is therefore the first line of bacterial defence against antibiotics. Pseudomonas
aeruginosa (P. aeruginosa) is intrinsically resistant to many antibiotics partly due to its
large number of porins and efflux pumps (Hancock and Brinkman, 2002). By this means, it
has a tight control over influx and efflux of molecules across the outer membrane, making
the development of novel therapeutic options even more challenging. The transport of
antibiotics across the outer membrane is thus a major issue.
An approach to circumvent the intrinsic resistance of pathogens, such as P. aeruignosa, is
the Trojan horse approach through the use of the bacterial transport machinery (Möllmann
et al., 2009; Mislin and Schalk, 2014). In a Trojan horse approach, a toxic compound
is efficiently transported across the outer membrane via endogenous bacterial active
transporters, i.e. the TonB-dependent transporters (TBDTs) in P. aeruginosa (Möllmann
et al., 2009; Mislin and Schalk, 2014). This includes non-iron metalloporphyrins, hybrid
siderophores and siderophore-antibiotic conjugates. The Trojan horse approach is by far
the most advanced strategy to solve the antibiotic translocation issue. However, several
studies reported a lack of correlation between in vitro efficacy and in vivo antibacterial
activity of such conjugates (McPherson et al., 2012a; Tomaras et al., 2013; Kim et al.,
2015a; Tillotson, 2016). Indeed, P. aeruginosa developed resistance to these conjugates
through facile inactivation of the TBDT transporting the conjugates (McPherson et al.,
2012a; Tomaras et al., 2013; Kim et al., 2015a; Tillotson, 2016). In order to prevent the
rapid development of resistance, the Trojan horse compound should target a subtrate
mimetics that is essential for the growth of P. aeruginosa in vivo. The substrate mimetic
would then be actively transported via one or several endogenous TBDTs, getting around
the vigilance of P. aeruginosa. Inactivation of the involved TBDT(s) would contribute
to the fitness reduction of the pathogen in vivo and would prevent the development of
antibacterial resistance.
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P. aeruginosa UCBPP-PA14 encodes a large number of TBDTs (Winsor et al., 2016).
Expression levels of the TBDTs are highly modulated by the environmental conditions
surrounding the pathogen: in vitro, preclinical and clinical environments might exhibit
different expression patterns of UCBPP-PA14 TBDTs. There have been several tran-
scriptomics studies on Pseudomonas to unravel its physiology in vivo (Son et al., 2007;
Bielecki et al., 2011; Bielecki et al., 2013), such as studies on biofilm formation, metabolic
networks (Turner et al., 2014), iron involvement during infection (Ochsner et al., 2002;
Damron et al., 2016) and secretion of virulence factors (Barbier et al., 2014; Wurtzel et al.,
2012). However the coverage of TBDTs remains poor, presumably due to their low level of
expression compared to the dominance of host materials in animal and human samples.
In order to develop successful Trojan horse compounds, we desperately need to get more
insights on bacterial transport capabilities in vivo. We thus developed an ultra-sensitive
targeted proteomic approach to determine absolutely the abundance of TBDTs in vitro
and in various hosts. Based on the expression data, we generated mutants lacking highly
expressed TBDTs and evaluated them in a competitive fitness assay in vivo.
7.1 Development of an ultra-sensitive targeted proteomic
approach
Advances made in discovery based proteomics approaches are largely due to techno-
logical improvements made in high performance mass spectrometers (Charretier and
Schrenzel, 2016). The development of increasing number of sophiticated techniques
allows for label-free quantification of P. aeruginosa bacterial proteins in different envi-
ronments (Charretier and Schrenzel, 2016). There have been several studies on the
identification and quantification of (i) enzymes responsible for antibiotic inhibition such
as cephasloporin AmpC (Glatter et al., 2015; Charretier and Schrenzel, 2016) and of
(ii) OprD porin loss (Choi et al., 2011; Toyofuku et al., 2012; Casabona et al., 2013) in
vitro. Two recent studies also measured the differential expression level of P. aeruginosa
in absence or presence of the antibiotics azithromycin and ciprofloxacin using the same
proteomic approach (Leal et al., 2016; Peng et al., 2017). To date, there are many studies
of quantitative proteomics of P. aeruginosa in vitro, however, only few studies on P. aerugi-
nosa proteome have been reported in vivo (Lassek et al., 2015; Charretier et al., 2015;
King et al., 2017). Indeed, proteomic analyses of P. aeruginosa in vivo are challenging
since the samples usually contain low loads of P. aeruginosa but a high excess of host
proteins.
We thus optimized with the proteomic core facility (PCF) of the Biozentrum, two targeted
proteomic assays to identify and absolutely quantify P. aeruginosa outer membrane
proteins: the selective monitoring reaction (SRM) and the parallel monitoring reaction
(PRM). SRM allows for reliable quantification of 10 – 100 target proteins in semi-complex
biological samples (Shi et al., 2012). This technique is widely used to identify and quantify
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protein biomarkers in different types of diseases (Shi et al., 2016). In contrast to SRM,
PRM enables higher resolution and higher sensitivity for absolute peptide quantification
in complex in vivo samples (Peterson et al., 2012). Indeed, this technique employs an
Orbitrap mass analyzer that reduces considerably the complex biological background
interferences with P. aeruginosa peptides. PRM methogology has been well documented
in several reviews (Shi et al., 2016) but in contrast to SRM, its reported applications
remain limited to analyses of plasma samples (Kim et al., 2015c; Lesur et al., 2015;
Thomas et al., 2015) and quantification of kinases in human cancer cell lines (Kim et al.,
2015b).
We collected and analyzed by PRM several preclinical and clinical samples containing
P. aeruginosa from different collaborators. PRM enables us to reach attomole sensitivity
and be able to detect as little as 10 copies per cell for certain peptides, despite the
excess of host proteins. This high sensitivity allowed for direct protein identification and
quantification in clinical samples from acute pneumonia patients that contain at least
around 100’000 CFUs per ml sputum/lavage. As a comparison, previous transcriptomic
studies were carried out with sputum from CF patients that contain up to 1000-fold higher
P. aeruginosa loads than in our samples (Palmer et al., 2005). The high level of resolution
and sensitivity of PRM enable us to quantify absolutely the TBDT abundance in several
in vivo samples. To our knowledge, we were the first to use PRM for bacterial protein
quantification in animal and human patients samples.
7.2 TBDTs expression levels correlate in human and animal
samples
P. aeruginosa physiology in vivo is poorly understood. In order to study the transport
capabilities of the pathogen, we would need a comprehensive list of the TBDTs expressed
in P. aeruginosa in vivo. P. aeruginosa gene expression has been extensively studied in
vitro, in animal models, and human patients (burn wounds (Bielecki et al., 2008; Turner
et al., 2014), bladder catheters (Sabharwal et al., 2014; Cole et al., 2014), CF sputum
with very high P. aeruginosa loads (Harmer et al., 2013)), but the expression of TBDTs
was overlooked, potentially because TBDTs are often poorly detected in vivo because of
the predominance of host material in the samples.
We analyzed the expression patterns of P. aeruginosa TBDTs in various samples: blood
from septicemia mouse model, mice and rat lung from intrabronchial model, and lung
and urine from acute pneumonia patients. Overall, proteomic analyses of P. aeruginosa
TBDTs revealed similar expression patterns in the animal models tested and in the human
patients samples, suggesting that P. aeruginosa presents similar transport capabilities
in these different conditions, despite of the potential differences in airway microbial
community and host innate immunity (Haley, 2003; Mestas and Hughes, 2004; Bryant
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and Monie, 2012). The expression data highlighted the presence of a subset of highly
abundant TBDTs among the different in vivo conditions. This subset included (i) the
engodenous siderophore TBDTs, especially the type I pyoverdine transporter FpvAI, (ii)
the non-iron heavy metal TBDTs (zinc-related ZnuD, cupper-related OprC) and, (iii) to a
lesser extent the heme TBDTs. The presence of these TBDTs indicated similar heavy
metal bioavailability in the different in vivo settings.
The highest abundance of pyoverdine transporter FpvAI was not unexpected in such
conditions since in vivo environment is characterized by iron scarcity (Parrow et al., 2013).
Therefore, P. aeruginosa might use its highest-affinity siderophore pyoverdine (1032 M-1)
to scavenge iron and to secrete PvdS-related proteases PrpL, AprA, exotoxin A and other
virulence factors (Balasubramanian et al., 2012). By this means, P. aeruginosa can thus
efficiently compete for iron against transferrin and lactoferrin (with binding constants of
1020-1021 M-1 and 1022-1024 M-1 respectively) (Xiao and Kisaalita, 1997; Majka et al.,
2013). In the lungs, the high-affinity pyochelin transporter FptA and the nicotianamine
transporter OptC, described to promote the growth of P. aeruginosa in an artificial lung
condition (Gi et al., 2014), were relatively highly expressed, suggesting that they might
partially contribute to iron scavenging in low oxygen conditions. Interestingly, OptC was
not detected in any of the human urine samples, which correlates with the potential
presence of ferrous iron, in the lung but not in urine, that nicotianamine binds with high
affinity in low-oxygen lung environment (Wirén et al., 1999; Callahan et al., 2007).
The high expression of ZnuD might reveal a poor bioavailability of zinc in these different
in vivo conditions. In the airway lumen, the high-affinity zinc transporter ZnuD abundance
could be explained by the presence of polymorphonuclear neutrophils that release calpro-
tectin, which sequesters zinc and manganese (D’Orazio et al., 2015). The copper-related
transporter OprC was also highly expressed, but so far we have no clear evidence on
OprC function in P. aeruginosa (Cunrath et al., 2015). Indeed, its role in the copper
acquisition is controversial (Cunrath et al., 2015), since OprC was shown to be repressed
by high concentration of copper (Yoneyama and Nakae, 1996) but it was not induce under
copper starvation in vitro, despite his high affinity for copper (Kd = 2.6 µM) (Frangipani
et al., 2008).
Heme transporters PhuR and HasR were relatively abundant in the animal lung samples,
whereas in human samples, we mainly found a constant expression of PhuR. The domi-
nance of PhuR over HasR was already described by Smith and coworkers (Smith and
Wilks, 2015). They showed that PhuR enables a heme transport that is more efficient
than HasR (Smith and Wilks, 2015). It was also shown in the Pseudomonas lineage DK2
clinical strain, that the loss of pyoverdine utilization was associated with mutations in the
promoter regions of the phu system, leading to an increased expression of PhuR (Marvig
et al., 2014). The absence of pyoverdine transporter FpvAI and the high abundance of
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PhuR in human lung samples seemed to correlate with an adaptation of P. aeruginosa
towards heme utilization as reporter by Marvig and coworkers (Marvig et al., 2014).
The expression levels of xenosiderophore TBDTs were quite variable among the dif-
ferent samples as expected due to the rich microbiome of the urinary tract (Whiteside
et al., 2015) and the lung environment (Dickson and Huffnagle, 2015). This information
might be valuable to identify the presence of other microorganisms at the site of infec-
tion, because the xenosiderophore TBDTs are induced in presence of their cognitive
siderophores. The ferri-alcalagin E transporter AleB, the ferrichrome transporter FiuA and
the ferri-mycobactin transporter FemA were relatively highly expressed compared to oth-
ers xenosiderophore TBDTs, their involvement in cell-surface signalling might contribute
to their higher expression (Llamas et al., 2014).
To summarize, PRM data revealed general insight into nutrient access in different hosts
during infection: heavy metal and heme were scarcely available during infection, therefore
P. aeruginosa harboured high affinity systems to scavenge these nutrients from the host.
TBDTs are considered as last resort transport systems employed upon starvation of
specific nutrients (Noinaj et al., 2010). It is thus surprising that P. aeruginosa employed
several TBDTs with similar transport capabilities. One possible explanation would be
that P. aeruginosa growth and/or pathogenesis might rely on few TBDTs that transport
essential nutrients while the other TBDTs are moderately expressed as part of a nutrient
surveillance program. We would still need to understand the reasons why P. aeruginosa
expressed so many TBDTs in vivo. Moreover, Turner and coworkers showed that gene
expression in vivo was not necessarily correlated with its importance for fitness in vivo
(Turner et al., 2014). Therefore, there is a crucial need to discriminate the relevant TBDTs
in vivo.
7.3 Unsuitable in vitro conditions might lead to misconceptions
According to the Committee for Laboratory Standards Institute (CLSI) or European Com-
mittee for Antimicrobial Susceptibility Testing (EUCAST), susceptibility testing should
be performed on specific standardized media, such as Mueller-Hinton broth (MHB) sup-
plemented with certain ions such as calcium and magnesium (Kahlmeter et al., 2006).
However, such rich media contain high levels of iron, e.g. 4 µM in LB (Cunrath et al.,
2015), which does not reflect the physiological concentration of iron in the host (10−24
M) (Raymond et al., 2003). Therefore, MIC determination of the Trojan horse conjugates
have been performed in iron-deficient conditions to evaluate their antibacterial acitivity
(Möllmann et al., 2009; Page et al., 2010; McPherson et al., 2012a; Kim et al., 2015a).
Despite these improvements, several studies reported a lack of correlation between in
vitro testing and in vivo efficacy of the conjugates (McPherson et al., 2012a; Tomaras
et al., 2013; Kim et al., 2015a; Tillotson, 2016), suggesting suboptimal in vitro assays. In
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order to prevent false positives and resistance emergence, the development of suitable in
vitro assays are critical to study the antibacterial activity of the conjugates and should be
representative of the in vivo restrictive conditions.
To assess this problem, we measured TBDTs expression level in commonly used lab-
oratory rich media (Mueller-Hinton broth (MHB) and Luria-Bertani medium (LB)), iron
restricted media (casamino acids medium (CAA)), iron-deficient media (M9 supplemented
with 30 mM succinate, BM2 with 20 mM acetonamine and chelexed CAA (chCAA) with
addition of essential metals). Expression levels of TBDTs in vitro exhibited a completely
different pattern than in vivo. Overall, all classes of TBDTs were constantly expressed
in rich and iron restricted/deficient media compared to the scattered in vivo expression.
Broad expression of TBDTs in rich media was not surprising as it was reported in a recent
study that even in a rich media like LB, growth of the bacteria depends on high affinity
transport capabilities (Cunrath et al., 2015). Even if the the absolute concentration of iron
is high in these conditions, iron is not necessarily bioavailable in its free form, it could be
either complexed to iron chelators present in the media or partially insoluble due to the
presence of oxygen.
P. aeruginosa showed 10 times higher TBDTs expression in CAA and chCAA than in
rich media, which was expected since CAA presents 200 times lower iron concentration
than LB (Cunrath et al., 2015). In contrast to CAA, expression level in minimal media
such as BM2 and M9 did not seem to rely on TBDTs, because iron concentration in these
media was higher than in CAA (Cunrath et al., 2015). P. aeruginosa growth in 100 %
human serum showed a different expression pattern than in human samples. Human
serum contains a variety of nutrients including proteins and peptides (such as albumins,
globulins, lipoproteins, enzymes and hormones), nutrients (such as carbohydrates, lipids
and amino acids), electrolytes, organic wastes and variety of other small organic molecules
suspended or dissolved in them (Psychogios et al., 2011). Iron concentration was
estimated as 9 mM in the human serum (Psychogios et al., 2011), which explains the low
contribution of the TBDTs to the growth of P. aeruginosa in this condition.
Together, our expression data suggested that CAA was the most suitable in vitro medium
among our media collection. In CAA, pyoverdine, pyochelin and heme TBDTs were
highly expressed, indicating severe restriction of iron in the medium, more than in vivo.
Moreover, levels of zinc did not correspond to in vivo, since the zinc-related transporter
ZnuD was expressed at basal level in CAA. In order to better reflect in vivo settings,
CAA should be depleted in zinc. Zinc deficiency could be achieve by using strong
zinc chelators: diethylenetriaminepentaacetic acid (DTPA) for mild zinc deficiency and
N,N,N’,N’-tetrakis(2-pyridylmethyl) ethylenediamine (TPEN) for severe zinc deficiency
(Cho et al., 2007). A number of xenosiderophore TBDTs were also highly expressed due
to the presence of siderophores such as enterobactin and ferrichrome, potentially derived
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from the bovine casein used to prepare the casamino acids mix (BD, 2017). Therefore,
CAA is also a good candidate to study xenosiderophore TBDTs. In order to mimic better
the lung environment, we might also consider to supplement CAA with mucin proteins
such as the principal component of mucin Muc5AC (WICKSTRÖM et al., 1998), in order
to induce the expression of the nicotianamine transporter OptC for example (Gi et al.,
2014). Other mucin-based media such as artificial lung media derived from human cell
lines or artificial sputum from porcine mucin might be a solution to mimic better the lung
environment.
Severe iron depletion, such as the one observed in CAA, would support the very high ex-
pression level of TBDTs. Because the siderophore-drug conjugates are mainly transported
by TBDTs, such severe iron restriction could lead to overly optimistic siderophore-drug
conjugate antibacterial activity in vitro. In MHB and LB, we showed that the expression
of PiuA and PirA, which transport most of the recent conjugates (Tomaras et al., 2013;
Kim et al., 2015a), were 5-10 times lower than in CAA, which might explain the increased
susceptibility of P. aeruginosa to BAL30072 in CAA (Van Delden et al., 2013; Moynié
et al., 2017). The difference in PiuA and PirA abundance between standard in vitro assay
and multiple in vivo conditions might also contribute to the inconsistent in vivo efficacy of
the recent siderophore-drug conjugates (Tomaras et al., 2013; Kim et al., 2015a).
Understanding the host microenvironment is thus essential for the development of in vitro
assays that better mimic in vivo phenotypes of P. aeruginosa. Deeper knowledge of P.
aeruginosa phenotypes in vivo is key to understand whether a specific in vitro assay is
suitable for the evaluation of the antibacterial activity of the Trojan horse mimetics.
7.4 Intranasal mouse infection model to evaluate bacterial
fitness in vivo
Animal models are a valuable tool to study lung physiology and pathology, they provide
insights in the initiation and the maintenance of P. aeruginosa infections. They are also
important resource for the development and the testing of new therapeutic options in
vivo. Rodents have been the most studied model organisms (Hudson-Shore, 2016).
Numerous in vivo infection models have been used to study P. aeruginosa virulence
(Kukavica-Ibrulj and Levesque, 2008). Acute pneumonia models are useful to study
non-CF-related pneumonia but might also be interesting to study the initial phase of lung
infection during P. aeruginosa colonization of CF airways. Acute pneumonia models are
mainly characterized by the introduction of free-living and mobile P. aeruginosa cells into
the lung (Kukavica-Ibrulj and Levesque, 2008).
Intranasal instillation is the most commonly used pneumonia mouse model for lung
infections (Miller et al., 2012). It has several advantages over its alternative methods
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(intubation and aerosol administration): (i) intranasal instillation is technically simple and
fast, since drops of inoculum are administrated at the nostril of the mouse; (ii) in contrast
to intubation, there are very little risk to injure the animals during the instillation. Most of P.
aeruginosa studies using the intranasal method employed the less virulent strain PAO1
(Minandri et al., 2016; Damron et al., 2016). Intranasal instillation with UCBPP-PA14 was
reported to be unsuccessful in establishing reproducible lung infection (Hilker et al., 2015).
Therefore, we developed an intranasal model, where the instillation was optimized using
inhaled anesthesia prior to mice instillation, as suggested by Miller and coworkers (Miller
et al., 2012).
Short inhalation of the general anesthetic isoflurane, prior to mice instillation, had a
significant impact on the success of the infection. Miller and coworkers speculated that
after the removal of the mice from the anesthesia chamber, the mice were in a transient
hypoxia, which resulted in deeper breathing and deeper inhalation of larger volumes
of inoculum per breath (Miller et al., 2012). This procedure may therefore facilitate
the efficient delivery of P. aeruginosa in the lower respiratory tract. By applying this
technique, we successfully managed to obtain reproducible results with UCBPP-PA14
using a intranasal method, in contrast to previous findings (Hilker et al., 2015).
The developed intranasal model was valuable for our in vivo analyses but it was not an
ideal model reflecting human pneumonia, because we used high loads of P. aeruginosa
cells (107 - 107 CFUs) and short period of infections (10 h), leading to few generations of
P. aeruginosa. However, it is common to use very high inocula in rodent models (Minandri
et al., 2016; Damron et al., 2016), unless we employ neutropenic mice. In addition, our
expression data showed patterns that were actually surprisingly similar from very artificial
rodent conditions to human pneumonia patients.
7.5 Endogenous siderophore TBDTs loss contributes to bacterial
fitness loss
Several studies highlighted the importance of TBDTs in vivo (Takase et al., 2000b; Noinaj
et al., 2010; Minandri et al., 2016; Damron et al., 2016). Inactivation of TonB1, which is
responsible for TBDTs substrates transport, was shown to render P. aeruginosa PAO1
completely avirulent in two mouse models of infection (Takase et al., 2000b; Minandri
et al., 2016), indicating that some TonB1-related TBDTs are crucial in vivo. In literature,
we found several reports on the relevance of pyoverdine, pyochelin and heme TBDTs in
vivo (Takase et al., 2000b; Marvig et al., 2014; Minandri et al., 2016; Damron et al., 2016).
On the other hand, the role of xenosiderophore TBDTs and their associated siderophores
have been poorly studied in vivo (Skurnik et al., 2013; Lee et al., 2016). In order to induce
the expression of xenosiderophore TBDTs (Gensberg et al., 1992; Llamas et al., 2006),
xenosiderophores from airway microbiota should be present in large quantities at the
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infection site and should successfully compete with endogenous siderophores (Hibbing
et al., 2010). Recently, inactivation of the ferrichrome transporter FiuA was shown to
reduce fitness and virulence of P. aeruginosa in vivo (Lee et al., 2016). Using a tranposon
library, the xenosiderophore TBDTS CirA, FoxA and OptL have also been associated with
virulence (Skurnik et al., 2013). Apart from FiuA, the other xenosiderophore TBDTs have
not yet been investigated in vivo, but seemed to have no impact on in vivo fitness in two
different mouse models (Skurnik et al., 2013; Turner et al., 2014).
Proteomic analyses revealed high expression levels for a subset of TBDTs. However, it
has been shown that high levels of expression were not always correlated with increased
fitness in vivo (Turner et al., 2014). Therefore, the contribution of these TBDTs was
investigated in vivo. Based on our expression data, series of TBDTs mutants were
generated and further tested in the developed intranasal model. In contrast to previous
studies, which all employed single-strain infections (Takase et al., 2000b; Minandri et al.,
2016; Damron et al., 2016), we used mixed infections to assess mutant fitness in presence
of a competing wild-type strain, a scenario more closely mimicking emergence of resistant
clones among wild-type bacteria.
In vivo competition assays revealed the dominant role of the endogenous siderophore
system pyoverdine in vivo. Inactivation of the pyoverdine TBDT or the pyoverdine system
(both transporter and synthesis of pyoverdine) (-PVD) led to a significant drop in fitness.
Pyoverdine is P. aeruginosa siderophore with the highest affinity to iron and its transporter
FpvA is involved in CSS, which induces the expression of several virulence factors (Llamas
et al., 2014; Hoegy et al., 2014). Therefore, the inactivation of the pyoverdine system
might affect both the iron acquisition and the virulence of P. aeruginosa in vivo as reported
by previous studies (Takase et al., 2000a; Turner et al., 2014; Lopez-Medina et al., 2015;
Minandri et al., 2016; Granato et al., 2016).
The inactivation of both pyoverdine and pyochelin systems (-PVD-PCH) did not contribute
to a fitness reduction, indicating that pyochelin was not compensating for iron acquisition
in our model. This was consistent with studies in P. aeruginosa that showed that pyochelin
was less important than pyoverdine in immunocompromized mice (Takase et al., 2000a).
Burkholderia cenocepacia, a similar respiratory pathogen to P. aeruginosa, produces
two siderophores, ornibactin, which shares high similarity with pyoverdine, and pyoche-
lin. Interestingly, it was shown that B. cenocepacia relied mostly on ornibactin for iron
acquisition in vivo (Visser et al., 2004). On the other hand, B. cenocepacia ferripyochelin
was shown to induce increased virulence (Sokol and Woods, 1988) through formation of
superoxide and hydrogen peroxide, increasing damages to the endothelial cells (Britigan
et al., 1997; Coffman et al., 1990), consistent with P. aeruginosa pyochelin involvement in
lung inflammation (Coffman et al., 1990).
7.5 Endogenous siderophore TBDTs loss contributes to bacterial fitness loss 135
The third endogenous siderophore nicotianamine was reported to have an important role
for iron acquisition in artificial lung condition (Gi et al., 2014). The inactivation of the
nicotianamine system (-NIC) did not affect P. aeruginosa growth in our intranasal model,
however the inactivation of the three systems (-PVD-PCH-NIC) decreased the fitness
of the strain, suggesting a contributing role of nicotianamine in iron acquisition in the
absence of pyoverdine. Nicotianamine presents serious advantages for P. aeruginosa in
the low-oxygen lung environment since the siderophore binds ferrous iron with high affinity
(Wirén et al., 1999). Additional inactivation of a potential fourth endogenous siderophore
system (-SidX: PA14_54940-PA14_54960) or the inner membrane ferrous iron sensor
FeoB did not further affect the fitness of the P. aeruginosa (Seyedmohammad et al.,
2016).
The heme transporter PhuR and HasR have been to shown to play an important role
in iron acquisition via heme in vivo in the absence of the siderophore systems (Takase
et al., 2000a; Damron et al., 2016). In CF patients, P. aeruginosa has been shown to
swtich to heme utilization during chronic infection (Nguyen et al., 2014; Marvig et al.,
2014). Contradicting data have been reported in pneumonia mouse models for heme
TBDTs (Damron et al., 2016; Minandri et al., 2016). Indeed in the study of Damron and
coworkers, a single deletion of hasR reduced considerably the fitness of PAO1 (Damron
et al., 2016), while in Minandri and coworkers’ study, the double mutant ∆phuR∆hasR
exhibited the same fitness as wild-type PAO1 (Minandri et al., 2016). Both mutants carried
functional siderophore systems, which might skewed the contribution of heme TBDTs
in iron acquisition. In our settings, inactivation of heme TBDTs had no contribution to
P. aeruginosa fitness in vivo in two models of infection, i.e. pneumonia and septicemia,
however inactivation of heme together with the endogenous siderophore systems (-PVD-
PCH-NIC-heme) reduced the fitness to the level of (-PVD-PCH-NIC) fitness. Our data
suggested thus that heme TBDTs are dispensable in vivo, at least in our in vivo settings.
Based on our expression data, we inactivated most of the TBDTs expressed in animal
samples. This led to ∆25, a mutant lacking 25 TBDTs that includes the heme TBDTs,
the non-iron metal TBDTs (except for BtuB, the cobalamine transporter) and most of the
xenosiderophore TBDTs. This strain showed no fitness change compared to wild-type
bacteria in the intranasal model, which was not surprising since it carried a functional
pyoverdine system. However, additional inactivation of these siderophore systems de-
creased the fitness of the strain to the fitness of (-PVD-PCH-NIC), highlighting again the
predominant role of pyoverdine in vivo.
Moreover, the loss of the xenosiderophore transporters CirA and OptL did not affect the
fitness of ∆25, contrary to what was suggested (Skurnik et al., 2013). Interestingly, ∆25
fitness, which missed the ferrichrome transporter FiuA, was not consistent with Lee and
coworkers study, where the single mutant ∆fiuA led to decrease in growth and virulence
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through overproduction of the protease elastase in vivo (Lee et al., 2016). Deletion of
fiuA might impair the acquisition of ferrichrome, but a second transporter FoxA has been
described to compensate for ferrichrome uptake (Hannauer et al., 2010). In addition,
pyoverdine has a higher affinity for iron and therefore might competes successfully against
ferrichrome. Therefore, the in vivo phenotype of ∆fiuA might be associated mainly to
the increased production of the elastase (Lee et al., 2016). Elastase was shown to
release iron from transferrin (Wolz et al., 1994) and to reduce pro-inflammatory responses
under physiological conditions (Van Der Plas et al., 2016). However, the connection
between elastase and FiuA needs to be further demonstrated, since no complementation
experiment was mentioned to confirm the phenotype of ∆fiuA (Lee et al., 2016).
Together, these data suggested that P. aeruginosa primarily used its high-affinity siderophore
pyoverdine for iron scavenging, whereas uptake capabilities for its other endogenous
siderophores, xenosiderophores, heme-associated substrates and possibly copper and
zinc uptake were all dispensable for in vivo fitness in an intranasal model. Most re-
ported studies employed the less virulent strain PAO1 and single TBDT-deletion mutants,
which might not fully represent the in vivo relevance of transport systems because of the
overlapping substrate spectra (Cornelis and Dingemans, 2013).
The role of siderophore in iron acquisition has been widely studied. However, it seems
clear that the siderophores plan an important role in virulence (Meyer et al., 1996; Cassat
and Skaar, 2013; Kirienko et al., 2015). However this function as virulence factors remains
poorly studied.
7.6 Opportunities for the Trojan horse approach
In order to find successful Trojan-horse-based conjugate, we should investigate which are
the essential substrates and their associated TBDT required for growth of P. aeruginosa
in vivo. Together with previous studies, our data revealed a major role for pyoverdine and
its associated receptor FpvA in vivo, which significantly affected P. aeruginosa fitness
in vivo (Takase et al., 2000a; Turner et al., 2014; Lopez-Medina et al., 2015; Minandri
et al., 2016; Granato et al., 2016). Such a candidate is ideal because it leaves the
bacteria few options to survive, either the bacteria inactivate the transporter reducing its
fitness and are cleared by the host immune system, or they keep the transporter and are
subject to the antibacterial activity of the Trojan horse compounds. However, pyoverdine
based compounds development presents hurdles due to the complex chemistry of the
pyoverdine molecule structure. To date, the pyoverdine based compounds were developed
by hemisynthesis (Mislin and Schalk, 2014), which might lead to difficulties in the industrial
up-scaling process of the drug. Moreover, pyoverdine is specific to Pseudomonas species
and the different types of pyoverdine are even specific to Pseudomonas strains, reducing
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the spectrum of treatable pathogens of pyoverdine-based compounds (Briskot et al., 1986;
Meyer et al., 1997).
Pyoverdine-based compounds would not be effective against installed Pseudomonas
infections such as in CF patients. Indeed, several studies have shown that over the course
of P. aeruginosa infections in the lungs of CF patients, there was an accumulation of
pyoverdine-deficient mutants (Martin et al., 2011; De Vos et al., 2001; Smith et al., 2006;
Konings et al., 2013; Dettman et al., 2013; Bianconi et al., 2015). In the absence of
pyoverdine, nicotianamine and its related transporter OptC would be an ideal alternative
for Trojan horse. Nicotianamine has been shown to play an important role in artificial
lung conditions (Gi et al., 2014) and our data highlighted its contributing role in the
absence of pyoverdine in vivo. The structure of nicotianamine is much less complex
than pyoverdine, encouraging promising developmental options for Trojan horse-based
conjugates. Moreover, nicotianamine and related molecules seem to be conserved in
several pathogens (Ghssein et al., 2016), which could extend the spectrum of treatable
pathogens to more than Pseudomonas species. More research is therefore needed to
unravel the mechanisms of biosynthesis, secretion and uptake of nicotianamine in P.
aeruginosa to guide rational the developement of nicotianamine based drugs.
Despite contradictory data in the literature (Bielecki et al., 2013; Damron et al., 2016;
Minandri et al., 2016) and our in vivo data, heme could also be considered as an alternative
for the Trojan horse strategy. In other models, heme transporters appeared relevant in
vivo as secondary transporters for iron uptake when P. aeruginosa was not relying on
its endogenous siderophores (Konings et al., 2013; Nguyen et al., 2014; Damron et al.,
2016). Moreover, our expression data showed the abundance of heme transporters in all
the conditions tested. Non-iron metalloporphyrins, such as gallium-porphyrin complexes,
are a family of antibacterial compounds of therapeutic potential using the Trojan horse
approach (Stojiljkovic et al., 1999; Anzaldi and Skaar, 2010; Hijazi et al., 2017). These
compounds presented several advantages because heme transporters are conserved
among several bacteria (Wandersman and Stojiljkovic, 2000), and could therefore reach
a broad spectrum of pathogens. In addition, this redundancy in heme-related TBDTs
would decrease the risk of development of resistance against heme-mimetics. Careful in
vivo studies must be undertaken to assess the toxicity of such compounds because they
could actually interfere with the host heme and jeopardize the host innate immune system
(Anzaldi and Skaar, 2010; Schulz et al., 2012).
Xenosiderophore TBDTs, including PiuA and PirA, showed low contribution to in vivo
fitness of P. aeruginosa. However, several studies showed that the siderophore-antibiotic
conjugates induce the expression of the transporter (Gasser et al., 2016), suggesting
that these conjugates have antibacterial potential despite low abundance and scattered
expression of these transporters in different conditions. In order to develop efficient
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conjugates, we should target TBDTs with overlapping substrate spectra to minimize the
risk of antibiotic resistance by facile inactivation of TBDT. Constant vigilance and basic
research on the processes associated with bacterial virulence and transport will continue
to aid the development of novel and effective therapeutics.
7.7 Implications of simple porins and eﬄux pumps in antibiotics
transport
7.7.1 Simple porins have a crucial role in nutrient uptake
Simple porins are open water filled channels that allow diffusion of molecules, such as
sugars, amino acids, phosphates and cations (Hancock and Brinkman, 2002). They have
been shown to be involved in antibiotic uptake. P. aeruginosa UCBPP-PA14 encodes 40
simple porins (Winsor et al., 2016). Among them, the most studied transporters belong
to the OprD family (Hancock and Brinkman, 2002), which transports basic amino acids
and derivatives but also carbapenems (Ochs et al., 1999a; Ochs et al., 1999b). One
mechanism of resistance to carbapenems is the inactivation of OprD, which decreases
carbapenems transport (Ochs et al., 1999b; Pirnay et al., 2002). Therefore, it is often
assumed that the P. aeruginosa outer membrane simple porins crucially determine
antibiotic translocation and efficacy. However, except for OprD, there is no clear evidence
that other simple porins are involved in antibiotic uptake.
We thus applied the same approach than for the TBDTs. We used targeted proteomics to
determine the abundance of simple porins in vivo. In contrast to the expression levels
of TBDTs, the data revealed a constant expression of a subset of simple porins (OprF,
OprD, FadL, OprG, OprQ, OprE) under the same in vivo conditions than for TBDTs, i.e.
rodents samples and human patients samples. In vivo expression correlated with in vitro
expression, suggesting that this subset of simple porins could be involved in the transport
of essential nutrients. As a result, we assessed the functional relevance of simple porins
by generating series of single and multiple gene deletions. A porin-free mutant ∆40 was
generated. However, none of the simple porins mutants, except for oprD, were affected in
MIC studies. ∆40 showed the same susceptibility as ∆oprD for carbapanems, suggesting
that the simple porins have a limited contribution to antibiotic uptake. Interestingly, ∆40
growth was affected on minimal media with single carbon source, indicating a role of
simple porins in nutrient uptake. This results was further motivated by the decrease of in
vivo fitness of ∆40.
Similar expression levels of simple porins in vivo and in vitro could mean that simple
porins enable transport of essential nutrients, however their substrate profile need to
be further investigated. It also surprising that P. aeruginosa expresses so many simple
porins and finally uses 12 of them. The overexpression of these cryptic porins showed
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an increase in susceptibility for several antibiotics, therefore they might be exploited as
antibiotic transport systems.
7.7.2 Eﬄux pumps have a limited contribution to antibiotics
resistance in clinical isolates
Efflux pumps are multicomponent protein complexes that are used by bacteria to secrete
waste, toxins and antibiotics (Hancock and Brinkman, 2002). The resistance-nodulation-
division (RND) superfamily are efflux pump exporters that mediate active efflux of small
molecules including many antibiotics (Hancock and Brinkman, 2002). They are associated
with significant clinical antibiotic resistance in clinical isolates (Sun et al., 2014; Blair et al.,
2015). However the direct connection between RND pumps expression and resistance
has not been shown yet.
We developed a method to generate rapid deletion of efflux pumps in diverse clinical
P. aeruginosa and ESBL E. coli isolates. We targeted the outer membrane channel of
the major pumps: OprM for P. aeruginosa and TolC for E. coli (Li et al., 1995). Despite
the deletions of the major efflux pumps in the isolates, the mutants remained resistant
to antibiotics and no compensation mechanism by other major efflux pumps could be
observed, indicating the presence of potent resistance mechanisms, alternative to efflux
pumps overexpression. This data suggested thus a limited contribution of efflux pumps
to the antibiotic resistance of the clinical isolates. Overexpression of efflux pumps might
have an important role in the switch from susceptibility to resistance phenotype of an
isolate, in helping this isolate to adapt to the antibiotic pressure (Poole, 2007). However,
once the resistance is acquired, the efflux pumps are thought to intend housekeeping
functions unrelated to drug export and resistance (Poole, 2007). This could explain
why the efflux pumps mutants are poorly, or not at all, affected by the loss of functional
efflux pumps. This limited contribution of efflux pumps also question the relevance of
efflux pumps inhibitors, which have been of interest these last years (Puzari and Chetia,
2017). Understanding the mechanisms of efflux pumps induction could provide insight
in P. aeruginosa adaptation in vivo and could prevent development of resistance upon
antibiotic pressure.
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8Conclusion
Antimicrobial resistance is a serious public health threat worldwide. Developing new
antibiotics is a considerable challenge because of the rapid emergence of resistance in
bacteria. The outer membrane of Gram-negative pathogen plays a crucial role as the first
line of bacterial defence against antibiotics. The opportunistic pathogen P. aeruginosa is
intrinsically resistant to many antibiotics partly due to its large number of porins and efflux
pumps that enable the pathogen to have a tight control control over influx and efflux across
the outer membrane. Therefore, getting antibiotics through the outer membrane is a diffi-
cult task. So far, the Trojan horse approach is the most advanced strategy to circumvent
this issue. In a Trojan horse approach, a toxic compound is efficiently transported across
the outer membrane via endogenous bacterial active transporters (TBDTs), by hijacking
essential substrate for P. aeruginosa growth in vivo. However the Trojan horse approach
is failing when P. aeruginosa develops resistance by facile inactivation of the TBDT(s)
involved in the process. In order to prevent the rapid development of resistance, transport
capabilities and substrate specifities of P. aeruginosa need to be seriously investigated
in vivo. Indeed, mimetics of substrates, found essential for the growth of P. aeruginosa
in vivo, should be targeted. By this means, the substrate mimetic would then be actively
transported via one or several endogenous TBDTs, getting around the vigilance of P.
aeruginosa and increasing intracellular antimicrobial concentration. Inactivation of the
involved TBDT(s) would contribute to the fitness reduction of the pathogen in vivo and
would lower the risk of resistance development.
By combining advanced targeted proteomics and in vivo competition assays, we were
able to quantify the abundance of TBDTs in vivo and assess their contribution to fitness
in vivo. Overall, our data suggested that P. aeruginosa mainly used its high-affinity
siderophore pyoverdine for iron scavenging, whereas uptake capabilities for its other
endogenous siderophores, xenosiderophores, heme-associated substrates and possibly
copper and zinc uptake were all dispensable for in vivo. However, pyoverdine is not a good
candidate for Trojan horse strategy due to its complex chemistry and its reduced spectrum
of treatable pathogens. Another potential candidate would be nicotianamine, because it
can bind a wide range of metals and seems to have significant role in the lung, especially
in absence of pyoverdine such as in CF patients lungs. Despite their low contribution in
vivo, heme and xenosiderophores mimetics would be potential candidates, since their
presence induce the expression of the associated TBDTs. Targeting substrate with
redundant transport capabilities might also lower the risk of resistance development.
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Understanding the host microenvironment is essential for the development of in vitro
media. Our data from preclinical and human patients provide benchmarks for developing
in vitro assays and animal models, that mimic better transport capabilities during infection.
Deeper knowledge of P. aeruginosa phenotypes in vivo is thus essential to guide rational
development of antimicrobials.
The requirement for iron has created an ongoing battle between hosts and pathogens.
Free iron is already limited in the bloodstream of hosts. In addition, bacterial infections trig-
ger the innate immune response, which sequesters iron even further. Pathogens such as P.
aeruginosa secrete siderophores to scavenge iron from the host. The role of siderophore
in iron acquisition is therefore extensively investigated. However, siderophores, such as
pyoverdine and pyochelin, seem to play a key role in virulence, but this function remains
poorly studied. Given the importance of siderophores as virulence factors, greater insight
into the contribution of siderophores to virulence is needed.
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PROFESSIONAL EXPERIENCE 
Medical & Technical Affairs Europe Leader – Procter and Gamble             Since Apr 2017 
Cold and Flu category - Personal Healthcare International        Geneva, CH 
● Claims substantiation assessment based on internal and external scientific literature 
● Key Opinion Leaders Strategy development and execution; 
● Regional and local claim/copy clearance process owner and trainer 
Research Assistant – Infection Biology, Prof. Bumann – Biozentrum      2013-2017 
European Innovative Medicine Initiatives, New Drugs 4 Bad Bugs, Translocation      Basel, CH 
Goal: Investigate the functions of P. aeruginosa active transporters during rodent/human infections 
● Optimization of several strategies for gene deletion, mouse infection model and proteomics; 
● Establishment of collaborations with industrial partners and European groups within IMI consortium; 
● Development of strong conceptual and oral communication skills at international conferences; 
● Supervision of a master project on the in vitro characterization of P. aeruginosa active transporters. 
Junior Research Assistant – Intern in Drug Development – Merck KGaA                       Sep - Mar 2013 
Physico-chemical characterization of solid-states group, Alex Becker            Darmstadt, DE 
Goal: Assessed in-silico approaches for better anti-cancer drug design 
● Assessment of different software to optimize in silico screening of potential API co-crystals; 
● Improvement in-house drug development pipeline by implementing the best in-silico solutions. 
 
Trainee in System Biology – EPFL               Jan - Aug 2012 
Laboratory of Computational Systems Biotechnology, Prof. Hatzimanikatis            Lausanne, CH 
Goal: Explored of sugar and lipid metabolism by exploiting the in-house algorithm BNICE 
● Semester project grade: 6/6, extended by trainee position; 
● Utilization of in-house algorithm to predict metabolic reactions in E. Coli; 
● Construction of metabolic network in E. Coli, focus on sugar and lipid metabolisms. 
EDUCATION 
PhD in Microbiology – Infection Biology, Biozentrum                             2017 
    Basel, CH 
MCC Summer Academy: Business beyond borders – Mathias Corvinus Collegium                  2016 
Business in International Relations, International Strategic Management and Marketing               Budapest, HU 
 
Master in Molecular and Biological Chemistry – EPFL                      2013 
Specialization in Computational chemistry                   Lausanne, CH 
Grenier Prize for best EPFL master thesis                  
 
Bachelor in Chemistry and Chemical Engineering – EPFL                    2011 
Specialization in Computational chemistry                 Lausanne, CH 
Enthusiastic researcher with an EPF training in Chemistry and Infectious Diseases, I benefit 
from a wide international experience in public speaking and visual communication. I’m a 
creative team player with experience in leadership and medical affairs gathered during my 
current position at Procter and Gamble. Stepping out of my comfort zone doesn’t scare me.  
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PRIZE AND HONORS 
Selected candidate for Keep-in-Touch Program – by McKinsey & Company              2016 
Selected candidate for Novartis International Biocamp – by Novartis                            2016 
European TRANSLOCATION for four years PhD project – IMI, New Drug 4 Bad Bugs             2013 
Grenier Prize for Best EPFL Master Thesis – EPFL, Fondation William Grenier              2013 
EXTRACURRICULAR ACTIVITIES 
Marketing and Public Relations co-chair – Healthcare Business Women’s Association (HBA)     2016 
● Lead and implement Basel HBA marketing and communication efforts; 
● Provide recommendations and insights on the overall marketing and communications strategy; 
● Liaise with HBA EU Director of Marketing and PR to align on strategies, objectives and tactics as well 
as share best practices. 
 
Manager of Microbiology Blockkurs week – Biozentrum             2015-2016 
● Team management (10 supervisors and 30-45 students); 
● Course planning: fitting 4 experiments in a week; 
● Creating the script of the course: from design to edition; 
● Student evaluation: >95% satisfied. Rated as 2nd best Blockkurs week, two times in a raw. 
 
Organizing Committee President Global Village 2016 – AIESEC Basel        Fall 2015 
● Team leader of newly created Project department at AIESEC Basel; 
● Team management (5 persons); 
● Event conception and initiation: Global Village to promote intercultural exchange at Basel University. 
 
Manager of Academic Matters at ADEC, Association of Chemistry EPFL Students               2011-2012 
● Guidance on undergraduate administration; 
● Mediator between chemistry department and students. 
 
Student Representative at the Basic Sciences Faculty Board, EPFL     2011-2012 
● Advice and voting on strategic faculty decisions; 
● Mediator between Basic sciences faculty and students. 
 
Head of Entertainment and Sports at AGEPoly, General Association of EPFL Students   2010-2012 
● Part of AGEPoly Board: frequent meeting with ETH Board, industrial partners and students; 
● Team management (20 persons): mobilise and motivate people to help along the year; 
● Event management: 5 external parties, 3 on-campus events. Budget from 1K-50K CHF per event; 
● Leading recruitment campaign for new team members; 
● Creating event promotion materials (event logo, posters and flyers). 
PROFESSIONAL TRAINING IN COMMUNICATION 
Conflict Management workshop                     2016 
3 Oral and Visual Communication courses         2014-2016 
Tutor and teaching assistant for several courses in Chemistry and Biology at university level   2012-2016 
Details on request. 
ADDITIONAL SKILLS 
Languages 
● French (Native),  
● English (Fluent C2),  
● German (Basic A2),  
● Spanish (Basic A1),  
● Tamil (Conversational) 
Computer skills 
● Adobe Illustrator  
● Latex  
● HTML  
● R 
 
Personal interests 
● Strong passion for design of visual communication 
materials: participation in online logo/posters/flyers 
design contests. 
● Enjoy travelling around the world to experience 
different cultures, food and challenges 
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